NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

Pancreatic Adenocarcinoma

NCCN Evidence Blocks™

Version 2.2017 — April 28, 2017

NCCN.org

Continue
NCCN Guidelines Version 2.2017 Panel Members
Pancreatic Adenocarcinoma
NCCN Evidence Blocks™

*Margaret A. Tempero, MD/Chair † ✧
UCSF Helen Diller Family
Comprehensive Cancer Center

Mokenge P. Malafa, MD/Vice Chair ¶
Moffitt Cancer Center

Mahmoud Al-Hawary, MD ~
University of Michigan
Comprehensive Cancer Center

Horacio Asbun, MD ¶
Mayo Clinic Cancer Center

Andrew Bain, MD =
Roswell Park Cancer Institute

Stephen W. Behrman, MD ¶
The University of Tennessee
Health Science Center

Al B. Benson III, MD †
Robert H. Lurie Comprehensive Cancer
Center of Northwestern University

Ellen Binder, MD ₪
Siteman Cancer Center at Barnes-Jewish Hospital
and Washington University School of Medicine

Dana B. Cardin, MD †
Vanderbilt-Ingram Cancer Center

Charles Cha, MD ¶
Yale Cancer Center/
Smilow Cancer Hospital

E. Gabriela Chiorean, MD †
Fred Hutchinson Cancer Research Center/
Seattle Cancer Care Alliance

Vincent Chung, MD †
City of Hope Comprehensive Cancer Center

Brian Czito, MD §
Duke Cancer Institute

Mary Dillhoff, MD ¶
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

Efrat Dotan, MD †
Fox Chase Cancer Center

Cristina R. Ferrone, MD ¶
Massachusetts General Hospital Cancer Center

Jeffrey Hardacre, MD ¶
Case Comprehensive Cancer Center/
University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute

William G. Hawkins, MD ¶
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Joseph Herman, MD, MSc §
The University of Texas
MD Anderson Cancer Center

Andrew H. Ko, MD †
UCSF Helen Diller Family
Comprehensive Cancer Center

Srinadh Komanduri, MD = ~
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Albert Koong, MD, PhD §
Stanford Cancer Institute

Noelle LoConte, MD †
University of Wisconsin Carbone Cancer Center

Andrew M. Lowy, MD ¶
UC San Diego Moores Cancer Center

Cassadie Moravek ¥
Pancreatic Cancer Action Network

Eric K. Nakakura, MD ¶
UCSF Helen Diller Family
Comprehensive Cancer Center

Eileen M. O’Reilly, MD † ♣
Memorial Sloan Kettering Cancer Center

Jorge Obando, MD =
Duke Cancer Institute

Sushanth Reddy, MD ¶
University of Alabama at Birmingham
Comprehensive Cancer Center

Courtney Scaife, MD ¶
Huntsman Cancer Institute
at the University of Utah

Sarah Thayer, MD ¶
Fred & Pamela Buffett Cancer Center

Colin D. Weekes, MD, PhD †
University of Colorado Cancer Center

Robert A. Wolff, MD †
The University of Texas
MD Anderson Cancer Center

Brian M. Wolpin, MD, MPH †
Dana-Farber/Brigham and Women’s Cancer Center

NCCN
Jennifer Burns
Susan Darlow, PhD

Gastroenterology
Surgery/Surgical oncology
Radiotherapy/Radiation oncology
Medical oncology
Hematology/Hematology oncology
Internal medicine
Geriatric medicine
Interventional radiology
Pathology
Patient advocacy
Discussion Writing Committee Member
Clinical Trials: NCCN believes that the best management for any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

To find clinical trials online at NCCN Member Institutions, click here: nccn.org/clinical_trials/physician.html.

NCCN Categories of Evidence and Consensus: All recommendations are category 2A unless otherwise specified.

See NCCN Categories of Evidence and Consensus.
### NCCN Evidence Blocks™

#### NCCN Evidence Blocks Categories and Definitions

<table>
<thead>
<tr>
<th></th>
<th>Efficacy of Regimen/Agent</th>
<th>Safety of Regimen/Agent</th>
<th>Quality of Evidence</th>
<th>Consistency of Evidence</th>
<th>Affordability of Regimen/Agent</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>Highly effective: Cure likely and often provides long-term survival advantage</td>
<td>Usually no meaningful toxicity: Uncommon or minimal toxicities; no interference with activities of daily living (ADLs)</td>
<td>High quality: Multiple well-designed randomized trials and/or meta-analyses</td>
<td>Highly consistent: Multiple trials with similar outcomes</td>
<td>Very inexpensive</td>
</tr>
<tr>
<td>4</td>
<td>Very effective: Cure unlikely but sometimes provides long-term survival advantage</td>
<td>Occasionally toxic: Rare significant toxicities or low-grade toxicities only; little interference with ADLs</td>
<td>Good quality: One or more well-designed randomized trials</td>
<td>Mainly consistent: Multiple trials with some variability in outcome</td>
<td>Inexpensive</td>
</tr>
<tr>
<td>3</td>
<td>Moderately effective: Modest impact on survival, but often provides control of disease</td>
<td>Mildly toxic: Mild toxicity that interferes with ADLs</td>
<td>Average quality: Low quality randomized trial(s) or well-designed non-randomized trial(s)</td>
<td>May be consistent: Few trials or only trials with few patients, whether randomized or not, with some variability in outcome</td>
<td>Moderately expensive</td>
</tr>
<tr>
<td>2</td>
<td>Minimally effective: No, or unknown impact on survival, but sometimes provides control of disease</td>
<td>Moderately toxic: Significant toxicities often occur but life threatening/fatal toxicity is uncommon; interference with ADLs is frequent</td>
<td>Low quality: Case reports or extensive clinical experience</td>
<td>Inconsistent: Meaningful differences in direction of outcome between quality trials</td>
<td>Expensive</td>
</tr>
<tr>
<td>1</td>
<td>Palliative: Provides symptomatic benefit only</td>
<td>Highly toxic: Significant toxicities or life threatening/fatal toxicity occurs often; interference with ADLs is usual and severe</td>
<td>Poor quality: Little or no evidence</td>
<td>Anecdotal evidence only: Evidence in humans based upon anecdotal experience</td>
<td>Very expensive</td>
</tr>
</tbody>
</table>

**Note:** For significant chronic or long-term toxicities, score decreased by 1.
Decisions about diagnostic management and resectability should involve multidisciplinary consultation at a high-volume center with use of appropriate imaging studies.
CLINICAL PRESENTATION

Clinical suspicion of pancreatic cancer or evidence of dilated pancreatic and/or bile duct (stricture)

WORKUP

- Pancreatic protocol CT (See PANC-A)
- Obtain family history

No mass in pancreas on imaging

- Mass in pancreas on imaging

No metastatic disease

- Multidisciplinary review
- Consider endoscopic ultrasonography (EUS)
- Liver function tests
- Chest CT (preferred) or x-ray

Surgical candidate (See PANC-2)

Metastatic disease

- Biopsy confirmation of metastatic site

See Metastatic Disease (PANC-8)

No metastatic disease

- Liver function tests
- Chest CT (preferred) or x-ray
- MRI/MRCP or ERCP as clinically indicated

If studies are consistent with pancreatic cancer, surgical consultation is recommended (See PANC-2)

No mass in pancreas on imaging

- EUS

Metastatic disease

- Biopsy confirmation of metastatic site

See Metastatic Disease (PANC-8)

---

a If pancreatic cancer is diagnosed, consider referral for genetic counseling for patients who are young, those with a family history of cancer, or those of Ashkenazi Jewish ancestry.

b Multidisciplinary review should ideally involve expertise from diagnostic imaging, interventional endoscopy, medical oncology, radiation oncology, surgery, and pathology. Consider consultation with a registered dietitian.

c EUS to confirm primary site of involvement; EUS-FNA if clinically indicated.

d Imaging with contrast unless contraindicated.

e MRCP = magnetic resonance cholangiopancreatography; ERCP = endoscopic retrograde cholangiopancreatography

Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page EB-1.

All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
CLINICAL PRESENTATION

WORKUP

No jaundice → Preoperative CA 19-9\(^g,h\)

Jaundice

Symptoms of cholangitis or fever present

Plastic stent or consider metal stent (if tissue diagnosis confirmed) and Antibiotic coverage

Resectable\(^{h,i,j}\) → See Workup and Treatment (PANC-3)

Borderline resectable\(^{h,i,j}\) → See Workup (PANC-4)

Locally advanced unresectable, no metastases

Preoperative CA 19-9\(^g,h\) (category 3)

No jaundice and fever\(^f\)

No symptoms of cholangitis and fever\(^f\)

No metastatic disease on physical exam and by imaging

\(^f\) Plastic or consider self-expanding metal stent (if tissue diagnosis confirmed) as clinically indicated in patients with select comorbidities or when surgery may be delayed. (See Discussion)

\(^g\) Elevated CA 19-9 does not necessarily indicate cancer or advanced disease. CA 19-9 may be elevated as a result of biliary infection (cholangitis), inflammation, or obstruction, benign or malignant. In addition, CA 19-9 will be undetectable in Lewis antigen-negative individuals. (See Discussion)

\(^h\) See Principles of Diagnosis, Imaging, and Staging (PANC-A).

\(^i\) See Criteria Defining Resectability Status (PANC-B).

\(^j\) See Principles of Surgical Technique (PANC-C) and Pathologic Analysis: Specimen Orientation, Histologic Sections, and Reporting (PANC-D).

Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page EB-1.

All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
**RESECTABLE**

Consider staging laparoscopy in high-risk patients or as clinically indicated.

**WORKUP**

Successful resection

Surgery (laparotomy or minimally invasive surgery)

Unresectable at surgery

Biopsy confirmation of adenocarcinoma, if not previously performed

No jaundice

Self-expanding metal stent or biliary bypass ± gastrojejunostomy (category 2B for prophylactic gastrojejunostomy) ± celiac plexus neurolysis if pain (category 2B if no pain)

Jaundice

Consider gastrojejunostomy if clinically indicated (category 2B for prophylactic gastrojejunostomy) ± celiac plexus neurolysis if pain (category 2B if no pain)

See Locally Advanced Unresectable (PANC-6)

See Metastatic Disease (PANC-8)

See Adjuvant Treatment and Surveillance (PANC-5)

**TREATMENT**

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page EB-1. All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
BORDERLINE RESECTABLEh,i NO METASTASES

WORKUP

Borderline resectable

- Biopsy, EUS-FNA preferredn
- Consider staging laparoscopyl
- Baseline CA 19-9g

Biopsy positive

- Short, self-expanding metal stent if biliary ductal obstruction is present
- Neoadjuvant therapyo

Cancer not confirmed

Repeat biopsy

Cancer not confirmed (exclude autoimmune pancreatitis)

TREATMENT

Surgical resectionj

Consider staging laparoscopy if not previously performed

Pancreatic protocol CT or MRI (abdomen and pelvis)
- Chest CTd (preferred) or x-ray
- Post-treatment CA 19-9g

Disease progression precluding surgerym

Unresectable at surgeryl,m

Jaundice

Consider surgical biliary bypass ± gastrojejunostomy (category 2B for prophylactic gastrojejunostomy) ± celiac plexus neurolysis if pain (category 2B if no pain)

No jaundice

See Adjuvant Treatment and Surveillance (PANC-5)

Refer to high-volume center for evaluation

See Locally Advanced Unresectable (PANC-6) or Metastatic Disease (PANC-8)

nImaging with contrast unless contraindicated.

oElevated CA 19-9 does not necessarily indicate cancer or advanced disease. CA 19-9 may be elevated as a result of biliary infection (cholangitis), inflammation, or obstruction, benign or malignant. In addition, CA 19-9 will be undetectable in Lewis antigen-negative individuals. (See Discussion)

lSee Principles of Diagnosis, Imaging, and Staging (PANC-A).

mSee Principles of Palliation and Supportive Care (PANC-E).

There is limited evidence to recommend specific neoadjuvant regimens off-study, and practices vary with regard to the use of chemotherapy and chemoradiation. See PANC-G for acceptable neoadjuvant options. Subsequent chemoradiation is sometimes included (see PANC-F).

Most NCCN Member Institutions prefer neoadjuvant therapy at or coordinated through a high-volume center. Performing surgery with a high likelihood of a positive margin is not recommended.

nSee Principles of Diagnosis, Imaging, and Staging #1 and #7 (PANC-A).

Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page EB-1.

All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
POSTOPERATIVE ADJUVANT TREATMENT

<table>
<thead>
<tr>
<th>No prior neoadjuvant therapy</th>
<th>No evidence of recurrence or metastatic disease</th>
<th>Clinical trial preferred or Chemotherapy alone or Induction chemotherapy followed by chemoradiation ± subsequent chemotherapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prior neoadjuvant therapy</td>
<td>No evidence of recurrence or metastatic disease</td>
<td>Consider additional chemotherapy</td>
</tr>
<tr>
<td>Identification of metastatic disease</td>
<td>See Metastatic Disease (PANC-8)</td>
<td>Surveillance every 3–6 mo for 2 years, then every 6–12 mo: • H&amp;P for symptom assessment • CA 19-9 level (category 2B) • Abdominal CT with contrast (category 2B)</td>
</tr>
<tr>
<td>Recurrence after resection (See PANC-9)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

pAdjuvant treatment should be administered to patients who have not had neoadjuvant chemotherapy and who have adequately recovered from surgery; treatment should be initiated within 12 weeks. If systemic chemotherapy precedes chemoradiation, restaging with imaging should be done after each treatment modality.

qPatients who have received neoadjuvant chemoradiation or chemotherapy may be candidates for additional chemotherapy following surgery and multidisciplinary review. The adjuvant therapy options are dependent on the response to neoadjuvant therapy and other clinical considerations.

rSee Principles of Chemotherapy (PANC-G).

sSee Principles of Radiation Therapy (PANC-F).

Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page EB-1.

All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
LOCALLY ADVANCED UNRESECTABLE

WORKUP

Adenocarcinoma confirmed → If jaundice, placement of self-expanding metal stent

See Treatment (PANC-7)

Biopsy if not previously done

Cancer not confirmed → If jaundice, placement of self-expanding metal stent (preferably a short metal stent) with brushings → Repeat biopsy

Follow pathway above

Other cancer confirmed → Refer to high-volume center for evaluation → Treat with appropriate NCCN Guideline

Other cancer confirmed

Locally advanced unresectable

Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page EB-1.
All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

See Principles of Palliation and Supportive Care (PANC-E).
See Principles of Diagnosis, Imaging, and Staging #1 and #7 (PANC-A).

Unless biliary bypass performed at time of laparoscopy or laparotomy.
EUS-FNA ± core biopsy at a center with multidisciplinary expertise is preferred.
# NCCN Guidelines Version 2.2017
## Pancreatic Adenocarcinoma

### NCCN Evidence Blocks™

### Locally Advanced Unresectable

**Good performance status**

**First-Line Therapy**

- Clinical trial (preferred) or Chemotherapy
  - Induction chemotherapy (preferably 4–6 mo) followed by chemoradiation or SBRT in selected patients (locally advanced without systemic metastases)
  - Chemoradiation or SBRT in selected patients who are not candidates for combination chemotherapy

**Second-Line Therapy**

- Previously treated with gemcitabine-based therapy
  - Good performance status and disease progression
  - Previously treated with fluoropyrimidine-based therapy

**Poor performance status**

- Single-agent chemotherapy
  - Palliative RTs
  - Other palliative and best supportive care

### Discussion

- **Clinical trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

---

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page EB-1.

All recommendations are category 2A unless otherwise indicated.

--

**See Principles of Palliation and Supportive Care (PANC-E).**
**See Principles of Chemotherapy (PANC-G).**
**See Principles of Radiation Therapy (PANC-F).**
**Defined as ECOG 0-1 with patent biliary stent and adequate nutritional intake.**
**See Principles of Diagnosis, Imaging, and Staging #10 (PANC-A).**
**Laparoscopy as indicated to evaluate distant disease.**
**Chemoradiation should be reserved for patients who do not develop metastatic disease while receiving systemic chemotherapy.**

**Based on preliminary data from the LAP-07 trial, there is no clear survival benefit with the addition of conventional chemoradiation following gemcitabine monotherapy. Chemoradiation may improve local control and delay the need for resumption therapy.** (Huguet F, et al. Impact of chemoradiotherapy on local control and time without treatment in patients with locally advanced pancreatic cancer included in the international phase III LAP 07 study. J Clin Oncol 2014; 32:5s. Abstract 4001.)

**Patients with a significant response to therapy may be considered for surgical resection.**

**Best reserved for patients who maintain a good performance status.**
### METASTATIC DISEASE

<table>
<thead>
<tr>
<th>Metastatic disease</th>
<th>Poor performance status</th>
<th>Clinical trial (preferred) or Chemotherapy</th>
<th>Good performance status</th>
<th>Good performance status and disease progression</th>
<th>Previously treated with gemcitabine-based chemotherapy</th>
<th>Previously treated with fluoropyrimidine-based chemotherapy</th>
<th>Second-Line Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>If jaundice: placement of self-expanding metal stent</td>
<td>Single-agent chemotherapy or Palliative RTs and/or Other palliative and best supportive care</td>
<td>Clinical trial (preferred) or Chemotherapy</td>
<td>Clinical trial (preferred) or Gemcitabine-based chemotherapy</td>
<td>Clinical trial (preferred) or Fluoropyrimidine-based chemotherapy or RTs for severe pain refractory to narcotic therapy</td>
<td>Clinical trial (preferred) or Fluoropyrimidine-based chemotherapy or RTs for severe pain refractory to narcotic therapy</td>
<td>Palliative and best supportive care or Clinical trial</td>
<td></td>
</tr>
</tbody>
</table>

#### FIRST-LINE THERAPY

- **Good performance status**
  - Clinical trial (preferred) or Chemotherapy
  - Good performance status and disease progression

- **Poor performance status**
  - Single-agent chemotherapy or Palliative RTs and/or Other palliative and best supportive care

#### SECOND-LINE THERAPY

- **Previously treated with gemcitabine-based chemotherapy**
  - Clinical trial (preferred) or Fluoropyrimidine-based chemotherapy or RTs for severe pain refractory to narcotic therapy

- **Previously treated with fluoropyrimidine-based chemotherapy**
  - Clinical trial (preferred) or Fluoropyrimidine-based chemotherapy or RTs for severe pain refractory to narcotic therapy

### Notes
- **m** See Principles of Palliation and Supportive Care (PANC-E).
- **r** See Principles of Chemotherapy (PANC-G).
- **s** See Principles of Radiation Therapy (PANC-F).
- **t** Unless biliary bypass performed at time of laparoscopy or laparotomy.

**v** Defined as ECOG 0-1 with patent biliary stent and adequate nutritional intake.

**w** See Principles of Diagnosis, Imaging, and Staging #10 (PANC-A).

**bb** Best reserved for patients who maintain a good performance status.

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page EB-1. All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
RECURRENCE AFTER RESECTION

**Pancreas only**

- **Local recurrence**
  - Consider biopsy for confirmation (category 2B)

- **Pancreatic bed**
  - Surgical consultation, see Principles of Surgical Techniques (PANC-C)

  - Clinical trial (preferred)
  - or
  - Consider chemoradiation (if not previously done)
  - or
  - Consider induction chemotherapy followed by SBRT (if radiation not previously done)
  - or
  - Alternative systemic chemotherapy
  - or
  - Palliative and best supportive care

**Metastatic disease with or without local recurrence\(^{cc}\)**

- **Greater than 6 mo from completion of primary therapy**
  - Clinical trial (preferred)
  - or
  - Systemic therapy as previously administered
  - or
  - Alternative systemic chemotherapy
  - or
  - Palliative and best supportive care

- **Less than 6 mo from completion of primary therapy**
  - Clinical trial (preferred)
  - or
  - Switch to alternative systemic chemotherapy
  - or
  - Palliative and best supportive care

**SECOND-LINE THERAPY\(^{bb}\)**

- Pancreas only
- Pancreatic bed

---

\(^{bb}\)Best reserved for patients who maintain a good performance status.

\(^{cc}\)For more information about the treatment of isolated pulmonary metastases, see Discussion.

\(^{m}\)See Principles of Palliation and Supportive Care (PANC-E).

\(^{r}\)See Principles of Chemotherapy (PANC-G).

\(^{s}\)See Principles of Radiation Therapy (PANC-F).

---

Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks\(^{TM}\), see page EB-1. All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
#1 Decisions about diagnostic management and resectability should involve multidisciplinary consultation at a high-volume center with reference to appropriate high-quality imaging studies to evaluate the extent of disease. Resections should be done at institutions that perform a large number (at least 15–20) of pancreatic resections annually.

#2 High-quality dedicated imaging of the pancreas should be performed at presentation (even if standard CT imaging is already available), preferably within 4 weeks of surgery, and following neoadjuvant treatment to provide adequate staging and assessment of resectability status. Imaging should be done prior to stenting, when possible.

#3 Imaging should include dedicated pancreatic CT (preferred) or MRI with contrast.
- Multi-detector computed tomography (MDCT) angiography, performed by acquiring thin, preferably sub-millimeter, axial sections using a dual-phase pancreatic protocol, with images obtained in the pancreatic and portal venous phase of contrast enhancement, is the preferred imaging tool for dedicated pancreatic imaging.\(^1\) Scan coverage can be extended to cover the chest and pelvis for complete staging as per institutional preferences. Multiplanar reconstruction is preferred as it allows precise visualization of the relationship of the primary tumor to the mesenteric vasculature as well as detection of subcentimeter metastatic deposits. See MDCT Pancreatic Adenocarcinoma Protocol, PANC-A (3 of 8).
- MRI is most commonly used as a problem-solving tool, particularly for characterization of CT-indeterminate liver lesions and when suspected pancreatic tumors are not visible on CT or when contrast-enhanced CT cannot be obtained (as in cases with severe allergy to iodinated intravenous contrast material). This preference for using MDCT as the main imaging tool in many hospitals and imaging centers is mainly due to the higher cost and lack of widespread availability of MRI compared to CT. See MRI Pancreatic Adenocarcinoma Protocol, PANC-A (4 of 8).
- MR cholangiopancreatography (MRCP) without IV contrast should not be utilized in the staging of pancreatic cancer, except in cases of renal failure or other contraindications to administration of gadolinium intravenous contrast.

#4 The decision regarding resectability status should be made by consensus at multidisciplinary meetings/discussions following the acquisition of dedicated pancreatic imaging including complete staging. Use of a radiology staging reporting template is preferred to ensure complete assessment and reporting of all imaging criteria essential for optimal staging, which will improve the decision-making process.\(^1\) See Pancreatic Cancer Radiology Reporting Template, PANC-A (5 of 8)

#5 The role of PET/CT (without iodinated intravenous contrast) remains unclear. Diagnostic CT or MRI with IV contrast as discussed above in conjunction with functional PET imaging can be used per institutional preference. PET/CT scan may be considered after formal pancreatic CT protocol in high-risk patients to detect extra pancreatic metastases. It is not a substitute for high-quality, contrast-enhanced CT.

#6 EUS is not recommended as a routine staging tool. In select cases, EUS may be complementary to CT for staging.

#7 EUS-FNA is preferable to a CT-guided FNA in patients with resectable disease because of better diagnostic yield, safety, and potentially lower risk of peritoneal seeding with EUS-FNA when compared with the percutaneous approach. Biopsy proof of malignancy is not required before surgical resection, and a non-diagnostic biopsy should not delay surgical resection when the clinical suspicion for pancreatic cancer is high.

#8 Diagnostic staging laparoscopy to rule out metastases not detected on imaging (especially for body and tail lesions) is used in some institutions prior to surgery or chemoradiation, or selectively in patients who are at higher risk for disseminated disease. Intraoperative ultrasound can be used as a diagnostic adjunct during staging laparoscopy.

#9 Positive cytology from washings obtained at laparoscopy or laparotomy is equivalent to M1 disease. If resection has been done for such a patient, he or she should be treated for M1 disease.

#10 For locally advanced/metastatic disease, the panel recommends serial CT with contrast (routine single portal venous phase or dedicated pancreatic protocol if surgery is still contemplated) or MRI with contrast of known sites of disease to determine therapeutic benefit. However, it is recognized that patients can demonstrate progressive disease clinically without objective radiologic evidence of disease progression.

2Indicators of high-risk patients may include borderline resectable disease, markedly elevated CA 19-9, large primary tumors, or large regional lymph nodes.

Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks, see page EB-1. All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
### PRINCIPLES OF DIAGNOSIS, IMAGING, AND STAGING

**MDCT Pancreatic Adenocarcinoma Protocol**

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Scan type</strong></td>
<td>Helical (preferably 64-multidetector row scanner or more)</td>
</tr>
<tr>
<td><strong>Section thickness</strong></td>
<td>Thinnest possible (&lt;3 mm). Preferably submillimeter (0.5–1 mm) if available</td>
</tr>
<tr>
<td><strong>Interval</strong></td>
<td>Same as section thickness (no gap)</td>
</tr>
<tr>
<td><strong>Oral contrast agent</strong></td>
<td>Neutral contrast (positive oral contrast may compromise the three-dimensional [3D] and maximum intensity projection [MIP] reformatted images)</td>
</tr>
<tr>
<td><strong>Intravenous contrast</strong></td>
<td>Iodine-containing contrast agents (preferably high concentration [&gt;300 mg I/L]) at an injection rate of 3–5 mL/sec. Lower concentration contrast can be used if low Kv setting is applied.</td>
</tr>
<tr>
<td><strong>Scan acquisition timing</strong></td>
<td>Pancreatic parenchymal phase at 40–50 sec and portal venous phase at 65–70 sec, following the commencement of contrast injection</td>
</tr>
</tbody>
</table>
| **Image reconstruction and display** | - Axial images and multiplanar reformats (in the coronal, and per institutional preference, sagittal plane) at 2- to 3-mm interval reconstruction  
- MIP or 3D volumetric thick section for vascular evaluation (arteries and veins) |

---

### PRINCIPLES OF DIAGNOSIS, IMAGING, AND STAGING

#### MRI Pancreatic Adenocarcinoma Protocol

<table>
<thead>
<tr>
<th>Sequences</th>
<th>Plane</th>
<th>Slice thickness</th>
</tr>
</thead>
<tbody>
<tr>
<td>T2-weighted single-shot fast spin-echo (SSFSE)</td>
<td>Coronal +/- axial</td>
<td>&lt;6 mm</td>
</tr>
<tr>
<td>T1-weighted in-phase and opposed-phase gradient echo (GRE)</td>
<td>Axial</td>
<td>&lt;6 mm</td>
</tr>
<tr>
<td>T2-weighted fat-suppressed fast spin-echo (FSE)</td>
<td>Axial</td>
<td>&lt;6 mm</td>
</tr>
<tr>
<td>Diffusion-weighted imaging (DWI)</td>
<td>Axial</td>
<td>&lt;6 mm</td>
</tr>
<tr>
<td>Pre and dynamic post IV contrast administration (gadolinium)</td>
<td>Axial</td>
<td>Thinnest possible 2–3 mm (4–6 mm if overlapping)</td>
</tr>
<tr>
<td>Three-dimensional [3D] T1-weighted fat-suppressed gradient-echo (in pancreatic, portal venous, and equilibrium phases)</td>
<td>Axial</td>
<td>Thinnest possible 2–3 mm (4–6 mm if overlapping)</td>
</tr>
<tr>
<td>T2-weighted MRCP (preferably three-dimensional [3D], fast relaxation fast spin-echo sequence [FRFSE])</td>
<td>Coronal</td>
<td>&lt;3 mm</td>
</tr>
</tbody>
</table>

---


4Unenhanced MRI can be obtained in cases of renal failure or contraindication to gadolinium intravenous contrast if enhanced CT cannot be obtained due to severe iodinated contrast allergy.

---

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#). All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
### PRINCIPLES OF DIAGNOSIS, IMAGING, AND STAGING

#### PANCREATIC CANCER RADIOLOGY REPORTING TEMPLATE¹

<table>
<thead>
<tr>
<th>Morphologic Evaluation</th>
<th>Hypoattenuating</th>
<th>Isoattenuating</th>
<th>Hyperattenuating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appearance (in the pancreatic parenchymal phase)</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Size (maximal axial dimension in centimeters)</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Location</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Pancreatic duct narrowing/abrupt cutoff with or without upstream dilatation</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Biliary tree abrupt cutoff with or without upstream dilatation</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
</tbody>
</table>


Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page EB-1. All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
### Arterial Evaluation

#### SMA Contact
- **Degree of solid soft-tissue contact**
  - Present
  - Absent
- **Degree of increased hazy attenuation/stranding contact**
  - ≤180
  - >180
- **Focal vessel narrowing or contour irregularity**
  - Present
  - Absent
- **Extension to first SMA branch**
  - Present
  - Absent

#### Celiac Axis Contact
- **Degree of solid soft-tissue contact**
  - Present
  - Absent
- **Degree of increased hazy attenuation/stranding contact**
  - ≤180
  - >180
- **Focal vessel narrowing or contour irregularity**
  - Present
  - Absent
- **Extension to celiac axis**
  - Present
  - Absent
- **Extension to bifurcation of right/left hepatic artery**
  - Present
  - Absent

#### CHA Contact
- **Degree of solid soft-tissue contact**
  - Present
  - Absent
- **Degree of increased hazy attenuation/stranding contact**
  - ≤180
  - >180
- **Focal vessel narrowing or contour irregularity**
  - Present
  - Absent
- **Extension to celiac axis**
  - Present
  - Absent
- **Extension to bifurcation of right/left hepatic artery**
  - Present
  - Absent

#### Arterial Variant
- **Variant anatomy**
  - Accessory right hepatic artery
  - Replaced right hepatic artery
  - Replaced common hepatic artery
  - Others (origin of replaced or accessory artery) __________________________
- **Variant vessel contact**
  - Present
  - Absent
- **Degree of solid soft-tissue contact**
  - ≤180
  - >180
- **Degree of increased hazy attenuation/stranding contact**
  - ≤180
  - >180
- **Focal vessel narrowing or contour irregularity**
  - Present
  - Absent

---

### Venous Evaluation

<table>
<thead>
<tr>
<th>MPV Contact</th>
<th>Present</th>
<th>Absent</th>
<th>Complete occlusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Degree of solid soft-tissue contact</td>
<td>≤180</td>
<td>&gt;180</td>
<td></td>
</tr>
<tr>
<td>Degree of increased hazy attenuation/stranding contact</td>
<td>≤180</td>
<td>&gt;180</td>
<td></td>
</tr>
<tr>
<td>Focal vessel narrowing or contour irregularity (tethering or tear drop)</td>
<td>Present</td>
<td>Absent</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SMV Contact</th>
<th>Present</th>
<th>Absent</th>
<th>Complete occlusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Degree of solid soft-tissue contact</td>
<td>≤180</td>
<td>&gt;180</td>
<td></td>
</tr>
<tr>
<td>Degree of increased hazy attenuation/stranding contact</td>
<td>≤180</td>
<td>&gt;180</td>
<td></td>
</tr>
<tr>
<td>Focal vessel narrowing or contour irregularity (tethering or tear drop)</td>
<td>Present</td>
<td>Absent</td>
<td></td>
</tr>
<tr>
<td>Extension</td>
<td>Present</td>
<td>Absent</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Other</th>
<th>Present</th>
<th>Absent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thrombus within vein (tumor, bland)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MPV</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SMV</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Splenic vein</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Venous collaterals</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Around pancreatic head</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Porta hepatis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Root of the mesentery</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left upper quadrant</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---


**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page EB-1. All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
## PRINCIPLES OF DIAGNOSIS, IMAGING, AND STAGING
### PANCREATIC CANCER RADIOLOGY REPORTING TEMPLATE

<table>
<thead>
<tr>
<th>Extrapancreatic Evaluation</th>
<th>Present</th>
<th>Suspicious</th>
<th>Indeterminate</th>
<th>Likely benign</th>
<th>Absent</th>
<th>Present</th>
<th>Suspicious</th>
<th>Porta hepatis</th>
<th>Celiac</th>
<th>Splenic hilum</th>
<th>Paraaortic</th>
<th>Aortocaval</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liver lesions</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>Peritoneal or omental nodules</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>Ascites</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>Suspicious lymph nodes</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>Other extrapancreatic disease</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td></td>
<td>Present</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>Impression</td>
<td></td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>Tumor size:</td>
<td></td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>Tumor location:</td>
<td></td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>Vascular contact</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td></td>
<td>Present</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td></td>
<td></td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>Metastasis</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td></td>
<td>Present</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
</tbody>
</table>


Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page EB-1. All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
CRITERIA DEFINING RESECTABILITY STATUS

<table>
<thead>
<tr>
<th>Resectability Status</th>
<th>Arterial</th>
<th>Venous</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resectable</td>
<td>No arterial tumor contact (celiac axis [CA], superior mesenteric artery [SMA], or common hepatic artery [CHA]).</td>
<td>No tumor contact with the superior mesenteric vein (SMV) or portal vein (PV) or ≤180° contact without vein contour irregularity.</td>
</tr>
</tbody>
</table>
| Borderline Resectable | **Pancreatic head/uncinate process:**  
  • Solid tumor contact with CA without extension to celiac axis or hepatic artery bifurcation allowing for safe and complete resection and reconstruction.  
  • Solid tumor contact with the SMA of ≤180°  
  • Solid tumor contact with variant arterial anatomy (ex: accessory right hepatic artery, replaced right hepatic artery, replaced CHA, and the origin of replaced or accessory artery) and the presence and degree of tumor contact should be noted if present as it may affect surgical planning.  
  **Pancreatic body/tail:**  
  • Solid tumor contact with the CA of ≤180°  
  • Solid tumor contact with the CA of >180° without involvement of the aorta and with intact and uninvolved gastroduodenal artery thereby permitting a modified Appleby procedure [some members prefer this criteria to be in the unresectable category]. | **Solid tumor contact with the SMV or PV of >180°, contact of ≤180° with contour irregularity of the vein or thrombosis of the vein but with suitable vessel proximal and distal to the site of involvement allowing for safe and complete resection and vein reconstruction.**  
  • Solid tumor contact with the inferior vena cava (IVC). |
| Unresectable         | **Distant metastasis (including non-regional lymph node metastasis)**  
  **Head/uncinate process:**  
  • Solid tumor contact with SMA >180°  
  • Solid tumor contact with the CA >180°  
  • Solid tumor contact with the first jejunal SMA branch  
  **Body and tail:**  
  • Solid tumor contact of >180° with the SMA or CA  
  • Solid tumor contact with the CA and aortic involvement | **Head/uncinate process**  
  • Unreconstructible SMV/PV due to tumor involvement or occlusion (can be due to tumor or bland thrombus)  
  • Contact with most proximal draining jejunal branch into SMV  
  **Body and tail**  
  • Unreconstructible SMV/PV due to tumor involvement or occlusion (can be due to tumor or bland thrombus) |


2Solid tumor contact may be replaced with increased hazy density/stranding of the fat surrounding the peri-pancreatic vessels (typically seen following neoadjuvant therapy); this finding should be reported on the staging and follow-up scans. Decision on resectability status should be made in these patients, in consensus at multidisciplinary meetings/discussions.

Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page EB-1. All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
Pancreatoduodenectomy (Whipple technique)
The goals of surgical extirpation of pancreatic carcinoma focus on the achievement of an R0 resection, as a margin-positive specimen is associated with poor long-term survival.1,2 Achievement of a margin-negative dissection must focus on meticulous perivascular dissection of the lesion in resectional procedures, recognition of the need for vascular resection and/or reconstruction, and the potential need for extra-pancreatic organ resection. Of course the biology of the cancer might not allow for an R0 resection even with the most meticulous surgery.
- Medial dissection of pancreatic head lesions is best achieved by complete mobilization of the PV and SMV from the uncinate process (assuming no evidence of tumor infiltration). Skeletalization of the lateral, posterior, and anterior borders of the superior mesenteric artery down to the level of the adventitia will maximize uncinate yield and radial margin.3,4
- In the absence of frank venous occlusion noted on preoperative imaging, the need for lateral venorrhaphy or complete portal or SMV resection and reconstruction to achieve an R0 resection may be suggested but is often not known until division of the pancreatic neck has occurred. Tethering of the carcinoma to the lateral wall of the PV is not uncommon and requires careful dissection to free the vein from the pancreatic head if in fact it is possible to do so. Differentiation of tumor infiltration into the vein wall from tumor-related desmoplasia is frequently impossible to ascertain. Data support an aggressive approach to partial or complete vein excision if tumor infiltration is suspected, although acceptance of this concept (particularly with respect to vein resection) is not universal.
- While further data with respect to arterial resection are clearly needed, judicious utilization of this technique would appear to be reasonable in very select populations.

Distal Pancreatectomy
The goals of left-sided resection are similar to those of pancreatoduodenectomy, although they are often more difficult to achieve due to the advanced stage at which most of these cancers are discovered.
- An R0 distal pancreatectomy for adenocarcinoma mandates en bloc organ removal beyond that of the spleen alone in up to 40% of patients.5,6
- Similar to the Whipple procedure, lateral venorrhaphy, vein excision and reconstruction, and dissection to the level of the celiac axis and SMA adventitia should be performed if complete tumor clearance can be achieved.5,7
- Spleen preservation is not indicated in adenocarcinoma.

Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page EB-1.
All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
 PATHOLOGIC ANALYSIS: SPECIMEN ORIENTATION, HISTOLOGIC SECTIONS, AND REPORTING

The primary purpose of pathologic analysis of the pancreatic specimen is to determine the pathologic stage of the tumor by evaluating the type, grade, size, and extent of the cancer.

Whipple Specimen

- Specimen orientation
  - Specimen orientation and inking involves both the pathologist and surgeon as this will help to ensure accurate assessment of the size and extent of the tumor. There should be either direct communication between the surgeon and pathologist for proper orientation and margin identification, or the surgeon should identify the important margins with a clearly understood and documented method (e.g., written on the pathology requisition); for example: the distal and proximal margins of the SMV and SMA and the bile duct margin should be marked.

- Margins
  - Definitions of the margins and uniformity of nomenclature are critical to accurate reporting.
    - SMA (retroperitoneal/uncinate) Margin: The most important margin is the soft tissue directly adjacent to the proximal 3–4 cm of the superior mesenteric artery. This margin is often referred to as the “retroperitoneal margin” or “posterior margin,” but has also been referred to as the “uncinate margin” or “mesenteric margin.” More recently, this margin has been referred to as the “SMA margin” to correlate with its location on the specimen. Radial rather than en face sections of this margin will more clearly demonstrate how closely this margin is approached by tumor. The simple step of palpating the specimen can help guide the pathologist as to the best spot along the SMA margin to select for sampling.
    - Posterior Margin: This margin is from the posterior caudad aspect of the pancreatic head that merges with the uncinate margin and that appears to be covered by loose connective tissue. Radial rather than en face sections of this margin will more clearly demonstrate whether it is involved by tumor. In some instances this margin can be included in the same section as the SMA margin section.
    - Portal Vein Groove Margin: This is the smooth-surfaced groove on the posterior-medial surface of the pancreatic head that rests over the PV. Radial rather than en face sections of this margin will more clearly demonstrate whether it is involved by tumor and also will provide the distance of the tumor from the margin. As is true for the posterior margin, in some instances this margin can be included in the same section as the SMA margin section.
    - Portal Vein Margins: If an en bloc partial or complete vein resection is added to the surgical specimen it should be marked separately. En face proximal and distal end margins of the vein should be separately submitted as Proximal Portal Vein Margin and Distal Portal Vein Margin. A section documenting tumor invasion into the vein wall should also be submitted. If feasible, this section should be a full thickness of the vein wall demonstrating the depth of tumor invasion, as this has been shown to have prognostic value.1
    - Pancreatic Neck (transection) Margin: This is the en face section of the transected pancreatic neck. The section should be placed into the cassette with the true margin facing up so that the initial section into the block represents the true surgical margin.
    - Bile Duct Margin: This is the en face section of the bile duct end. The section should be removed from the unopened duct and placed into the cassette with the true margin facing up so that the initial section into the block represents the true surgical margin.
  - Other margins analyzed in Whipple specimens include the proximal and distal enteric margins (en face sections) and anterior surface (closest representative). The anterior surface is not a true margin, but identification and reporting of this surface when positive may portend a risk of local recurrence, and therefore should be reported in all cases.2-5
  - Collectively, these pancreatic tissue surfaces constitute the circumferential transection margin. Designating the various specific margins with different colored inks will allow recognition on microscopy.

Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page EB-1. All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

Continued on next page
PATHOLOGIC ANALYSIS: SPECIMEN ORIENTATION, HISTOLOGIC SECTIONS, AND REPORTING

• Histologic sectioning
  ▶ The approach to histologic sectioning is determined by the unique characteristics of the tumor, but is also influenced by institutional preferences, expertise, and experience. Options include axial, bi- or multi-valve slicing, and perpendicular sliding. Some experts in the field bisect the pancreas along probes placed in the bile and pancreatic ducts and then serially section along each half of the pancreas.
  ▶ Axial slicing provides an overall assessment of the epicenter of the tumor relative to the ampulla, bile duct, duodenum, and pancreas, and all of the pancreatic circumferential tissue margins mentioned above.
  ▶ There is no one correct way to dissect a Whipple specimen. The most important aspects of dissection are clear and accurate assessment of the margins.
  ▶ It is currently unknown what constitutes an adequate margin in pancreatic carcinoma resection specimens. A standardized definition of this would allow better stratification of patients into adjuvant regimens following surgical extirpation. For instance, if less than 1-mm clearance is associated with an unacceptably high incidence of local recurrence, then strong consideration for postoperative radiation therapy (RT) might be indicated if not received preoperatively. Tumor clearance should be reported in millimeters for all margins described above to allow prospective accumulation of these important data for future analysis.
  ▶ Attached organs resected with the specimen en bloc require serial sectioning to assess not only direct extension, but metastatic deposits as well. One section that demonstrates direct invasion of the organ and/or a separate metastatic deposit is required.
  ▶ Consider frozen section analysis of the pancreatic neck and bile duct. To avoid cautery artifact that may confound the frozen section, assess the pancreatic neck and bile duct at time of surgery by frozen section approximately 5 mm from the transection margin. If tumor is located within 5 mm of margins, consider further excision of the pancreas and bile duct to ensure at least 5 mm of clearance.

Distal Pancreatectomy

• In left-sided resections the peripancreatic soft tissue margins and the pancreatic neck are assessed. Additionally, involvement of the splenic vessels should be documented and invasion of the spleen is important to determine, as direct tumor invasion constitutes a pT3 pathologic stage.

• Margin definitions are as follows:
  ▶ Proximal Pancreatic (transection) Margin: A full en face section of the pancreatic body along the plane of transection. The section should be placed into the cassette with the true margin facing up so that the initial section into the block represents the true surgical margin. More than one block may be needed.
  ▶ Anterior (cephalad) Peripancreatic (peripheral) Surface: This surface demonstrates the relationship between the tumor and the anterior or cephalad peripancreatic soft tissue and can be representative if grossly positive. Several such sections should be taken closest to the tumor to document absence of involvement; the exact number is dependent on the degree of ambiguity of gross involvement.
  ▶ Posterior (caudad) Peripancreatic (peripheral) Margin: This margin demonstrates the relationship between the tumor and the posterior or caudad peripancreatic soft tissue and can be representative if grossly positive. Several such sections should be taken closest to the tumor to document absence of involvement; the exact number is dependent on the degree of ambiguity of gross involvement.
PATHOLOGIC ANALYSIS: SPECIMENT ORIENTATION, HISTOLOGIC SECTIONS, AND REPORTING

• The NCCN Pancreatic Cancer Panel currently supports pathology synoptic reports from the College of American Pathologists (CAP). The proposal included herein is an abbreviated minimum analysis of pancreatic cancer specimens from the CAP recommendations. In addition to the standard TNM staging, other variables are included, all of which have prognostic implications in the evolution of this disease.\(^6,7\)

• Treatment effect should be assessed and reported by the pathologist as tumor viability may impact postoperative therapy options. For more information about pathologic analysis, refer to the CAP Cancer Protocol Template for carcinoma of the pancreas. (Branton P, et al. Protocol for the Examination of Specimens from Patients with Carcinoma of the Exocrine Pancreas. College of American Pathologists. Cancer Protocol Templates; 2016.)

Specimen type

• Tumor size (obtained from careful gross measurement of the largest dimension of the tumor in cm)
• Histologic grade (G (x-4))
• Primary tumor extent of invasion (T (x-4))
• Regional lymph nodes (N (x-1))\(^a\)
  ‣ # Nodes recovered
  ‣ # Nodes involved
• Metastases (M (0-1))
• Margins: (Involvement should be defined and surgical clearance measured in mm)
  ‣ Whipple resection:
    ‣ SMA (retroperitoneal/uncinate) Margin
    ‣ Posterior Margin
    ‣ Portal Vein Groove Margin
    ‣ Pancreatic Neck (transsection) Margin
    ‣ Bile Duct Margin
    ‣ Enteric Margins
    ‣ Anterior Surface
  ‣ Distal pancreatectomy:
    ‣ Proximal Pancreatic (transsection) Margin
    ‣ Anterior (cephalad) Peripancreatic (peripheral) Surface (optional)
    ‣ Posterior (caudad) Peripancreatic (peripheral) Margin
• Lymphatic (small vessel) Invasion (L)
• Vascular (large vessel) Invasion (V)
• Perineural Invasion (P)
• Additional pathologic findings
  ‣ Pancreatic Intraepithelial Neoplasia
  ‣ Chronic Pancreatitis
Final stage: G, T, N, M, L, V, P

\(^a\)Every effort should be made to identify all regional lymph nodes within the pancreatectomy specimen (see Discussion).
PATHOLOGIC ANALYSIS: SPECIMEN ORIENTATION, HISTOLOGIC SECTIONS, AND REPORTING

References


2 Verbeke CS. Resection margins and R1 rates in pancreatic cancer--are we there yet? Histopathol Jun 2008;52(7):787-796.


Objectives: Prevent and ameliorate suffering while ensuring optimal quality of life

- Biliary obstruction
  - Endoscopic biliary metal stent (preferred method)
  - Percutaneous biliary drainage with subsequent internalization
  - Open biliary-enteric bypass

- Gastric outlet obstruction
  - Good performance status
    - Gastrojejunostomy (open or laparoscopic) ± J-tube
    - Consider enteral stent\(^b\)
  - Poor performance status
    - Enteral stent\(^b\)
    - Venting percutaneous endoscopic gastrostomy (PEG) tube for gastric decompression

- Severe tumor-associated abdominal pain that is unresponsive to optimal, around-the-clock narcotic administration, or if patient experiences undesirable narcotic associated side effects (See NCCN Guidelines for Adult Cancer Pain)
  - EUS-guided celiac plexus neurolysis (fluoroscopic- or CT-guided if unavailable)
  - Consider palliative radiation with or without chemotherapy if not already given as part of primary therapy regimen. See Principles of Radiation Therapy (PANC-F).

- Depression, pain, and malnutrition (See NCCN Guidelines for Supportive Care)
  - Formal Palliative Medicine Service evaluation when appropriate
  - Nutritional evaluation with a registered dietitian when appropriate

- Pancreatic exocrine insufficiency
  - Pancreatic enzyme replacement

- Thromboembolic disease
  - Low-molecular-weight heparin preferred over warfarin\(^c\)

\(^a\)Palliative surgical procedures are best reserved for patients with a longer life expectancy.
\(^b\)Placement of an enteral stent is particularly important for patients with poor performance status and should be done after biliary drainage is assured.
PRINCIPLES OF RADIATION THERAPY (1 OF 9)

General Principles:

• Patients with pancreatic cancer are best managed by a multidisciplinary team.\(^1\)
• The role of laparoscopic evaluation prior to radiation therapy (RT) is controversial, although common at some institutions, especially when neoadjuvant chemoradiation is planned.\(^2\)
• Prior to initiation of RT, staging is optimally determined with a modern contrast-enhanced abdominal CT (3D-CT) and/or MRI with thin cuts through the pancreas.
• If patients present with biliary obstruction (jaundice/elevated direct bilirubin), plastic or metal stents should be placed by endoscopic retrograde cholangiopancreatography (ERCP) prior to initiation of RT. A percutaneous drain can also be used if ERCP stent placement is unsuccessful. (See PANC-E)
• Stereotactic body radiotherapy (SBRT) should be avoided if direct invasion of the bowel or stomach is observed on CT, MRI, or endoscopy.
• Recommendations for RT for such patients are typically made based upon five clinical scenarios:
  1) Resectable/Borderline resectable (neoadjuvant)
  2) Locally advanced/unresectable (definitive)
  3) Resectable (adjuvant)
  4) Palliative (non-metastatic and metastatic)
  5) Recurrent

For definitions of these scenarios, See Criteria Defining Resectability Status (PANC-B).

• In all scenarios, the goal of delivering RT is to sterilize vessel margins, and enhance the likelihood of a margin-negative resection, and provide adequate local control to prevent or delay progression of local disease while minimizing the risk of RT exposure to surrounding organs at risk (OARs). Radiation can also be used to palliate pain and bleeding or relieve obstructive symptoms in patients who have progressed or recurred locally.

**Note: It is not known whether one regimen is necessarily more effective than another in the 5 clinical scenarios mentioned above. Therefore, the following recommendations are given as examples of commonly utilized regimens. However, other recommendations based on similar principles are acceptable. See Principles of Chemotherapy (PANC-G) for details on chemotherapy regimens used for chemoradiation.**
PRINCIPLES OF RADIATION THERAPY (2 of 9)
TREATMENT PLANNING: RADIATION DELIVERY

Simulation:

• For localized pancreatic cancer (neoadjuvant, borderline, and unresectable), placement of 1–5 (preferably ≥3) gold fiducial markers is recommended for targeting purposes. Place fiducial markers directly into the tumor and/or periphery under endoscopic ultrasound (preferred) or CT guidance. Stents can assist with targeting; however, they can shift and are therefore less reliable than fiducials.

• Position patient supine with arms up in an Alpha Cradle or equivalent immobilization device that will be custom-made for each patient. The simulation scan range should include approximately T4/T5 to L5/S1 (upper abdomen).

• CT simulation (2- to 3-mm slices) should be done with IV (assuming adequate kidney function) and oral contrast. Patients with a contrast allergy may premedicate with steroids and antihistamines. If premedication is contraindicated, use an MRI (ideally in a similar treatment position) or with a recent diagnostic scan for treatment planning, if available.

• For body and tail lesions it may be ideal to simulate with an empty stomach to increase the separation from the tumor. Ideally, the patient should be given the same volume of water prior to treatment each day to mimic simulation anatomy.

Motion Management:

• Respiratory motion should be accounted for determining the internal target volume (ITV) during a 4D-CT scan, breath hold with active breathing control (ABC), or a compression device.

• Motion management using respiratory gating or breath-hold, respiratory tracking, or abdominal compression should be used to reduce cranio-caudal fiducial marker motion from typically 11- to 22-mm peak to ≤5 mm.

• Use of respiratory gating, ABC, or respiratory tracking requires real-time cone-beam CT, fluoroscopy, or kV imaging for setup and to confirm fiducial location during treatment.

• 3-D conformal RT (3D-CRT), intensity-modulated RT (IMRT), and stereotactic body RT (SBRT) with breathhold/gating techniques can result in improved planning target volume (PTV) coverage with decreased dose to OARs.

Dose and Fractionation:

• It is imperative to evaluate the dose-volume histogram (DVH) of the PTV and the critical OARs such as the duodenum, stomach, liver, kidneys, spinal cord, and bowel. No clear dose constraints for SBRT currently exist but are emerging.

• (See Table 1. Normal Tissue Dose Volume Recommendations) While these examples of limits are empirical they differ based on dose per fraction, total dose delivered, and disease status (adjuvant vs. unresectable). Studies have shown that the tolerability of radiation is largely dependent on PTV size/elective nodal irradiation (ENI), types of concurrent systemic/targeted therapy, and whether conformal (3-D, IMRT, SBRT) vs. conventional radiation is used.
Resectable/Borderline Resectable (Neoadjuvant):

- Data are limited to support specific neoadjuvant treatment options for resectable or borderline resectable pancreatic cancer; however, data suggest that RT in the neoadjuvant setting may lead to an increased likelihood of a margin-negative resection. It is sometimes recommended that patients receive ≥2–6 cycles of neoadjuvant chemotherapy prior to RT (See Principles of Chemotherapy, PANC-G).
- Neoadjuvant therapy for patients with resectable tumors should ideally be conducted in a clinical trial.
- Subsequent chemoradiation is sometimes an option following neoadjuvant chemotherapy (See Principles of Chemotherapy, PANC-G)
  - For chemoradiation, the following RT doses have been reported: 36 Gy in 2.4 Gy fractions or 45–54 Gy in 1.8–2.0 Gy fractions (doses higher than 54 Gy may be considered if clinically appropriate).
- For resectable cases, it may be reasonable to resect within a few weeks of RT. However, with borderline resectable cases, it may be optimal to resect 4–8 weeks after RT to allow for downstaging and sterilization of the margin. Surgical resection can be performed >8 weeks following RT; however, radiation-induced fibrosis may potentially increase the difficulty of the resection.
- Treatment Planning:
  - ENI is controversial for unresectable/neoadjuvant/borderline resectable disease. If ENI is done, patients should receive concurrent fluoropyrimidine-based chemotherapy or dose-reduced gemcitabine. (See Principles of Chemotherapy, PANC-G)
Resected (Adjuvant):a

• In the adjuvant setting, treatment with chemotherapy is recommended; the role of radiation is being evaluated in clinical studies.

• After resection, patients may receive adjuvant RT for features that pose them at a high risk for local recurrence (ie, positive resection margins and/or lymph nodes).

• If no prior neoadjuvant therapy and no evidence of recurrence or metastatic disease after resection, RT is included in the following adjuvant therapy option:
  ▶ Induction chemotherapy followed by chemoradiation ± subsequent chemotherapy (See Principles of Chemotherapy, PANC-G)
    ◇ For chemoradiation, RT dose generally consists of 45–46 Gy in 1.8–2.0 Gy fractions to the tumor bed, surgical anastomoses (hepaticojejunostomy and gastrojejunostomy may be omitted if clinically appropriate), and adjacent lymph node basins, followed by an additional 5–9 Gy to the tumor bed and anastomoses, if clinically appropriate.11 Careful attention to the bowel and stomach dose is warranted. Escalation above 54 Gy should ideally be avoided or used only in a clinical trial.

• Treatment Planning:
  ▶ Several clinical trials (RTOG) now refer to atlases to assist with contouring and adjuvant RT planning: (http://www.rtog.org/CoreLab/ContouringAtlases.aspx).
  ▶ Preoperative CT scans and strategically placed surgical clips are used to determine the tumor bed, ideally with the surgeon’s assistance.
  ▶ A clinical target volume (CTV) includes high-risk peri-pancreatic lymph nodes, anastomoses (hepaticojejunostomy and gastrojejunostomy may be omitted if clinically appropriate), pancreatic tumor bed derived from presurgical imaging, and surgical clips. CTV expansions are needed to include possible microscopic disease. Further expansion to PTV includes ITV for target/breathing motion and additional patient setup error margin (SM).5,12,13 Image guidance methods should be considered when constructing the PTV. OARs should also be contoured and evaluated in the DVH.

---

a Adjuvant options listed apply only to patients who did not receive prior neoadjuvant therapy. For those who received prior neoadjuvant therapy, the adjuvant therapy options are dependent on the response to neoadjuvant therapy and other clinical considerations.

Continued on next page
Unresectable/Locally Advanced (Definitive):

- For unresectable/locally advanced pancreatic cancer, the goal of RT is to prevent or delay local progression that may result in pain and/or local obstructive symptoms.

- Data are limited to support specific RT recommendations for unresectable disease. Options may include:
  - Chemoradiation\(^b\) or SBRT\(^b,c\) in selected patients who are not candidates for combination chemotherapy
  - Induction chemotherapy followed by chemoradiation or SBRT in select patients (locally advanced without systemic metastases)\(^b,c,15-19\)
    - For chemoradiation, RT dose generally consists of 45–54 Gy in 1.8–2.0 Gy fractions. Doses higher than 54 Gy may be considered on a clinical trial.
    - For chemoradiation options, see Principles of Chemotherapy (PANC-G).
    - There are limited data to support a specific RT dosing for SBRT; therefore, it should preferably be utilized as part of a clinical trial or at an experienced, high-volume center. SBRT doses of 3 fractions (total dose 30–45 Gy) or 5 fractions (total dose 25–45 Gy) have been reported.\(^19\)

- For chemoradiation, standard margin expansions for unresectable cases include the gross tumor volume (GTV) and any pathologic lymph nodes plus a 0.5–1.5 cm margin to target microscopic extension (CTV) and an additional 0.5–2 cm volume to account for tumor/breathing motion and patient setup errors (PTV). With these expansions, peripancreatic nodes are generally included. For free-breathing radiation treatments it is important to perform a 4D-CT simulation to assess tumor motion due to breathing and determine the ITV.

\(^b\)SBRT should be delivered at an experienced, high-volume center with technology that allows for image-guided radiation therapy or on a clinical trial.\(^21,22\) Furthermore, since patients with locally advanced disease are less likely to undergo surgery, every effort should be made to limit dose to the duodenum and stomach in order to limit treatment-related toxicity.

\(^c\)SBRT should be avoided if direct invasion of the bowel or stomach is observed on CT, MRI, or endoscopy.
Palliative (Non-Metastatic and Metastatic):

- The goal of palliative RT is to relieve pain and bleeding and/or ameliorate local obstructive symptoms in patients with non-metastatic or metastatic disease. See Principles of Palliation and Supportive Care (PANC-E).
  - Non-metastatic disease: Palliative RT can be considered for patients who are elderly and/or not candidates for definitive therapy due to poor performance status or comorbidities.
  - Metastatic Disease:
    - Metastatic sites causing pain (ie, osseous) may be palliated with a short course of RT (1–15 treatments).
    - RT alone to the primary tumor plus a small margin is reasonable for patients with metastatic disease who require local palliation for obstruction, pain refractory to narcotic therapy, or bleeding.20
- For patients with severe tumor-associated abdominal pain, palliative RT may be considered with or without chemotherapy if not already given as part of primary therapy.
- Palliative RT dose of 30 Gy in 10 fractions is commonly used.
  - For chemoradiation, RT dose generally consists of 25–36 Gy in 2.4–5 Gy fractions. Dose and fractionation recommendations should take into account burden of metastatic disease, normal tissue tolerance, and expected survival.

Recurrent Pancreatic Cancer (pancreatic bed):

- Data are limited to support specific RT recommendations for recurrent pancreatic cancer; the options for patients with recurrent unresectable disease may include:
  - Consider chemoradiation (if not previously done) (See Principles of Chemotherapy, PANC-G)
    - For chemoradiation, RT dose generally consists of 45–54 Gy in 1.8–2.0 Gy fractions. Doses higher than 54 Gy may be considered on a clinical trial.
  - Consider induction chemotherapy followed by SBRT (if radiation not previously done)b,c,17-19
    - There are limited data to support specific RT dosing for SBRT; therefore, it should preferably be utilized as part of a clinical trial or at an experienced, high-volume center. SBRT doses of 3 fractions (total dose 30–45 Gy) or 5 fractions (total dose 25–45 Gy) have been reported.19

bSBRT should be delivered at an experienced, high-volume center with technology that allows for image-guided radiation therapy or on a clinical trial.21,22 Furthermore, since patients with locally advanced disease are less likely to undergo surgery, every effort should be made to limit dose to the duodenum and stomach in order to limit treatment-related toxicity.

cSBRT should be avoided if direct invasion of the bowel or stomach is observed on CT, MRI, or endoscopy.
## PRINCIPLES OF RADIATION THERAPY (7 of 9)

Table 1: Normal Tissue Dose Volume Recommendations for Chemoradiation

<table>
<thead>
<tr>
<th>Organ at Risk (OAR)</th>
<th>Neoadjuvant/Definitive/Palliative and Recurrent Recommendations&lt;sup&gt;d&lt;/sup&gt;</th>
<th>Adjuvant Recommendations&lt;sup&gt;e&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kidney (right and left)</td>
<td>Not more than 30% of the total volume can receive ≥18 Gy. If only one kidney is functional, not more than 10% of the volume can receive ≥18 Gy.</td>
<td>If two functioning kidneys present, not more than 50% of the right and 65% of the left kidney should receive &gt;18 Gy. For IMRT planning mean dose to bilateral kidneys should be ≤18 Gy. If only one kidney is present not more than 15% should receive ≥18 Gy and no more than 30% should receive ≥14 Gy.</td>
</tr>
<tr>
<td>Stomach, duodenum, jejunum</td>
<td>Max dose ≤55 Gy; not more than 30% of the volume can be between 45 and 55 Gy.</td>
<td>Max dose ≤55 Gy; &lt;10% of each organ volume can receive between 50–53.99 Gy. &lt;15% of each organ volume can receive 45–49.99 Gy.</td>
</tr>
<tr>
<td>Liver</td>
<td>Mean dose cannot exceed 30 Gy.</td>
<td>Mean liver dose ≤25 Gy.</td>
</tr>
<tr>
<td>Spinal cord</td>
<td>Max dose to a volume of ≥0.03 cc must be ≤45 Gy.</td>
<td>Max dose ≤45 Gy.</td>
</tr>
</tbody>
</table>

<sup>d</sup>Adapted from RTOG 0936 (3-D conformal, 1.8–50.5) and RTOG 1102 (IMRT, 2.2–54 Gy)

<sup>e</sup>Adapted from RTOG 0848 (3-D or IMRT)
Table 2: Commonly Used Radiation Therapy Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>3D-CRT</td>
<td>3-D Conformal Radiation Therapy</td>
</tr>
<tr>
<td>IMRT</td>
<td>Intensity-Modulated Radiation Therapy</td>
</tr>
<tr>
<td>SBRT</td>
<td>Stereotactic Body Radiation Therapy</td>
</tr>
<tr>
<td>SABR</td>
<td>Stereotactic Ablative Radiation Therapy</td>
</tr>
<tr>
<td>EBRT</td>
<td>External Beam Radiation Therapy</td>
</tr>
<tr>
<td>ENI</td>
<td>Elective Nodal Irradiation</td>
</tr>
<tr>
<td>IORT</td>
<td>Intraoperative Radiation Therapy</td>
</tr>
<tr>
<td>DVH</td>
<td>Dose-Volume Histogram</td>
</tr>
<tr>
<td>GTV</td>
<td>Gross Tumor Volume</td>
</tr>
<tr>
<td>CTV</td>
<td>Clinical Target Volume</td>
</tr>
<tr>
<td>IM</td>
<td>Internal Margin: Variations in shape/size of CTV due to respiration and adjacent structures</td>
</tr>
<tr>
<td>ITV</td>
<td>Internal Target Volume: encompasses the CTV and IM (ITV = CTV + IM)</td>
</tr>
<tr>
<td>PTV</td>
<td>Planning Target Volume</td>
</tr>
<tr>
<td>BED</td>
<td>Biologically Effective Dose</td>
</tr>
<tr>
<td>OAR</td>
<td>Organ At Risk</td>
</tr>
<tr>
<td>ABC</td>
<td>Airway Breathing Control</td>
</tr>
<tr>
<td>IGRT</td>
<td>Image-Guided Radiation Therapy</td>
</tr>
<tr>
<td>4DCT</td>
<td>Four-Dimensional Computed Tomography</td>
</tr>
<tr>
<td>CBCT</td>
<td>Cone Beam Computed Tomography</td>
</tr>
</tbody>
</table>
PRINCIPLES OF RADIATION THERAPY (9 of 9)

References

General Principles:
• Systemic therapy is used in all stages of pancreatic cancer, including neoadjuvant (resectable or borderline resectable), adjuvant, locally advanced unresectable, and metastatic disease.
• Goals of systemic therapy should be discussed with patients prior to initiation of therapy, and enrollment in a clinical trial is strongly encouraged.
• Close follow-up of patients undergoing chemotherapy is indicated.
• For regimens where RT or chemoradiation is included, see Principles of Radiation Therapy (PANC-F) for more details related to radiation delivery, including recommended technique and dose.

Neoadjuvant Therapy (Resectable/Borderline Resectable Disease)
• There is limited evidence to recommend specific neoadjuvant regimens off-study, and practices vary with regard to the use of chemotherapy and radiation. Subsequent chemoradiation is sometimes included. When considering neoadjuvant therapy, consultation at a high-volume center is preferred. When feasible, treatment with neoadjuvant therapy at or coordinated through a high-volume center is preferred. Participation in a clinical trial is encouraged.
• Options include:
  ▶ FOLFIRINOX ± subsequent chemoradiation*
  ▶ Gemcitabine + albumin-bound paclitaxel ± subsequent chemoradiation*
  ▶ Gemcitabine + cisplatin (≥2–6 cycles) followed by chemoradiation* (reserved for patients with BRCA1/BRCA2 or other DNA repair mutations)

*Chemoradiation:
• Fluoropyrimidine (capecitabine, CI 5-FU, or 5-FU/cisplatin) + concurrent RT (preferred)
• Gemcitabine + concurrent RT

Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page EB-1. All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
Adjuvant Therapy

- The CONKO 001 trial demonstrated significant improvements in disease-free survival and overall survival with use of postoperative gemcitabine as adjuvant chemotherapy versus observation in resectable pancreatic adenocarcinoma.\(^1\)
- ESPAC-3 study results showed no significant difference in overall survival between 5-FU/leucovorin versus gemcitabine following surgery. When the groups receiving adjuvant 5-FU/leucovorin and adjuvant gemcitabine were compared, median survival was 23.0 months and 23.6 months, respectively.\(^2\)
- Data from ESPAC-4 support the use of gemcitabine combined with capecitabine (1,660 mg/m\(^2\)/d d1–21 q 4 weeks) with superiority demonstrated compared to gemcitabine alone (HR, 0.82; 95% CI, 0.68, 0.98; \(P = .032\)).\(^3\)
- No significant differences were observed in the RTOG 97-04 study comparing pre- and post-chemoradiation 5-FU with pre- and post-chemoradiation gemcitabine for postoperative adjuvant treatment.\(^4\)

- Recommended adjuvant therapy options apply to patients who did not receive prior neoadjuvant therapy. For those who received prior neoadjuvant therapy, the adjuvant therapy options are dependent on the response to neoadjuvant therapy and other clinical considerations.

- Options include:
  - Gemcitabine (category 1)
  - 5-FU/leucovorin (category 1)
  - Gemcitabine + capecitabine (category 1)
  - Continuous infusion 5-FU (CI 5-FU)
  - Capecitabine (category 2B)
  - Induction chemotherapy (gemcitabine, 5-FU/leucovorin, or CI 5-FU) followed by chemoradiation*\(^4\)
  - Induction chemotherapy (gemcitabine, 5-FU/leucovorin, or CI 5-FU) followed by chemoradiation* followed by subsequent chemotherapy:
    - Gemcitabine followed by chemoradiation* followed by gemcitabine
    - Bolus 5-FU/leucovorin followed by chemoradiation* followed by bolus 5-FU/leucovorin
    - CI 5-FU followed by chemoradiation* followed by CI 5-FU

**Chemoradiation:**
- Fluoropyrimidine (capecitabine, CI 5-FU, or 5-FU/cisplatin) + concurrent RT (preferred)
- Gemcitabine + concurrent RT\(^5\)
Locally Advanced/Unresectable Disease (First-Line Therapy)

- Depending on performance status, mono- or combination systemic chemotherapy may be considered as initial therapy prior to radiation (chemoradiation or SBRT) for appropriate patients with locally advanced, unresectable disease.\(^a\)
- Patients should be evaluated for recovery from hematologic and non-hematologic toxicity prior to initiation of chemoradiation.

- Options for patients with good performance status include:
  - FOLFIRINOX\(^a,b,6\)
  - Gemcitabine + albumin-bound paclitaxel\(^a,7\)
  - Gemcitabine + erlotinib\(^c,8\)
  - Gemcitabine + capecitabine9
  - Gemcitabine + cisplatin\(^{10}\) (especially for patients with \(BRCA1/BRCA2\) or other DNA repair mutations)
  - Gemcitabine
  - Capecitabine (category 2B)
  - CI 5-FU (category 2B)
  - Fixed-dose-rate gemcitabine, docetaxel, capecitabine (GTX regimen)\(^{11}\) (category 2B)
  - Fluoropyrimidine + oxaliplatin (category 2B) (eg, 5-FU/leucovorin/oxaliplatin\(^{12}\) or CapeOx\(^{13}\))
  - Induction chemotherapy with any of the chemotherapy options above (\(\geq 4–6\) cycles) followed by chemoradiation*\(^{a,d}\) or SBRT\(^{14}\) (in selected patients, locally advanced disease without systemic metastases)\(^{15}\)
  - Chemoradiation*\(^{a,e}\) or SBRT\(^e\) (in select patients who are not candidates for combination therapy)

- Options for patients with poor performance status include:
  - Gemcitabine
    - 1000 mg/m\(^2\) over 30 minutes, weekly for 3 weeks every 28 days (category 1)
    - Fixed-dose-rate gemcitabine (10 mg/m\(^2\)/min) may substitute for standard infusion of gemcitabine over 30 minutes (category 2B)
  - Capecitabine (category 2B)
  - CI 5-FU (category 2B)

\[\text{Chemoradiation:}\]
- Fluoropyrimidine (capecitabine, CI 5-FU, or 5-FU/cisplatin) + concurrent RT (preferred)
- Gemcitabine + concurrent RT\(^5\)

\(^a\)The recommendations for FOLFIRINOX and gemcitabine + albumin-bound paclitaxel in patients with locally advanced disease are based on extrapolations from randomized trials in patients with metastatic disease.

\(^b\)Due to the high toxicity of this regimen, bolus 5-FU is often omitted.

\(^c\)Although this combination significantly improved survival, the actual benefit was small, suggesting that only a small subset of patients benefit.

\(^d\)Based on preliminary data from the LAP-07 trial, there is no clear survival benefit with the addition of conventional chemoradiation following gemcitabine monotherapy. Chemoradiation may improve local control and delay the need for resumption therapy.\(^{16}\)

\(^e\)If patients present with poorly controlled pain or local obstructive symptoms, it may be preferable to start with upfront chemoradiation or SBRT. See Principles of Radiation Therapy (PANC-F).
### EVIDENCE BLOCKS FOR FIRST-LINE THERAPY

<table>
<thead>
<tr>
<th>Regimens</th>
<th>Locally Advanced, Unresectable Disease, Good Performance Status</th>
<th>Metastatic Disease, Good Performance Status</th>
<th>Locally Advanced, Unresectable Disease, Poor Performance Status</th>
<th>Metastatic Disease, Poor Performance Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Continuous infusion 5-FU</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5-FU/leucovorin/oxaliplatin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Capecitabine</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Capecitabine/oxaliplatin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FOLFIRINOX</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gemcitabine (fixed-dose-rate)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gemcitabine (standard infusion)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gemcitabine/albun-bound paclitaxel</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gemcitabine/capecitabine</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fixed-dose-rate gemcitabine/docetaxel/capecitabine (GTX)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gemcitabine/cisplatin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gemcitabine/cisplatin (DNA repair mutation such as BRCA1/2)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gemcitabine/erlotinib</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Note:** For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page EB-1.

All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
Metastatic Disease (First-Line Therapy)

• Patients who progress with metastatic disease are not candidates for radiation unless required for palliative purposes.

• Options for patients with good performance status include:
  › FOLFIRINOX\(^b,f,6\) (category 1) (preferred)
  › Gemcitabine + albumin-bound paclitaxel\(^f,7\) (category 1) (preferred)
  › Gemcitabine + erlotinib\(^c,8\) (category 1)
  › Gemcitabine (category 1)
  › Gemcitabine + capecitabine\(^9\)
  › Gemcitabine + cisplatin\(^10\) (Can be considered as an alternative to FOLFIRINOX in patients with possible hereditary cancers involving DNA repair mutations)
  › Fixed-dose-rate gemcitabine, docetaxel, capecitabine (GTX regimen)\(^11\) (category 2B)
  › Fluoropyrimidine + oxaliplatin (category 2B) (eg, 5-FU/leucovorin/oxaliplatin\(^12\) or CapeOx\(^13\))

• Options for patients with poor performance status include:
  › Gemcitabine
    ◊ 1000 mg/m\(^2\) over 30 minutes, weekly for 3 weeks every 28 days (category 1)
    ◊ Fixed-dose-rate gemcitabine (10 mg/m\(^2\)/min) may substitute for standard infusion of gemcitabine over 30 minutes (category 2B)
  › Capecitabine (category 2B)
  › CI 5-FU (category 2B)

\(^b\) Due to the high toxicity of this regimen, bolus 5-FU is often omitted.

\(^c\) Although this combination significantly improved survival, the actual benefit was small, suggesting that only a small subset of patients benefit.

\(^f\) FOLFIRINOX should be limited to those with ECOG 0-1. Gemcitabine + albumin-bound paclitaxel is reasonable for patients with KPS ≥70. 5-FU + leucovorin + liposomal irinotecan is a reasonable second-line option for patients with KPS ≥70.

See Evidence Blocks on PANC-G (3 of 6) (EB-1)
See Second-Line Therapy on PANC-G (5 of 6)
Second-line Therapy for Locally Advanced/Unresectable/Metastatic Disease and Good Performance Status

• If previously treated with gemcitabine-based therapy, options include:
  ▶ 5-FU + leucovorin + liposomal irinotecan (category 1 for metastatic disease)
  ▶ FOLFIRINOX
  ▶ Oxaliplatin/5-FU/leucovorin
  ▶ FOLFOX
  ▶ Capecitabine/oxaliplatin
  ▶ Capecitabine
  ▶ CI 5-FU
  ▶ Chemoradiation* (Only for locally advanced disease; if not previously given, and if primary site is the sole site of progression)

• If previously treated with fluoropyrimidine-based therapy, options include:
  ▶ Gemcitabine + albumin-bound paclitaxel
  ▶ Gemcitabine
  ▶ Gemcitabine + cisplatin
  ▶ Gemcitabine + erlotinib
  ▶ 5-FU + leucovorin + liposomal irinotecan (if no prior irinotecan)
  ▶ Chemoradiation* (Only for locally advanced disease; if not previously given, and if primary site is the sole site of progression)

Recurrent Disease

• If resected patients with good performance status relapse after receiving adjuvant therapy, FOLFIRINOX or gemcitabine + albumin-bound paclitaxel are options depending on the length of time since completion of adjuvant therapy.

*Chemoradiation:
  • Fluoropyrimidine (capecitabine, CI 5-FU, or 5-FU/cisplatin) + concurrent RT (preferred)
  • Gemcitabine + concurrent RT

FOLFIRINOX should be limited to those with ECOG 0-1. Gemcitabine + albumin-bound paclitaxel is reasonable for patients with KPS ≥70. 5-FU + leucovorin + liposomal irinotecan is a reasonable second-line option for patients with KPS ≥70.
PRINCIPLES OF CHEMOTHERAPY (6 of 6)

References


### American Joint Committee on Cancer (AJCC) TNM Staging of Pancreatic Cancer (2010)

Because only a few patients with pancreatic cancer undergo surgical resection of the pancreas (and adjacent lymph nodes), a single TNM classification must apply to both clinical and pathologic staging.

**Primary Tumor (T)**
- **TX**: Primary tumor cannot be assessed
- **T0**: No evidence of primary tumor
- **Tis**: Carcinoma in situ*
- **T1**: Tumor limited to the pancreas, 2 cm or less in greatest dimension
- **T2**: Tumor limited to the pancreas, more than 2 cm in greatest dimension
- **T3**: Tumor extends beyond the pancreas but without involvement of the celiac axis or the superior mesenteric artery
- **T4**: Tumor involves the celiac axis or the superior mesenteric artery (unresectable primary tumor)

**Regional Lymph Nodes (N)**
- **NX**: Regional lymph nodes cannot be assessed
- **N0**: No regional lymph node metastasis
- **N1**: Regional lymph node metastasis

**Distant Metastases (M)**
- **M0**: No distant metastases
- **M1**: Distant metastasis

**Stage Grouping**

<table>
<thead>
<tr>
<th>Stage</th>
<th>Tis</th>
<th>N0</th>
<th>M0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage 0</td>
<td>Tis</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IA</td>
<td>T1</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IB</td>
<td>T2</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IIA</td>
<td>T3</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IIB</td>
<td>T1</td>
<td>N1</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T2</td>
<td>N1</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T3</td>
<td>N1</td>
<td>M0</td>
</tr>
<tr>
<td>Stage III</td>
<td>T4</td>
<td>Any N</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IV</td>
<td>Any T</td>
<td>Any N</td>
<td>M1</td>
</tr>
</tbody>
</table>

* This also includes the “PanInIII” classification.

---

Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original and primary source for this information is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer Science+Business Media, LLC (SBM). (For complete information and data supporting the staging tables, visit [www.springer.com](http://www.springer.com).) Any citation or quotation of this material must be credited to the AJCC as its primary source. The inclusion of this information herein does not authorize any reuse or further distribution without the expressed, written permission of Springer SBM, on behalf of the AJCC.
NCCN Guidelines Version 2.2017
Pancreatic Adenocarcinoma

Discussion

NCCN Categories of Evidence and Consensus

Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise noted.

Table of Contents

Overview ..................................................................................... MS-2
Literature Search Criteria and Guidelines Update Methodology .... MS-2
Risk Factors and Genetic Predisposition ................................ MS-3
  Diabetes and Pancreatic Cancer ............................................. MS-3
  Genetic Predisposition ........................................................... MS-4
Premalignant Tumors of the Pancreas ..................................... MS-6
Pancreatic Cancer Screening ..................................................... MS-6
Diagnosis and Staging ............................................................. MS-7
  Imaging Evaluations ............................................................. MS-8
  Laparoscopy ........................................................................ MS-10
  Biopsy ................................................................................ MS-11
  Biomarkers .......................................................................... MS-12
  Differential Diagnoses ........................................................ MS-14
Systemic Therapy Approaches ................................................. MS-14
  Gemcitabine Monotherapy .................................................. MS-15
  Fixed-Dose-Rate Gemcitabine .............................................. MS-16
  Gemcitabine Combinations ................................................ MS-16
  5-FU/Leucovorin ................................................................... MS-20
  FOLFIRINOX ..................................................................... MS-20
  Capecitabine and Continuous Infusion 5-FU ....................... MS-21
  Fluoropyrimidine Plus Oxaliplatin ....................................... MS-22
  Possible Role of Maintenance Therapy in Advanced Disease . MS-22
  Second-Line Systemic Therapy in the Advanced Setting ...... MS-22
Radiation and Chemoradiation Approaches .......................... MS-24
  Adjuvant Chemoradiation ................................................... MS-24
  Chemoradiation and SBRT for Locally Advanced Disease .... MS-26
  Advanced Radiation Techniques ......................................... MS-28
  Management of Metastatic Disease ..................................... MS-29
  Management of Locally Advanced Disease ....................... MS-30
  Management of Resectable and Borderline Resectable Disease MS-31
  Surgical Management ........................................................ MS-31
  Pathology .......................................................................... MS-38
  Perioperative Therapy ......................................................... MS-41
  Surveillance of Patients with Resected Disease ................. MS-46
  Management of Recurrent Disease After Resection .......... MS-46
  Management of Isolated Pulmonary Metastases ................. MS-46
Palliative and Supportive Care ................................................ MS-47
  Biliary Obstruction ............................................................. MS-47
  Gastric Outlet Obstruction ................................................... MS-48
  Severe Tumor-Associated Abdominal Pain ....................... MS-48
  Pancreatic Exocrine Insufficiency ....................................... MS-49
  Thromboembolic Disease ................................................... MS-49
  Depression, Pain, and Malnutrition .................................... MS-50
  Future Clinical Trials: Recommendations for Design ........ MS-50
  Neoadjuvant Clinical Trials ............................................... MS-51
  Targeted Therapies ............................................................ MS-51
Summary ................................................................................... MS-52
References ................................................................................ MS-61
Overview

During the year 2017 in the United States, an estimated 53,670 people will be diagnosed with pancreatic cancer, and approximately 43,090 people will die of pancreatic cancer.\(^1\) This disease is the fourth most common cause of cancer-related death among U.S. men (after lung, prostate, and colorectal cancer) and women (after lung, breast, and colorectal cancer).\(^1\) Although incidence is roughly equal in both sexes, African Americans have a higher incidence of pancreatic cancer than white Americans.\(^2,3\) Furthermore, the incidence of pancreatic cancer in the United States increased from 1999 to 2008, possibly because of the increasing prevalence of obesity, an aging population, and other unknown factors.\(^3-5\) Mortality rates have remained largely unchanged.\(^6,7\)

In these NCCN Guidelines for Pancreatic Adenocarcinoma, the diagnosis and management of adenocarcinomas of the exocrine pancreas are discussed; neuroendocrine tumors are not included (please see the NCCN Guidelines for Neuroendocrine Tumors, available at [www.NCCN.org](http://www.NCCN.org)). These NCCN Guidelines are intended to assist with clinical decision-making, but they cannot incorporate all possible clinical variations and are not intended to replace good clinical judgment or individualization of treatments. Exceptions to the rule were discussed among the panel members during the process of developing and updating these guidelines. A 5% rule (omitting clinical scenarios that comprise less than 5% of all cases) was used to eliminate uncommon clinical occurrences or conditions from these guidelines. A study of 3706 patients treated for pancreatic cancer in large California hospitals showed that compliance with these NCCN Guidelines for Pancreatic Adenocarcinoma, defined very permissively, improves survival.\(^8\)

As an overall guiding principle of these guidelines, the panel believes that decisions about diagnostic management and resectability of pancreatic cancer should involve multidisciplinary consultation at high-volume centers with use of appropriate imaging studies. In addition, the panel believes that increasing participation in clinical trials (only 4.6% of patients enroll in a pancreatic cancer trial\(^9\)) is critical to making progress in this disease. Thus, the panel unanimously endorses participation in a clinical trial over standard or accepted therapy.

Literature Search Criteria and Guidelines Update Methodology

Prior to the update of this version of the NCCN Guidelines for Pancreatic Adenocarcinoma, an electronic search of the PubMed database was performed to obtain key literature in the field of pancreatic cancer published between July 21, 2015 and July 14, 2016, using the following search terms: (pancreatic cancer) OR (pancreatic adenocarcinoma) OR (pancreas adenocarcinoma) OR (pancreas cancer). The PubMed database was chosen because it remains the most widely used resource for medical literature and indexes only peer-reviewed biomedical literature.\(^10\)

The search results were narrowed by selecting studies in humans published in English. Results were confined to the following article types: Clinical Trial, Phase II; Clinical Trial, Phase III; Clinical Trial, Phase IV; Practice Guideline; Guidelines; Randomized Controlled Trial; Meta-Analysis; Systematic Reviews; and Validation Studies.

The PubMed search resulted in 104 citations, and their potential relevance was examined. The data from key PubMed articles and articles from additional sources deemed as relevant to these Guidelines and discussed by the panel have been included in this version of the Discussion section (eg, e-publications ahead of print, meeting...
abstracts). Recommendations for which high-level evidence is lacking are based on the panel’s review of lower-level evidence and expert opinion.

The complete details of the Development and Update of the NCCN Guidelines are available on the NCCN website (www.NCCN.org).

Risk Factors and Genetic Predisposition

Although the increase in risk is small, pancreatic cancer is firmly linked to cigarette smoking. Exposure to chemicals and heavy metals such as beta-naphthylamine, benzidine, pesticides, asbestos, benzene, and chlorinated hydrocarbons is associated with increased risk for pancreatic cancer, as is heavy alcohol consumption. An increased body mass index (BMI) is associated with an increased risk for pancreatic cancer, with BMI during early adulthood being associated with increased pancreatic cancer mortality. A meta-analysis including 22 cohort studies with 8,091 patients with pancreatic cancer showed that those who engage in low levels of physical activity have an increased risk for pancreatic cancer, relative to those who engage in high levels of physical activity (RR, 0.93; 95% CI, 0.88–0.98). Regarding diet, there is some evidence that increased consumption of red/processed meat and dairy products is associated with an elevation in pancreatic cancer risk, although other studies have failed to identify dietary risk factors for the disease. The association between tea consumption and pancreatic cancer risk has been examined, with mostly null associations being found. A meta-analysis including 14 studies showed that regular tea consumption is associated with a lower risk for pancreatic cancer in Chinese populations (RR, 0.76; 95% CI, 0.59–0.98; \( P = .036 \)) and in those >60 years (RR, 0.76; 95% CI, 0.60–0.96, \( P = .023 \)). A meta-analysis focusing on green tea consumption that included three case-control and five prospective studies from China and Japan failed to show a statistically significant association with pancreatic cancer risk.

Studies examining the association between vitamin D and risk for pancreatic cancer have shown contradictory results. Some data suggest that low plasma 25-hydroxyvitamin D levels may increase the risk for pancreatic cancer. A recent pooled analysis of nine case-control studies, including 2,963 patients with pancreatic cancer and 8,527 control subjects, showed a positive association between vitamin D intake and pancreatic cancer risk (OR, 1.13; 95% CI, 1.07–1.19; \( P < .001 \)). This association may be stronger in those with low retinol/Vitamin A intake.

Chronic pancreatitis has been identified as a risk factor for pancreatic cancer, with one study demonstrating a 7.2-fold increased risk for pancreatic cancer for patients with a history of pancreatitis. A meta-analysis including two case-control studies and one cohort study (1,636 patients with pancreatic cancer) showed that hepatitis B infection is associated with pancreatic cancer (OR, 1.50; 95% CI, 1.21–1.87). Overall, further epidemiologic studies involving careful evaluation of these possible risk factors with adjustments for potential confounders are needed to clarify their impact on pancreatic cancer risk.

Diabetes and Pancreatic Cancer

The association between diabetes mellitus and pancreatic cancer is particularly complicated. A population-based study of 2122 patients with diabetes found that approximately 1% of patients diagnosed with diabetes who are age 50 years or younger will be diagnosed with pancreatic cancer within 3 years. Prediabetes may also be associated with increased risk for pancreatic cancer. A recent systematic review and dose-response meta-analysis including nine prospective studies (\( N = 2,408 \)) showed that every 0.56 mmol/L increase in fasting blood
Numerous studies have shown an association between new-onset non-insulin–dependent diabetes and the development of pancreatic cancer, especially in those who are elderly, have a lower BMI, experience weight loss, or do not have a family history of diabetes. In these short-onset cases of diabetes diagnosed prior to pancreatic cancer diagnoses, diabetes is thought to be caused by the cancer, although the physiologic basis for this effect is not yet completely understood.

Long-term diabetes, on the other hand, appears to be a risk factor for pancreatic cancer, as some studies have shown an association of pancreatic cancer with diabetes of 2- to 8-year duration. However, certain risk factors such as obesity, associated with both diabetes and pancreatic cancer, may confound these analyses. A meta-analysis including 44 studies showed that the strength of the association between diabetes and pancreatic cancer risk decreases with duration of diabetes, potentially due to the effects of long-term treatment of diabetes.

The use of diabetic medications has been reported to alter pancreatic cancer risk. The use of insulin or sulfonylureas has been found to be associated with an increased risk for pancreatic cancer. On the other hand, metformin may be associated with a reduced risk for pancreatic and other cancers, though a retrospective cohort study (N = 980) showed that metformin did not significantly improve survival in diabetic patients diagnosed with pancreatic cancer.

In addition, diabetes and diabetic medication may affect outcomes in patients with pancreatic cancer. Metformin use has been reported to result in higher pancreatic cancer survival in diabetics. A retrospective analysis of 302 patients with pancreatic cancer and diabetes treated at The University of Texas MD Anderson Cancer Center found that metformin use was associated with increased survival at 2 years (30.1% vs. 15.4%; P = .004) and increased overall survival (OS, 15.2 months vs. 11.1 months; P = .009). The OS difference was significant only in patients without distant metastases and remained significant when insulin users were excluded. In contrast, data from a meta-analysis of more than 38,000 patients show that those with pancreatic cancer and diabetes have a significantly lower OS than those without diabetes (14.4 vs. 21.7 months; P < .001). A similar result was seen in a prospective cohort study, in which the survival of 504 patients with and without diabetes who developed pancreatic cancer in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial was compared. After multivariable adjustment, mortality was significantly higher in participants with diabetes compared to those without (hazard ratio [HR], 1.52; 95% CI, 1.14–2.04; P < .01).

Genetic Predisposition
Pancreatic cancer is thought to have a familial component in approximately 10% of cases, and familial excess of pancreatic cancer is associated with high risk. A retrospective review of 175 families in which a family history of pancreatic cancer was present showed that a genetic mutation was present in 28% of families. A prospective registry-based study of 5179 individuals from 838 kindreds found that having just 1 first-degree relative with pancreatic cancer raises the risk for pancreatic cancer by 4.6-fold, whereas having 2 affected first-degree relatives raises the risk by about 6.4-fold. An analysis of 9,040 family members of 1,718 kindreds with pancreatic cancer showed that a family history of early-onset pancreatic cancer (ie, <50 years) was associated with greater risk of pancreatic cancer (standardized incidence ratio 1.52; 95% CI, 1.14–2.04; P < .01).
Germline mutations in the \textit{STK11} gene result in Peutz-Jeghers syndrome, in which individuals have gastrointestinal polyps and a highly elevated risk for colorectal cancer.\textsuperscript{70-72} These individuals also have a highly elevated risk for developing pancreatic cancer, reported to be increased by as much as 132-fold.\textsuperscript{73,74} Furthermore, \textit{STK11} undergoes somatic mutation in approximately 5\% of pancreatic cancers.\textsuperscript{75}

As with non-hereditary forms of pancreatitis, familial pancreatitis is also associated with an increased risk for pancreatic cancer.\textsuperscript{76} Several genes are associated with the familial form of pancreatitis, including \textit{PRSS1}, \textit{SPINK1}, and \textit{CFTR}.\textsuperscript{77} The increased risk for the development of pancreatic cancer in these individuals is estimated to be 26-fold to as high as 87-fold.\textsuperscript{36,78-80}

Familial malignant melanoma syndrome (also known as melanoma-pancreatic cancer syndrome or familial atypical multiple mole melanoma [FAMMM]) syndrome is caused by germline mutation of the \textit{CDKN2A} (p16INK4a/p14ARF) gene.\textsuperscript{81} This syndrome is associated with a 20-fold to 47-fold increased risk for pancreatic cancer.\textsuperscript{82,83} In addition, patients with Melanoma-Pancreatic Cancer syndrome may experience an earlier onset of pancreatic cancer than the general population.\textsuperscript{84} In an analysis of 515 probands with a family history of pancreatic cancer, 2.5\% had a germline mutation in \textit{CDKN2A}, while 7.8\% of probands with a family history of both pancreatic cancer and melanoma (\textit{n = 77}) had this genetic mutation.\textsuperscript{85} In a sample of 178 \textit{CDKN2A} mutation carriers undergoing surveillance at three expert centers in Europe, pancreatic cancer was detected in 7.3\%.\textsuperscript{86} In an unselected series of 225 patients with pancreatic cancer in Italy, 5.7\% had mutations in \textit{CDKN2A}.\textsuperscript{87}

Lynch syndrome is the most common form of genetically determined colorectal cancer predisposition and is caused by germline mutations in DNA mismatch repair (MMR) genes (\textit{MLH1}, \textit{MSH2}, \textit{MSH6}, or \textit{PMS2}).\textsuperscript{88-93} Patients with Lynch syndrome also have an estimated 9- to 11-fold elevated risk for pancreatic cancer.\textsuperscript{94,95} In a sample of 96 patients with pancreatic cancer, two mutations were found in the \textit{MSH6} MMR gene.\textsuperscript{96}

An excess of pancreatic cancer is also seen in families harboring \textit{BRCA1}/2 (breast cancer susceptibility gene-1 and -2) mutations, although the link with \textit{BRCA2} is better established.\textsuperscript{95,96-102} Studies of unselected patients with pancreatic cancer have detected \textit{BRCA1}/2 mutations at a frequency of 4\% to 7\%.\textsuperscript{103,104} The risk for pancreatic cancer is elevated 2- to 6-fold in these patients, and the age of onset is younger than average in the general population.\textsuperscript{97,101,102} Patients with pancreatic cancer who have Ashkenazi Jewish ancestry may have a greater likelihood of testing positive for a \textit{BRCA1}/2 mutation, with prevalence of detected mutations in this group ranging from 5.5\% to 19\%, with mutations being more common for \textit{BRCA2}.\textsuperscript{99,104-106}

\textit{BRCA1}/2 is also involved in the Fanconi DNA anemia/\textit{BRCA} pathway. This pathway is responsible for the repair of DNA interstrand cross-links, and particular mutations in other Fanconi anemia/\textit{BRCA} pathway genes, including in \textit{PALB2}, \textit{FANCC}, and \textit{FANCG}, have also been identified as increasing pancreatic cancer susceptibility.\textsuperscript{85,107-109}
Whole-genome sequencing allowed for the identification of germline mutations in \textit{ATM}, a DNA damage response gene, in 2 kindreds with familial pancreatic cancer.\textsuperscript{110} Further analyses then revealed \textit{ATM} mutations in 4 of 166 individuals with familial pancreatic cancer. In a sample of 96 patients with pancreatic cancer, 4\% had a mutation in \textit{ATM}.\textsuperscript{96}

Patients with pancreatic cancer for whom a hereditary cancer syndrome is suspect should be considered for genetic counseling.\textsuperscript{111} The panel emphasizes the importance of taking a thorough family history when seeing a new patient with pancreatic cancer. In particular, a family history of pancreatitis, melanoma, and cancers of the pancreas, colorectum, breast, and ovaries should be noted. A free online pancreatic cancer risk prediction tool, called PancPRO, is available and may help determine risk.\textsuperscript{66} Referral for genetic counseling may be considered for patients diagnosed with pancreatic cancer who have a family history of cancer or who are young, as well as those of Ashkenazi Jewish ancestry. The panel currently does not identify a specific age to define early-onset pancreatic cancer, though age 50 has been used in previous studies of familial pancreatic cancer.\textsuperscript{69} If a cancer syndrome is identified, at-risk relatives should be offered genetic counseling. With or without a known syndrome, individuals with a suspicious family history should be advised on risk-reducing strategies including smoking cessation and weight loss. In addition, the possibility of screening for pancreatic (see below) and other cancers should be discussed.

**Premalignant Tumors of the Pancreas**

Mucinous cystic neoplasms (MCNs) and intraductal papillary mucinous neoplasms (IPMNs) of the pancreas are cystic lesions that can be small and asymptomatic and are often discovered incidentally; MCNs have an ovarian-like stroma.\textsuperscript{112-114} IPMNs can occur in the main duct and/or in the branch ducts. Lesions involving the main duct have a higher malignant potential than those in the branches, with the risk of malignancy at around 62\%.\textsuperscript{115} The risk of malignancy in MCNs is <15\%.\textsuperscript{115}

An international group of experts has established guidelines for the management of pancreatic IPMNs and MCNs,\textsuperscript{115} as has a European group.\textsuperscript{116} The international group strongly recommends resection in fit patients with main duct IPMNs.\textsuperscript{115} For branch-duct IPMNs, surveillance is considered an appropriate option in patients who are older or unfit or for cysts lacking suspicious features. Branch-duct IPMNs that are greater than or equal to 10 mm, have an enhancing solid component, or are in the head of the pancreas causing obstructive jaundice should be considered for resection.\textsuperscript{115} Patients with resected IPMNs are followed with imaging studies to identify recurrences. For MCNs, the international group recommends resection for all fit patients, and recurrences are not observed.\textsuperscript{115} The European group gives similar recommendations.\textsuperscript{116}

**Pancreatic Cancer Screening**

Routine screening for pancreatic cancer is generally not recommended for asymptomatic individuals. However, a systematic review including five studies showed that screening asymptomatic individuals with a family history of pancreatic cancer was associated with more curative resections ($P = 0.011$) and longer median survival ($P < .001$).\textsuperscript{117} Asymptomatic individuals at high risk for pancreatic cancer (ie, those with first-degree relatives with pancreatic cancer) were assessed using endoscopic ultrasound (EUS) in the Cancer of the Pancreas Screening 2 (CAPS2) project.\textsuperscript{118} Preinvasive pancreatic neoplasms were detected in 10\% of high-risk patients, suggesting that EUS may have a promising role in screening high-risk patients. The CAPS Consortium reported results of its CAPS3 study, in which 225 asymptomatic high-risk
individuals were independently (in a blinded manner) screened once with CT, MRI, and EUS. In this study, 42% of individuals were found to have an abnormality; 5 individuals underwent surgical interventions, 3 of whom had high-grade dysplasia in small IPMNs and intraepithelial neoplasias. When results of the 3 screening modalities were compared, EUS detected abnormalities in 42% of individuals versus 33% and 11% for MRI and CT, respectively. Interestingly, results from a prospective cohort study that followed high-risk individuals for an average of 4.2 years showed that, although 32% of 262 participants were found to have pancreatic abnormalities, and some IPMNs and intraepithelial neoplasias were resected, 3 patients developed pancreatic adenocarcinoma (2 metastatic, 1 recurrent 30 months post-resection) despite screening. These results could be due to rapid malignant progression, but they are more likely a result of inadequate imaging by MRI.

The diagnostic yield of pancreatic cancer screening with EUS in asymptomatic individuals at high risk for familial disease was also investigated in the Netherlands, while a German study used EUS plus MRI/magnetic resonance cholangiopancreatography (MRCP) in a similar high-risk population. Although results from these trials seem promising overall, the malignant potential of some preinvasive pancreatic lesions and the impact of screening on survival are presently unclear. Results suggest that MRI/MRCP may be a useful adjunct or a noninvasive alternative to EUS for pancreatic cancer screening.

Newer screening methods to identify patients with early pancreatic cancer rather than those with preinvasive lesions may prove to be beneficial in the future. Examples of techniques being investigated are microRNA biomarkers in whole blood and serum metabolism profiling. In addition, circulating cell-free DNA is being investigated as a possible biomarker for screening. One study showed that methylation patterns in cell-free plasma DNA can differentiate between pancreatitis and pancreatic cancer with a sensitivity of 91.2% and specificity of 90.8%. In addition, CA 19-9 levels may be elevated in patients up to 2 years before a pancreatic cancer diagnosis, indicating that CA 19-9 has potential as a biomarker for screening high-risk patients.

An international CAPS Consortium summit with 49 multidisciplinary experts was held in 2011 to develop consensus guidelines for pancreatic cancer screening. The group recommends screening with EUS and/or MRI/MRCP for high-risk individuals, defined as first-degree relatives of patients with pancreatic cancer from familial kindreds; carriers of p16 or BRCA2 mutations with an affected first-degree relative; patients with Peutz-Jeghers syndrome; and patients with Lynch syndrome and an affected first-degree relative with pancreatic cancer. The group also concluded that more evidence is needed regarding optimal management of patients with detected lesions, the age to begin screening, and screening intervals.

**Diagnosis and Staging**

Ductal adenocarcinoma and its variants account for over 90% of pancreatic malignancies. The presenting symptoms of this disease can include weight loss, jaundice, floating stools, pain, dyspepsia, nausea, and depression; however, no early warning signs of pancreatic cancer have been established. As previously noted, sudden onset of adult type 2 diabetes in patients 50 years or older may be linked to a new diagnosis of pancreatic cancer; patients with long-standing diabetes may also develop pancreatic cancer (see *Diabetes and Pancreatic Cancer*, above). Thus, pancreatic carcinoma should be considered in...
diabetic patients with unusual manifestations, such as abdominal symptoms and continuous weight loss.

Unlike many other cancers, imaging is the primary means through which the stage of pancreatic cancer is determined. High-quality multi-phase imaging can help to preoperatively distinguish between patients eligible for resection with curative intent and those with unresectable disease. The criteria for defining resectable disease favor specificity over sensitivity to avoid denying surgery to patients with a potentially resectable tumor. All patients for whom there is clinical suspicion of pancreatic cancer or evidence of a dilated duct (stricture) should therefore undergo initial evaluation by CT performed according to a dedicated pancreas protocol. In addition, the panel recommends imaging after neoadjuvant treatment to provide adequate staging and assessment of resectability status. Subsequent decisions regarding diagnostic management and resectability should involve multidisciplinary consultation, with use of appropriate studies to evaluate the extent of disease. The panel recommends that a multidisciplinary review ideally involve expertise from surgery, diagnostic imaging, interventional endoscopy, medical oncology, radiation oncology, and pathology.

The AJCC has developed staging criteria for adenocarcinoma of the pancreas that follow the tumor/node/metastasis (TNM) system. Although the TNM staging criteria for pancreatic cancer in the 7th edition of the AJCC Cancer Staging Manual have taken into account the fact that tumors of the pancreas are evaluated preoperatively by CT or MRI to determine resectability status, these staging criteria also include information that can be determined only through postsurgical pathologic evaluation of resected tumor. Validation of concordance between AJCC stage and OS has been provided through evaluation of 121,713 patients with pancreatic adenocarcinoma included in the National Cancer Data Base (NCDB).

For clinical purposes, however, most NCCN Member Institutions use a clinical classification system based mainly on results of presurgical imaging studies. Following staging by pancreatic protocol CT (and EUS and/or MRI/MRCP or endoscopic retrograde cholangiopancreatography [ERCP] in some cases), liver function tests, and chest imaging, disease is classified as: 1) resectable; 2) borderline resectable (ie, tumors that are involved with nearby structures so as to be neither clearly resectable nor clearly unresectable with a high chance of an R1 resection); 3) locally advanced unresectable (ie, tumors that are involved with nearby structures to an extent that renders them unresectable despite the absence of evidence of metastatic disease); or 4) disseminated, and this system is used throughout the guidelines. See Criteria for Resection below for more detailed definitions.

Imaging Evaluations

Pancreatic Protocol CT and MRI

Multi-detector CT angiography, performed by acquiring thin, preferably sub-millimeter, axial sections using a dual-phase pancreatic protocol, with images obtained in the pancreatic and portal venous phase of contrast enhancement, is the preferred imaging tool for dedicated pancreatic imaging. Scan coverage can be extended to cover the chest and pelvis for complete staging as per institutional preferences. Multiplanar reconstruction is preferred as it allows precise visualization of the relationship of the primary tumor to the mesenteric vasculature as well as detection of subcentimeter metastatic deposits. Studies have shown that 70% to 85% of patients determined by CT imaging to have resectable tumors were able to undergo resection. However, the sensitivity of CT for small hepatic and peritoneal
metastases is limited. High-quality CT imaging should occur no more than 4 weeks before surgery.\(^{140}\)

The difference in contrast enhancement between the parenchyma and adenocarcinoma is highest during the late arterial phase, thereby providing a clear distinction between a hypodense lesion in the pancreas and the rest of the organ. A multi-phasic pancreatic protocol also allows for selective visualization of important arterial (e.g., celiac axis, superior mesenteric artery [SMA], peripancreatic arteries) and venous structures (e.g., superior mesenteric vein [SMV], splenic vein, portal vein [PV]), thereby providing an assessment of vascular invasion by the tumor. All of this information can improve the prediction of resectability. Software allowing for 3-D reconstruction of imaging data can provide additional valuable information on the anatomic relationship between the pancreatic tumor and the surrounding blood vessels and organs, and multiplanar reconstruction is preferred. However, further development of this technology may be needed before it is routinely integrated into clinical practice.\(^{138}\)

Patients commonly present to the oncologist with a non-pancreas protocol CT already performed. The panel feels that if the CT scan is of high quality, it can be sufficient. If not, a pancreas protocol CT is recommended. Such selective reimaging was shown to change the staging and management of patients with pancreatic adenocarcinoma in 56% of cases retrospectively reviewed at one institution.\(^{141}\)

Pancreas protocol MRI with contrast can be a helpful adjunct to CT in the staging of pancreatic cancer, particularly for characterization of CT-indeterminate liver lesions and when suspected pancreatic tumors are not visible on CT or in cases of contrast allergy.\(^{142,143}\)

Recently, a multidisciplinary expert consensus group defined standardized language for the reporting of imaging results.\(^{131}\) Such uniform reporting can help improve the accuracy and consistency of staging to determine optimal treatment strategies for individual patients and can allow cross-study and cross-institutional comparisons for research purposes. Use of the template also ensures a complete assessment and reporting of all imaging criteria essential for optimal staging and can therefore aid in determining optimal management. The use of the radiology staging reporting template is thus recommended by the panel. The template recommended by the panel includes morphologic, arterial, venous, and extrapancreatic evaluations.\(^{131}\) The morphologic evaluation includes documentation of tumor appearance, size, and location, as well as the presence of narrowing or abrupt cut-off of pancreatic duct or biliary tree. The arterial evaluation should include assessment of the celiac axis, the SMA, and the common hepatic artery. Arterial variations should also be noted, such as vessel contact, solid soft-tissue contact, hazy attenuation or stranding contact, and focal vessel narrowing or contour irregularity. Venous evaluation should include an assessment of the main PV and the SMV. Documentation of thrombus within the vein and venous collaterals should also be done. The extrapancreatic evaluation should include documentation of liver lesions, peritoneal or omental nodules, ascites, suspicious lymph nodes, and other present extrapancreatic disease sites.

**Endoscopic Ultrasound**

NCCN Member Institutions vary in the use of additional staging technologies, such as EUS. An analysis of 20 studies and 726 cases of pancreatic cancer showed that EUS for T1-2 staging has a sensitivity and specificity of 0.72 and 0.90, respectively.\(^{144}\) Sensitivity and specificity for T3-4 staging is 0.90 and 0.72, respectively. The role of EUS in staging is felt to be complementary to CT, providing additional information for patients whose initial scans show no lesion or whose
lesions have questionable involvement of blood vessels or lymph nodes. In particular, EUS may provide assessment of certain types of vascular invasion. The sensitivity and specificity values for nodal staging (0.62 and 0.74, respectively) are lower than the values for vascular invasion (0.87 and 0.92, respectively). It is the consensus of the panel that while the accuracy of EUS in assessing the involvement of certain veins (e.g., PV) is high, this technique is less accurate in imaging tumor invasion of the SMA. Therefore, EUS is not recommended as a routine staging tool.

EUS is also used to discriminate between benign and malignant strictures or stenosis, because severe stenosis and marked proximal dilatation most often indicate malignancy. EUS can also be used to evaluate periampullary masses, separating invasive from noninvasive lesions. In addition, EUS plays a role in better characterizing cystic pancreatic lesions due to the ability to aspirate the cyst contents for cytologic, biochemical, and molecular analysis. On EUS, malignant cystic lesions may present as a hypoechoic cystic/solid mass or as a complex cyst, and they are frequently associated with a dilated main pancreatic duct. Some therapeutic interventions can also be done with EUS (e.g., celiac neurolysis, removal of ascites). Because this procedure is operator dependent, some divergence in use may occur because of differing technical capabilities and available expertise.

**Endoscopic Retrograde Cholangiopancreatography and MRI/Magnetic Resonance Cholangiopancreatography**

ERCP is a technique that combines endoscopic and fluoroscopic procedures and is generally limited to therapeutic interventions. In the guidelines, ERCP with duct brushing cytology is recommended as clinically indicated for patients without a mass in the pancreas and without evidence of metastatic disease who require biliary decompression and who undergo additional imaging with EUS to help establish a diagnosis. Thus from a therapeutic standpoint, ERCP allows for stent placement and can be used to palliate biliary obstruction when surgery is not elected or if surgery must be delayed.

MRI/MRCP is considered to be equivalent to EUS/ERCP in the diagnostic setting; brushings can be obtained with either. MRI/MRCP can also be performed with secretin to increase secretion of pancreatic juices from the proximal pancreas for better delineation of a pancreatic duct that has a subtle stricture.

**PET/CT**

The utility of PET/CT for upstaging patients with pancreatic cancer has also been evaluated. In a retrospective study, the use of PET/CT following a standard CT protocol showed increased sensitivity for detection of metastatic disease when compared with the standard CT protocol or PET/CT alone. The sensitivity of detecting metastatic disease for PET/CT alone, standard CT alone, and the combination of PET/CT and standard CT were 61%, 57%, and 87%, respectively. In this study, the clinical management of 11% of patients with invasive pancreatic cancer was changed as a result of PET/CT findings. Nevertheless, the role of PET/CT in this setting is evolving and has not yet been established. PET/CT is not a substitute for high-quality contrast-enhanced CT, although it can be considered as an adjunct to a formal pancreatic CT protocol in high-risk patients. Indicators of high risk for metastatic disease may include borderline resectable disease, markedly elevated carbohydrate antigen (CA) 19-9, large primary tumors, large regional lymph nodes, and patients who are very symptomatic.

**Laparoscopy**

Laparoscopy is another potentially valuable diagnostic tool for staging; it can identify peritoneal, capsular, or serosal implants or studding of
metastatic tumor on the liver that may be missed even with the use of a pancreatic CT protocol. The yield of laparoscopy is dependent on the quality of preoperative imaging and the likelihood of metastatic disease. A key goal is to avoid unnecessary laparotomy, which can be accomplished in an estimated 23% of patients in whom curative intent surgery is planned, although routine use of staging laparoscopy is controversial. There is some concern that laparoscopy may promote trocar-site recurrences and peritoneal disease progression, but these concerns are based on clinical observation and experimental data from animal and in vitro studies, and one retrospective study (N = 235) found that staging laparoscopy was not significantly associated with poor outcomes. The panel does not consider staging laparoscopy to be a substitute for poor-quality preoperative imaging.

Some evidence provides support for a selective approach to staging laparoscopy (ie, it is performed if the presence of occult metastatic disease is suggested by high-quality imaging or certain clinical indicators). For example, preoperative serum CA 19-9 levels >100 U/mL or >215 U/mL (see discussion of Biomarkers, below) have been associated with a greater likelihood of advanced disease and an increased probability of a positive finding on staging laparoscopy. In a prospective review of 838 patients who were diagnosed with resectable pancreatic tumors on imaging evaluation between 1999 and 2005, 14% were found to have unresectable disease (21% yield if only pancreatic adenocarcinoma was considered) following subsequent laparoscopy. Characteristics associated with an increased laparoscopic yield of unresectable disease include the location of the tumor, tumor histology, the presence of weight loss and jaundice, and the facility conducting the imaging evaluation.

Diagnostic staging laparoscopy to rule out metastases not detected on imaging (especially for patients with body and tail lesions) is used routinely in some NCCN Member Institutions prior to surgery or chemoradiation, or selectively in patients who are at higher risk for disseminated disease (ie, borderline resectable disease; markedly elevated CA 19-9; large primary tumors; large regional lymph nodes; highly symptomatic). Thus, the panel believes that staging laparoscopy can be considered for patients staged with resectable pancreatic cancer who are considered to be at increased risk for disseminated disease and for patients with borderline resectable disease prior to administration of neoadjuvant therapy. Intraoperative ultrasound may be used as a diagnostic adjunct during staging laparoscopy to further evaluate the liver and tumor and vascular involvement. The panel considers positive cytology from washings obtained at laparoscopy or laparotomy to be equivalent to M1 disease.

**Biopsy**

Although a pathologic diagnosis is not required before surgery, it is necessary before administration of neoadjuvant therapy and for patients staged with locally advanced, unresectable pancreatic cancer or metastatic disease. A pathologic diagnosis of adenocarcinoma of the pancreas is often made using fine-needle aspiration (FNA) biopsy with either EUS guidance (preferred) or CT. EUS-FNA is preferable to CT-guided FNA in patients with resectable disease because of better diagnostic yield, safety, and potentially lower risk of peritoneal seeding with EUS-FNA when compared with the percutaneous approach. Additional risks of CT-directed FNA biopsy include the potential for greater bleeding and infection because of the need to traverse vessels and bowel. EUS-FNA also gives the benefit of additional staging information at the time of biopsy.

EUS-FNA is highly accurate and reliable for determining malignancy. A recent retrospective analysis of 317 patients with EUS-FNA results from
2 institutions found that 97% of cases deemed malignant were in fact malignant on clinical follow-up. In contrast, 13% of cases that were classified as benign were actually malignant. In rare cases when EUS-FNA cannot be obtained from a patient with borderline resectable or unresectable disease, other acceptable methods of biopsy exist. For instance, intraductal biopsies can be obtained via endoscopic cholangioscopy. A percutaneous approach or a laparoscopic biopsy are other alternatives. Pancreatic ductal brushings or biopsies can also be obtained at the time of ERCP, often revealing malignant cytology consistent with pancreatic adenocarcinoma.

If a biopsy does not confirm malignancy, at least 1 repeat biopsy should be performed; EUS-FNA with or without a core biopsy at a center with multidisciplinary expertise is preferred, though new methods are being developed for diagnosis of pancreatic malignancies (eg, cholangiopancreatography) when repeat biopsy is needed. Alternative diagnoses including autoimmune pancreatitis should be considered (see Differential Diagnoses, below). A positive biopsy is required before administration of chemotherapy. However, it is important to reiterate that biopsy proof of malignancy is not required before surgical resection for clearly resectable or borderline resectable disease and that a nondiagnostic biopsy should not delay surgical resection when the clinical suspicion for pancreatic cancer is high. The NCCN Pancreatic Adenocarcinoma Panel strongly recommends that all diagnostic and surgical management decisions involve multidisciplinary consultation.

Evolving changes in molecular analyses of pancreatic cancer have led some institutions to attempt to procure additional tumor-rich, formalin-fixed, paraffin-embedded tissue to bank for future genomic studies. Several methods can be used to obtain such tissue samples, including core biopsy, but the panel believes that core biopsies should not replace EUS-FNA, but rather can be done in addition to EUS-FNA. Some of the most common somatic mutations in pancreatic cancer are KRAS, TP53, CDKN2A, and SMAD4. Molecularly targeted therapies for pancreatic cancer are being developed and investigated.

**Biomarkers**

Many tumor-associated antigens have been studied in connection with pancreatic adenocarcinoma, including carcinoembryonic antigen (CEA), pancreatic anti-oncotic antigen, tissue polypeptide antigen, CA 125, and CA 19-9. The panel recognizes the importance of identifying biomarkers for early detection of this difficult disease, and they emphasize the need for collection and sharing of tissue to help accelerate the discovery of prognostic biomarkers (see Future Clinical Trials: Recommendations for Design, below). For example, a meta-analysis including eight studies found that S100 calcium-binding protein P (S100P) shows high sensitivity (0.87; 95% CI, 0.83–0.90) and specificity (0.88; 95% CI, 0.82–0.93) for diagnosis of pancreatic cancer. A biomarker panel consisting of the immunoassays TIMP1 and LRG1, along with CA 19-9 improved the detection of early-stage pancreatic cancer, relative to CA 19-9 alone.

**CA 19-9**

The best-validated and most clinically useful biomarker for early detection and surveillance of pancreatic cancer is CA 19-9, a sialylated Lewis A blood group antigen. CA 19-9 is commonly expressed and shed in pancreatic and hepatobiliary disease and in many malignancies; thus, it is not tumor-specific. However, the degree of increase in CA 19-9 levels may be useful in differentiating pancreatic adenocarcinoma from inflammatory conditions of the pancreas (see Differential Diagnoses, below). CA 19-9 has potential uses in diagnosis, in screening, in staging, in determining resectability, as a prognostic marker after resection, and as a predictive marker for response to chemotherapy.
CA 19-9 is a good diagnostic marker, with sensitivity of 79% to 81% and specificity of 80% to 90% in symptomatic patients, but its low positive predictive value makes it a poor biomarker for screening. Preoperative CA 19-9 levels correlate with both AJCC staging and resectability and thus can provide additional information for staging and determining resectability, along with information from imaging, laparoscopy, and biopsy.

CA 19-9 also seems to have value as a prognostic and a predictive marker for pancreatic cancer in various settings. In resectable disease, for instance, low postoperative serum CA 19-9 levels or a serial decrease in CA 19-9 levels following surgery have been found to be prognostic for survival for patients undergoing resection. In a prospective study of patients undergoing surgery with curative intent, median survival for the group of patients with post-resectional CA 19-9 levels of <180 U/mL was significantly higher compared with the group with higher levels of CA 19-9 following surgery (HR, 3.53; P < .0001).

Also in the resectable setting, data from an analysis of 260 consecutive patients support the predictive role of postoperative CA 19-9 levels for benefit of adjuvant therapy. Among patients with CA 19-9 levels of <90 U/mL, those who received adjuvant therapy (mostly gemcitabine-based) had a longer disease-free survival (DFS) than those who did not (26.0 months vs. 16.7 months; P = .011). In contrast, patients with higher CA 19-9 levels did not appear to benefit from adjuvant therapy, with DFS of 16.2 months and 9.0 months for those receiving or not receiving adjuvant therapy, respectively (P = .719). In this same study, the 11 patients with post-adjuvant therapy CA 19-9 levels less than 37 U/mL did not die of pancreatic cancer, while the 8 patients with increased CA 19-9 levels post-adjuvant therapy had a median DFS of 19.6 months, suggesting a possible prognostic benefit of post-adjuvant therapy CA 19-9 levels in this setting.

In the neoadjuvant/borderline resectable setting, a recent study of 141 patients treated at MD Anderson Cancer Center found that post-treatment CA 19-9 levels were a good prognostic marker in patients receiving neoadjuvant therapy with or without subsequent resection. This study found that a normalization of CA 19-9 to less than 40 U/mL was associated with improvements in OS in non-resected (15 months vs. 11 months; P = .02) and resected (38 months vs. 26 months; P = .02) disease.

In the advanced disease setting, data support the role of CA 19-9 as a prognostic marker. In a prospective study of patients with advanced pancreatic cancer, pretreatment CA 19-9 serum levels were shown to be an independent prognostic factor for survival. In addition, the change in CA 19-9 levels during chemotherapy in patients with advanced disease has been shown to be useful for evaluating the benefit of treatment, although the data are not entirely consistent.

For example, a study that pooled individual patients' data from 6 prospective trials found that a decline in CA 19-9 levels from baseline to after surgery and 2 rounds of adjuvant therapy were associated with a better outcome. In fact, increases of <5% in CA 19-9 were also associated with improved outcomes compared to patients with larger increases (OS, 10.3 months vs. 5.1 months; P = .002).

It is important to note that CA 19-9 may be undetectable in Lewis antigen-negative individuals. Furthermore, CA 19-9 may be falsely positive in cases of biliary infection (cholangitis), inflammation, or biliary obstruction (regardless of etiology) and does not necessarily indicate cancer or advanced disease. Preoperative measurement of CA 19-9 levels (category 3) is therefore best performed after biliary decompression is complete and bilirubin is normal. If biliary decompression is not performed in a patient with jaundice, CA 19-9 levels may be higher than the true baseline level.
levels can be assessed (category 3), but they do not represent an accurate baseline.

The panel recommends measurement of serum CA 19-9 levels prior to surgery (category 3), following surgery immediately prior to administration of adjuvant therapy, and for surveillance (category 2B). The panel emphasizes the importance of obtaining a CA 19-9 measurement immediately before the therapeutic intervention to have an accurate baseline from which to follow response; for example, before and after neoadjuvant therapy in patients with tumors that are borderline resectable. Of note, a number of different methods are commercially available for quantifying this tumor-associated antigen. Measurements of serum levels of CA 19-9 using one testing method cannot be extrapolated to results obtained using a different procedure.

**Differential Diagnoses**

Chronic pancreatitis and other benign conditions are possible differential diagnoses of patients suspected of having pancreatic cancer. Autoimmune pancreatitis, a rare form of chronic pancreatitis also known as lymphoplasmacytic sclerosing pancreatitis, is a heterogeneous disease that can present with clinical and radiologic characteristics of pancreatic cancer, such as jaundice, weight loss, an elevated CA 19-9 level, and the presence of diffuse pancreatic enlargement, a pancreatic ductal stricture, or a focal pancreatic mass. The classic appearance of the pancreas on abdominal CT in patients with diffuse pancreatic involvement is a sausage-shaped enlargement of the organ with a capsule-like peripheral rim surrounding the pancreas, although focal enlargement of the pancreas is observed in some cases. Cardinal histologic features of autoimmune pancreatitis include prominent lymphocytic infiltration of the pancreatic parenchyma with associated fibrosis.

In addition, fine-needle aspirates can be misinterpreted as malignant or suspicious for malignancies. As a benign disease that can be effectively treated with corticosteroids, autoimmune pancreatitis must be distinguished from pancreatic cancer to avoid unnecessary surgery and prevent delay in the initiation of appropriate treatment.

The finding of increased serum immunoglobulin (Ig) G levels is supportive of a diagnosis of autoimmune pancreatitis, although an elevated level of serum IgG4 specifically is the most sensitive and specific laboratory indicator. A recent study found that IgG4 levels of >1.0 g/L combined with CA 19-9 levels of <74 U/mL distinguished patients with autoimmune pancreatitis from those with adenocarcinoma with 94% sensitivity and 100% specificity. Jaundiced patients with locally advanced disease should be reviewed for autoimmune pancreatitis, and IgG4 levels should be assessed.

Autoimmune pancreatitis can, however, be negative for IgG4, thus closely mimicking pancreatic adenocarcinoma when there is a large pancreatic mass. For patients with borderline resectable disease and cancer not confirmed after 2 or 3 biopsies, a second opinion is recommended. Alternative diagnoses should be considered, especially autoimmune pancreatitis, and a short course of steroid treatment may be an appropriate first approach. If no response is seen, the patient should undergo laparotomy for removal of the mass. Consultation with an expert pancreatologist is also recommended.

**Systemic Therapy Approaches**

Systemic therapy is used in all stages of pancreatic adenocarcinoma. It is important that biopsy confirmation of pancreatic adenocarcinoma be obtained before treatment in all cases (see Table 2, below). At least 2 or 3 negative or indeterminate biopsies should be obtained before entertaining alternative diagnoses (see Differential Diagnoses, above).
A second opinion should also be obtained in such a case. Occasionally, other cancer types are confirmed, and the patient should be treated according to the appropriate NCCN Guideline. The data supporting the regimens used in pancreatic cancer are described below.

**Gemcitabine Monotherapy**

For patients with locally advanced or metastatic disease, gemcitabine has been established as providing clinical benefit and a modest survival advantage over treatment with bolus 5-FU. The panel recommends gemcitabine monotherapy as one option for front-line therapy for patients with metastatic disease (category 1) or locally advanced disease and a good performance status. Because the approved indications for gemcitabine include the relief of symptoms, the panel also recommends gemcitabine monotherapy as a reasonable option for symptomatic patients with metastatic or locally advanced unresectable disease with poor performance status (category 1).

Gemcitabine monotherapy also has category 1 evidence supporting its use in the adjuvant setting. In the large phase III CONKO-001 trial, in which 368 patients without prior chemotherapy or RT were randomly assigned to adjuvant gemcitabine versus observation following macroscopically complete resection, an intention-to-treat (ITT) analysis of the data showed that the primary endpoint of increased DFS was met (13.4 months vs. 6.9 months; \( P < .001 \), log rank). Final results from this study showed median OS to be improved significantly for patients in the gemcitabine arm (22.8 months vs. 20.2 months; HR, 0.76; 95% CI, 0.61–0.95; \( P = .01 \)). An absolute survival difference of 10.3% was observed between the two groups at 5 years (20.7% vs. 10.4%).

**Gemcitabine Response: hENT1**

Human equilibrative nucleoside transporter 1 (hENT1) is a nucleoside transporter that has been studied as a predictor for response to gemcitabine. Preliminary clinical data have shown that hENT1 expression may in fact predict response to gemcitabine.

hENT1 has been validated in 2 retrospective analyses as a predictive biomarker for benefit from gemcitabine. A recent retrospective analysis of core tissue from patients treated on the adjuvant gemcitabine ESPAC-3 trial found that hENT1 expression was predictive of response to gemcitabine but not to 5-FU. Median survival for patients treated with gemcitabine was 17.1 months versus 26.2 months for those with low versus high hENT1 expression, respectively (\( P = .002 \)). In the 5-FU group, median survival was 25.6 months versus 21.9 months for the low and high hENT1 groups, respectively (\( P = .36 \)). A similar analysis was performed on samples of patients treated on RTOG 9704. As with the ESPAC-3 study, hENT1 expression was associated with OS (HR, 0.40; 95% CI, 0.22–0.75; \( P = .03 \)) and DFS (HR, 0.39; 95% CI, 0.21–0.73; \( P = .003 \)) in patients receiving gemcitabine, but hENT1 expression was not associated with OS (HR, 0.78; 95% CI, 0.47–1.27; \( P = .31 \)) and DFS (HR, 0.72; 95% CI, 0.45–1.16; \( P = .18 \)) in the group given 5-FU.

Thus, hENT1 appears to be an excellent predictive biomarker in the adjuvant setting based on the assay used in both of these studies (IHC with the 10D7G2 antibody). Other separate retrospective analyses of results from the adjuvant CONKO-001 trial and the AIO-PK0104 trial were unable to confirm these results using a different antibody for the IHC analysis (SP120).

Unfortunately, hENT1 could not be validated in the metastatic setting in the LEAP trial, which also used the SP120 assay to determine hENT1 expression. Results from the phase II, randomized, open-label LEAP trial, which compared a lipid-conjugated form of gemcitabine that does not require hENT1 for cell entry (CO-1.01) with gemcitabine in patients with metastatic disease with high versus low expression of hENT1,
found that hENT1 expression was not predictive of outcomes in patients treated with gemcitabine.\textsuperscript{229} Trial results also found no differences in OS between the 2 treatments in patients with low hENT2 expression (HR, 0.99; 95% CI, 0.75–1.33).

Further studies based on hENT1 expression using the 10D7G2 assay are limited by the fact that no commercial source of the antibody and no CLIA-approved testing are available.

**Fixed-Dose-Rate Gemcitabine**

Studies have suggested that the infusion rate of gemcitabine may be important for its efficacy. Gemcitabine is a prodrug, which must be phosphorylated for antitumor activity. Clinical studies have shown that administering gemcitabine at a fixed dose rate (FDR) maximizes intracellular concentrations of the phosphorylated forms of gemcitabine.\textsuperscript{230} In a randomized phase II trial of patients with locally advanced or metastatic pancreatic cancer, the infusion of gemcitabine at an FDR led to better survival compared with gemcitabine delivered at a higher dose, over 30 minutes.\textsuperscript{231} In the phase III randomized ECOG-6201 trial of patients with advanced pancreatic cancer, median survival was increased in the group receiving FDR gemcitabine vs. standard gemcitabine (6.2 months vs. 4.9 months; \(P = .04\)), although this outcome did not satisfy the protocol-specified criteria for superiority.\textsuperscript{232}

When gemcitabine is considered for the treatment of advanced pancreatic cancer, the NCCN Panel views FDR gemcitabine (10 mg/m\(^2\)/min) as a reasonable alternative to the standard infusion of gemcitabine over 30 minutes (category 2B).

FDR gemcitabine is incorporated into some commonly used gemcitabine-based regimens (eg, GEMOX [gemcitabine, oxaliplatin]; GTX [gemcitabine, docetaxel, and capecitabine]). See *Gemcitabine Combinations*, below.\textsuperscript{233,234} The combination of FDR gemcitabine and capecitabine has also been found to be active and well-tolerated.\textsuperscript{235}

**Gemcitabine Combinations**

The NCCN Panel acknowledges that, historically, combination chemotherapy did not appear to be superior to monotherapy in the era of 5-FU–based therapy. However, because gemcitabine is superior to bolus 5-FU in the advanced setting when efficacy endpoints of survival and relief from symptoms are used, it is now often combined with other chemotherapeutic agents for patients with good performance status. Gemcitabine has been investigated in combination with potentially synergistic agents (such as cisplatin, oxaliplatin, capecitabine, 5-FU, and irinotecan) or in a multidrug combination (eg, cisplatin, epirubicin, gemcitabine, 5-FU).\textsuperscript{232-234,236-246} Two meta-analyses of randomized controlled trials (RCTs) found that gemcitabine combinations give a marginal benefit in OS over gemcitabine monotherapy in the advanced setting, with a significant increase in toxicity.\textsuperscript{247,248}

Combinations recommended in the advanced setting are discussed below. The panel does not consider the combination of gemcitabine plus docetaxel\textsuperscript{249} or gemcitabine plus irinotecan\textsuperscript{246,249,250} to meet the criteria for inclusion in the guidelines. In addition, gemcitabine plus sorafenib is not recommended. The multi-center, double-blind, placebo-controlled, randomized phase III BAYPAN trial compared gemcitabine plus either sorafenib or placebo in chemotherapy-naïve patients with advanced or metastatic disease.\textsuperscript{251} This trial did not meet its primary endpoint of progression-free survival (PFS) in its 104 patients (5.7 months vs. 3.8 months; \(P = .90\)). Gemcitabine combinations are currently being studied in the adjuvant setting.
Of note, results from several studies have indicated that the benefit of gemcitabine combination chemotherapy is predominantly seen in patients with good performance status.\(^{240,241,243}\)

**Gemcitabine Plus Albumin-Bound Paclitaxel**

Albumin-bound paclitaxel is a nanoparticle form of paclitaxel. In a publication of a phase I/II trial, 67 patients with advanced pancreatic cancer received gemcitabine plus albumin-bound paclitaxel. At the maximum tolerated dose, the partial response rate was 48%, with an additional 20% of patients demonstrating stable disease for 16 or more weeks. The median OS at this dose was 12.2 months.\(^{252}\)

Based on these results, the large, open-label, international, randomized phase III MPACT trial was initiated in 861 patients with metastatic pancreatic cancer and no prior chemotherapy.\(^{253}\) Participants were randomized to receive gemcitabine plus albumin-bound paclitaxel or gemcitabine alone. The trial met its primary endpoint of OS (8.7 months vs. 6.6 months; \(P < .0001; \text{HR}, 0.72\)).\(^{253}\) The addition of albumin-bound paclitaxel also improved other endpoints, including 1-year survival, 2-year survival, response rate, and PFS. OS was associated with a decrease in CA 19-9 (HR, 0.53; 95% CI, 0.36–0.78; \(P = .001\)).\(^{254}\) Tumor response was validated with PET imaging.\(^{255}\) The most common grade 3 or higher adverse events attributable to albumin-bound paclitaxel were neutropenia, fatigue, and neuropathy. Development of peripheral neuropathy was associated with longer treatment duration and greater treatment efficacy.\(^{256}\) Updated results of the MPACT trial show that long-term survival is possible with gemcitabine plus albumin-bound paclitaxel, as 3% of patients from that arm were alive at 42 months, whereas no patients were alive from the control arm at that time.\(^{257}\) Factors associated with survival in this trial include KPS score and absence of liver metastases.\(^{258}\)

For the 2013 guidelines, the panel upgraded the combination of gemcitabine plus albumin-bound paclitaxel from a category 2B to a category 1 recommendation for the treatment of patients with metastatic disease and good performance status based on these results, and it is listed as a preferred option in this setting. Good performance status for this regimen is defined as KPS \(\geq 70\), so some patients with an ECOG score of 2 may be eligible to receive this regimen.\(^{259,260}\) By extrapolation of the data, the panel recommends this combination in the locally advanced, good performance status setting as well (category 2A). The panel also notes that this combination is an acceptable option in the neoadjuvant/borderline resectable setting.

**Gemcitabine Plus Erlotinib and Other Targeted Therapeutics**

Although phase II trial results of gemcitabine combined with new targeted drugs (eg, bevacizumab, cetuximab) were encouraging,\(^{261,262}\) results of phase III studies of combinations of gemcitabine with a biologic agent have indicated that only the combination of gemcitabine plus erlotinib is associated with a statistically significant increase in survival when compared to gemcitabine alone.\(^{263-267}\) In the phase III, double-blind, placebo-controlled NCIC CTG PA.3 trial of 569 patients with advanced or metastatic pancreatic cancer randomly assigned to receive erlotinib (which is an inhibitor of EGFR tyrosine kinase) plus gemcitabine versus gemcitabine alone, patients in the erlotinib arm showed statistically significant improvements in OS (HR, 0.82; \(P = .038\)) and PFS (HR, 0.77; \(P = .004\)) when compared to patients receiving gemcitabine alone.\(^{263}\) Median survival was 6.24 months and 1-year survival was 23%, compared with 5.91 months and 17% in the control arm. Adverse events, such as rash and diarrhea, were increased in the group receiving erlotinib, but most were grade 1 or 2.\(^{263}\) This trial, other trials, and community experience show that occurrence of grade 2 or
higher skin rash is associated with better response and OS of patients receiving erlotinib.263,268,269

Several targeted therapies besides erlotinib have been assessed in combination with gemcitabine, but none have been shown to significantly impact outcomes. Agents assessed in phase III trials include bevacizumab (an anti-vascular endothelial growth factor [VEGF] antibody),264,265,267 axitinib,266 ziv-aflibercept,270,271 rigosertib (kinase inhibitor),272 dasatinib (competitive inhibitor of Src kinase),273 and ganitumab (an insulin-like growth factor 1 receptor monoclonal antibody).274 The angiogenesis inhibitor sunitinib and the sonic hedgehog antagonist vismodegib were assessed in phase II randomized trials.275,276 However, it is important to note that impact on outcomes may depend on setting. For example, there is evidence from a phase II randomized trial that sunitinib as maintenance therapy may improve outcomes (see section on maintenance therapy, below).277

The NCCN Panel recommends gemcitabine-erlotinib combination therapy as another option for patients with locally advanced or metastatic disease and good performance status, with this combination being a category 1 recommendation for patients with metastatic disease. However, the panel notes that although this combination significantly improved survival, the actual benefit was small, suggesting that only a small subset of patients benefit.

**Gemcitabine Plus Cisplatin**

Data regarding the survival impact of combining gemcitabine with a platinum agent are conflicting, and results of RCTs have not provided support for use of gemcitabine plus cisplatin in the treatment of patients with advanced pancreatic cancer. Three phase III trials evaluating the combination of gemcitabine with cisplatin versus gemcitabine alone in patients with advanced pancreatic cancer failed to show a significant survival benefit for the combination over the single agent.237,238,241

Nevertheless, selected patients may benefit from this regimen because patients with breast and ovarian cancers who are carriers of a BRCA mutation278-280 and selected patients with inherited forms of pancreatic cancer99 may have disease that is particularly sensitive to a platinum agent. A retrospective study from Johns Hopkins University School of Medicine of patients with metastatic pancreatic cancer and a family history of breast, ovarian, or pancreatic cancers suggested that response to gemcitabine and cisplatin was superior even with one affected relative.281 Patients with a family history of pancreatic cancer alone demonstrated a large survival advantage when treated with platinum-based chemotherapy (6.3 vs. 22.9 months; HR, 0.34; 95% CI, 0.15–0.74; P < .01).281 Furthermore, a report of 5 of 6 patients with known BRCA mutations and metastatic pancreatic adenocarcinoma treated with a platinum-based regimen at Memorial Sloan Kettering Cancer Center showed a radiographic partial response.282 Thus, gemcitabine plus cisplatin may be a good choice in selected patients with disease characterized by hereditary risk factors (eg, BRCA or PALB2 mutations). The panel recommends gemcitabine plus cisplatin for patients with metastatic or locally advanced disease, especially as an alternative to FOLFIRINOX in patients with a hereditary cancer syndrome involving a DNA repair mutation.

**Gemcitabine Plus Capecitabine**

A number of randomized trials have investigated the combination of gemcitabine with capecitabine, a fluoropyrimidine, in patients with advanced pancreatic cancer. A randomized study in 533 patients with advanced disease found that PFS and objective response rates were significantly improved in patients receiving gemcitabine plus capecitabine when compared with gemcitabine alone, although a trend
toward an improvement in OS for the combination arm did not reach statistical significance.\textsuperscript{239} Similarly, results from another smaller phase III trial evaluating this combination did not demonstrate an OS advantage for overall study population receiving the combination of gemcitabine with capecitabine, although a post-hoc analysis showed OS to be significantly increased in the subgroup of patients with good performance status.\textsuperscript{243} In a recent meta-analysis of 8 RCTs, OS was better in patients receiving gemcitabine plus capecitabine than in patients receiving gemcitabine alone (HR, 0.87; \( P = 0.03 \)).\textsuperscript{283} Although there are concerns about dosing and toxicity of capecitabine in a U.S population, a biweekly regimen of fixed-dose gemcitabine in combination with capecitabine may be both effective and well tolerated in patients with advanced disease.\textsuperscript{235}

The panel includes the combination of gemcitabine, docetaxel, and capecitabine (GTX regimen) as a category 2B recommendation for the treatment of patients with metastatic or locally advanced disease and good performance status. In a report of 35 patients with metastatic pancreatic cancer treated with this regimen, the authors reported an overall response rate of 29\% (all had partial responses), with an additional 31\% of patients exhibiting a minor response or stable disease.\textsuperscript{234} The median survival was 11.2 months for all patients and 13.5 months for patients exhibiting a partial response. This regimen demonstrated significant toxicities, however, with 14\% of patients having grade 3/4 leukopenia, 14\% having grade 3/4 thrombocytopenia, and 9\% having grade 3/4 anemia. A retrospective case-review study at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins found similar results, with a median OS of 11.6 months and grade 3 or greater hematologic and non-hematologic toxicity rates of 41\% and 9\%, respectively.\textsuperscript{284}

Gemcitabine combined with capecitabine and oxaliplatin (GEMOXEL) was recently assessed in a randomized phase II trial (\( N = 67 \)) for the metastatic setting.\textsuperscript{285} Disease control rate (\( P = .004 \)), PFS (\( P < .001 \)), and OS (\( P < .001 \)) were all superior in patients randomized to receive the GEMOXEL regimen, compared to patients randomized to receive gemcitabine alone.

The NCCN Panel considers gemcitabine-based combination therapy with capecitabine to be a reasonable option (category 2A) for patients with locally advanced or metastatic disease and a good performance status who are interested in pursuing more aggressive therapy outside a clinical trial.

**Gemcitabine and Other Fluoropyrimidine-Based Therapies**

Gemcitabine has been examined in combination with other fluoropyrimidine-based therapies. A recent meta-analysis of 8 RCTs, including more than 2000 patients, found that OS was significantly improved when a fluoropyrimidine was added to gemcitabine.\textsuperscript{283} In a phase II randomized trial, the effects of the FIRGEM regimen \{irinotecan delivered before and after infusion of 5-FU/leucovorin (FOLFIRI.3), alternating with FDR gemcitabine\} were assessed in 98 patients with metastatic pancreatic cancer.\textsuperscript{286} Patients were randomized to receive the FIRGEM regimen or FDR gemcitabine monotherapy. The primary objective of a 45\% PFS rate at six months was reached, and PFS was a median of 5.0 months in those randomized to receive the FIRGEM regimen, while those randomized to receive only gemcitabine had a median PFS of 3.4 months (HR, 0.59; 95\% CI, 0.38–0.90). Rates of hematologic toxicity were higher in those who received the FIRGEM regimen, relative to those who received gemcitabine only. Study investigators deemed FIRGEM to be effective and feasible in the metastatic setting.
The ECOG E2297 trial compared gemcitabine monotherapy with gemcitabine and bolus 5-FU/leucovorin in patients with advanced pancreatic cancer; no statistically significant survival advantage was observed for patients receiving the combination regimen.\(^{236}\)

Recent randomized trials from Asia show that gemcitabine combined with the oral fluoropyrimidine S-1 may improve response and survival in patients with locally advanced pancreatic cancer, though trial results are inconsistent regarding whether outcomes are improved over gemcitabine monotherapy.\(^{287-289}\)

**5-FU/Leucovorin**

5-FU with leucovorin is listed in the guidelines as a category 1 option in the adjuvant setting. Results from the European Study Group for Pancreatic Cancer (ESPAC)-1 trial, reported by Neoptolemos and colleagues, suggested that 5-FU/leucovorin is superior to observation.\(^{290}\) In addition, results from the ESPAC-3 trial of bolus 5-FU/leucovorin versus gemcitabine following surgery showed no difference in median OS between the arms (23.0 months and 23.6 months, respectively).\(^{291}\)

**Leucovorin Shortage**

There is currently a shortage of leucovorin in the United States. There are no specific data to guide management under these circumstances, and all proposed strategies are empiric. The panel recommends several possible options to help alleviate the problems associated with this shortage. One is the use of levo-leucovorin, which is commonly used in Europe. A dose of 200 mg/m\(^2\) of levo-leucovorin is equivalent to 400 mg/m\(^2\) of standard leucovorin. Another option is for practices or institutions to use lower doses of leucovorin for all doses in all patients, since the panel feels that lower doses are likely to be as efficacious as higher doses, based on several studies. The QUASAR study found that 175 mg leucovorin gave similar survival and 3-year recurrence rates as 25 mg leucovorin when given with bolus 5-FU to patients as adjuvant therapy following R0 resections for colorectal cancer.\(^{292}\) Another study showed no difference in response rate or survival in patients with metastatic colorectal cancer receiving bolus 5-FU with either high-dose (500 mg/m\(^2\)) or low-dose (20 mg/m\(^2\)) leucovorin.\(^{293}\) Also, the Mayo Clinic and North Central Cancer Treatment Group (NCCTG) determined that there was no therapeutic difference between the use of high- (200 mg/m\(^2\)) or low- (20 mg/m\(^2\)) dose leucovorin with bolus 5-FU in the treatment of advanced colorectal cancer, although 5-FU doses were different in the 2 arms.\(^{294}\) Finally, if none of the above options is available, treatment without leucovorin would be reasonable. For patients who tolerate this without grade II or higher toxicity, a modest increase in 5-FU dose (in the range of 10%) may be considered.

**FOLFIRINOX**

In 2003, a French group reported the results of an open phase I study to assess the feasibility of a combination therapy consisting of 5-FU/leucovorin plus oxaliplatin and irinotecan (FOLFIRINOX) for the treatment of patients with metastatic solid tumors.\(^{295}\) Their study included 2 patients with pancreatic cancer, and the regimen showed anti-tumor activity. A subsequent multicenter phase II trial specifically for patients with advanced pancreatic adenocarcinoma demonstrated promising response rates.\(^{296}\) A later randomized phase II trial showed a response rate of greater than 30% to FOLFIRINOX in patients with metastatic pancreatic cancer.\(^{297}\)

Results from the randomized phase III PRODIGE trial evaluating FOLFIRINOX versus gemcitabine in patients with metastatic pancreatic cancer and good performance status showed dramatic improvements in both median PFS (6.4 months vs. 3.3 months; \(P < .001\)) and median
OS (11.1 months vs. 6.8 months; \( P < .001 \)), in favor of the group receiving FOLFIRINOX.\(^{298}\) Eligibility criteria for this trial, however, were stringent, limiting real-world generalizability.\(^{299}\) For example, patients with abnormal bilirubin levels were excluded from participating.

A systematic review including 11 studies and 315 patients with locally advanced pancreatic cancer showed a pooled median OS of 24.2 months (95% CI, 21.7–26.8).\(^{300}\) A recent observational study including 101 patients with locally advanced unresectable disease who were treated with FOLFIRINOX as induction therapy showed that 29% of the sample (20% without administration of chemoradiation) had a reduction in tumor size of greater than 30%, and half of the patients who experienced a reduction in tumor size underwent resection.\(^{301}\) Out of the patients who underwent resection, 55% achieved an R0 resection. Prospective randomized trials are needed to validate these results.

Because of the strong results from the PRODIGE trial, in 2011 the panel added FOLFIRINOX as a preferred, category 1 recommendation for first-line treatment of patients with good performance status (ie, ECOG 0-1) with metastatic pancreatic cancer. It is listed as a category 2A recommendation for patients with locally advanced unresectable disease by extrapolation. The panel also lists this regimen as an acceptable option in the neoadjuvant/borderline resectable setting.

There are some concerns about the toxicity of the FOLFIRINOX regimen. In the PRODIGE trial, some of the grade 3/4 toxicity rates that were significantly greater in the FOLFIRINOX group than in the gemcitabine group were 45.7% for neutropenia, 12.7% for diarrhea, 9.1% for thrombocytopenia, and 9.0% for sensory neuropathy.\(^{298}\) Despite the high levels of toxicity, no toxic deaths have been reported.\(^{296-298}\) Furthermore, the PRODIGE trial determined that, despite this toxicity, fewer patients in the FOLFIRINOX group than in the gemcitabine group experienced a degradation in their quality of life at 6 months (31% vs. 66%, \( P < .01 \)).\(^{298}\) A more detailed analysis of the quality of life of patients in this trial has been published and shows that FOLFIRINOX maintained and even improved quality of life more so than gemcitabine.\(^{302}\)

The panel appreciates that toxicity of FOLFIRINOX can be managed with a variety of approaches. For example, a group from Memorial Sloan Kettering Cancer Center reported good activity and acceptable toxicity of first-line FOLFIRINOX at 80% dose intensity with routine growth factor support in carefully selected patients with metastatic or locally advanced disease.\(^{303}\) Median OS was 12.5 months in the metastatic setting and 13.7 months in patients with locally advanced disease. The efficacy and toxicity of a modified FOLFIRINOX regimen in which the initial dosing of bolus 5-FU and irinotecan were each reduced by 25% were assessed in a phase II single-arm prospective trial (\( N = 75 \)).\(^{304}\) In patients with metastatic disease, the efficacy of the modified regimen was comparable to that of the standard regimen (median OS = 10.2 months). In patients with locally advanced disease, the median OS was 26.6 months. Patients who received the modified regimen experienced significantly less neutropenia, fatigue, and vomiting, relative to patients who received the standard FOLFIRINOX regimen.

**Capecitabine and Continuous Infusion 5-FU**

The panel lists capecitabine monotherapy and continuous infusion 5-FU as first-line treatment options for patients with locally advanced unresectable (category 2B), and for patients with poor performance status and metastatic disease (category 2B). They are also recommended as options in the adjuvant settings (category 2A for continuous infusion 5-FU and category 2B for capecitabine). The capecitabine recommendation is supported by a randomized phase III
trial from the Arbeitsgemeinschaft Internistische Onkologie (AIO) group in which OS was similar in patients with advanced pancreatic cancer receiving capecitabine plus erlotinib followed by gemcitabine monotherapy or gemcitabine plus erlotinib followed by capecitabine monotherapy.\(^{305}\)

Note that the capecitabine dose recommended by the panel (1000 mg/m\(^2\) PO twice daily) is less than the dose described by Cartwright and colleagues, because the higher dose has been associated with increased toxicity (eg, diarrhea, hand and foot syndrome).\(^{306}\)

**Fluoropyrimidine Plus Oxaliplatin**

The combination of a fluoropyrimidine (5-FU/leucovorin or capecitabine) with oxaliplatin is listed as a possible first-line treatment for metastatic or locally advanced disease (category 2B). The panel bases these recommendations on the randomized phase III CONKO-003 trial (5-FU/leucovorin/oxaliplatin vs. best supportive care) and on a phase II study (CapeOx).\(^{307,308}\) Both of these studies only enrolled patients who had received 1 prior chemotherapy regimen, but the panel feels the extrapolation to first-line therapy is appropriate (category 2B).

**Possible Role of Maintenance Therapy in Advanced Disease**

With the success of more effective regimens in patients with advanced disease, questions have been raised about how best to manage the treatment-free interval prior to disease progression. Options include stopping treatment, dropping the most toxic agents, and using different agents for maintenance therapy.

A randomized phase II trial (PACT-12) had intriguing results that suggest maintenance therapy with sunitinib after a full course of first-line treatment may have a benefit in some patients with metastatic disease.\(^{277}\) Patients without evidence of progression after 6 months of initial therapy (n = 55; mostly gemcitabine combinations) were randomized to sunitinib or observation. Median OS was 9.2 months in the observation group versus 10.6 months in the sunitinib group (HR, 0.71; 95% CI, 0.40–1.26; \(P = .11\)). The small sample size precludes strong conclusions; however, the 1- and 2-year survival rates were 36% and 7% in the observation arm compared with 41% and 23% in the sunitinib arm, suggesting that a subset of patients derive significant benefit. Anti-angiogenic agents have not been successful in the treatment of pancreatic cancer to date. However, results of the PACT-12 trial suggest that there may in fact be a role for these compounds in this disease. Angiogenesis inhibitors may be more useful after more effective first-line treatments. Clearly, additional trials in this important area are needed.

**Second-Line Systemic Therapy in the Advanced Setting**

A systematic review of clinical trials that assessed the efficacy of second-line therapy after gemcitabine in pancreatic cancer concluded that, while data are very limited, evidence suggests an advantage of additional chemotherapy over best supportive care.\(^{309}\) For patients with advanced disease who have received prior gemcitabine-based therapy, fluoropyrimidine-based chemotherapy regimens are acceptable second-line options.\(^{307,308,310,311}\) Gemcitabine-based therapy can be given to those previously treated with fluoropyrimidine-based therapy. Second-line systemic therapy should be administered to patients with good performance status only.

Results from the phase III CONKO-003 trial presented in 2008 showed significant improvements in both median PFS (13 weeks vs. 9 weeks; \(P = .012\)) and median OS (20 weeks vs. 13 weeks; \(P = .014\)) when oxaliplatin was added to 5-FU/leucovorin,\(^{312,313}\) making this regimen the standard approach for second-line therapy for patients without prior
exposure to fluoropyrimidine-based therapy at that time. Final results of the trial were published in 2014. The median OS in the OFF arm was 5.9 months (95% CI, 4.1–7.4), whereas it was 3.3 months (95% CI, 2.7–4.0) in the 5-FU/LV arm, for a significant improvement in the HR (0.66; 95% CI, 0.48–0.91; \( P = .01 \)).

However, results from the open-label phase III PANCREOX trial show that the addition of oxaliplatin to 5-FU/LV in second-line treatment may be detrimental. In this trial, 108 patients with advanced pancreatic cancer who progressed on gemcitabine-based treatment were randomized to receive second-line mFOLFOX6 or infusional 5-FU/LV. No difference was seen in median PFS (3.1 vs. 2.9 months; \( P = .99 \)), but median OS was worse in those in the FOLFOX arm (6.1 vs. 9.9 months; \( P = .02 \)). Furthermore, the addition of oxaliplatin resulted in increased toxicity, with rates of grade 3/4 adverse events of 63% in the FOLFOX arm and of 11% in the 5-FU/LV arm. However, this trial was limited by imbalances in PS 2 proportion between the study arms and possible crossover in treatment delivered following progression.

In the recent NAPOLI-1 phase III randomized trial, the effects of nanoliposomal irinotecan were examined in patients with metastatic pancreatic cancer who previously received gemcitabine-based therapy. Patients were randomized to receive the nanoliposomal irinotecan monotherapy, 5-FU/leucovorin, or both (\( N = 417 \)). Median PFS (3.1 months vs. 1.5 months; HR, 0.56; 95% CI, 0.41–0.75; \( P < .001 \)) was significantly greater for patients who received nanoliposomal irinotecan with 5-FU/leucovorin, compared to patients who did not receive irinotecan. Updated analyses showed that median OS (6.2 months vs. 4.2 months; HR, 0.75; \( P = .042 \)) was significantly greater for patients who received nanoliposomal irinotecan with 5-FU/leucovorin, compared to patients who received 5-FU/leucovorin without irinotecan. Grade 3 or 4 adverse events that occurred most frequently with this regimen were neutropenia (27%), fatigue (14%), diarrhea (13%), and vomiting (11%). Irinotecan liposomal injection, combined with 5-FU/leucovorin, was recently approved by the FDA to be used as second-line treatment following gemcitabine-based therapy in patients with metastatic disease. The panel recommends this regimen as second-line treatment for patients with good performance status and disease progression.

The AIO-PK0104 trial also assessed second-line therapy in a randomized crossover trial and found capecitabine to be efficacious after progression on gemcitabine/erlotinib in patients with advanced disease. In this trial, capecitabine/erlotinib followed by gemcitabine gave similar outcomes to the aforementioned sequence. Results from a recently published phase II trial of patients with disease progression on or following gemcitabine (\( N = 127 \)) showed that survival rates in patients randomized to receive the JAK1/JAK2 inhibitor ruxolitinib, combined with capecitabine, did not significantly differ from that of patients randomized to receive a placebo with capecitabine, except in patients with inflammation (assessed based on serum C-reactive protein levels; \( n = 60 \); HR, 0.47; 95% CI, 0.26–0.85; \( P = .011 \)).

Second-line treatment options for patients previously treated with gemcitabine-based therapy include: 5-FU/leucovorin/nanoliposomal irinotecan (category 1 for metastatic disease), FOLFIRINOX, 5-FU/leucovorin/oxaliplatin, FOLFOX, CapeOx, capecitabine, and continuous infusion 5-FU. Options for patients previously treated with fluoropyrimidine-based therapy include: 5-FU/leucovorin/nanoliposomal irinotecan (if no prior irinotecan administered), gemcitabine/albumin-bound paclitaxel, gemcitabine/cisplatin, gemcitabine/erlotinib, and gemcitabine monotherapy. Chemoradiation is a second-line treatment option in select patients (see Management of Locally Advanced Disease below).
Radiation and Chemoradiation Approaches

In patients with pancreatic cancer, radiation is usually given concurrently with gemcitabine- or fluoropyrimidine-based chemotherapy. Chemotherapy is used as a radiosensitizer, increasing the toxicity of radiation to tumor cells. Although the mechanism of radiosensitization is not entirely clear, it is postulated that gemcitabine and fluoropyrimidines decrease the number of tumor cells in the S phase of the cell cycle, a stage at which cells are resistant to radiation damage.321

Radiation and chemoradiation are sometimes used for pancreatic cancer in the resectable and adjuvant settings, because of the potential of these treatment methods to decrease the likelihood of local recurrence. A major goal of radiation therapy (RT) in these settings is to sterilize vessel margins and increase the likelihood of a margin-negative resection. It also may be used to enhance local control and prevent disease progression, while minimizing the risk of RT exposure to surrounding organs at risk. Chemoradiation is also often incorporated into neoadjuvant regimens, although randomized trials demonstrating the role of chemoradiation in this setting have not been done. Chemoradiation can also be given as second-line therapy in patients with locally advanced unresectable disease, if chemoradiation was not previously given and if the primary site is the sole site of progression. Finally, radiation without chemotherapy is used in the metastatic setting as palliation for pain refractory to narcotic therapy. Varying levels of evidence support the use of chemoradiation in each setting, as discussed in more detail below.

Stereotactic body radiotherapy (SBRT) is another technique aimed at increasing dose to the gross tumor while sparing radiation to nearby healthy tissue.322-328 Results from a prospective trial showed that SBRT was associated with less severe radiation-induced lymphopenia one month after beginning treatment, relative to conventional chemoradiation (13.8% vs. 71.7%, respectively; \( P < .001 \)).329 SBRT should not be used if direct invasion of the bowel or stomach is observed on imaging, and care should be taken to limit dose to these areas to reduce treatment-related toxicity, particularly in patients with unresectable disease. SBRT delivered in 3 to 5 fractions may reduce toxicity, though longer follow-up may then be needed.330 Since the data regarding appropriate use of SBRT is evolving, the panel recommends that it should be used preferably in the context of a clinical trial and at an experienced high-volume center.

Adjuvant Chemoradiation

In 1985, the Gastrointestinal Tumor Study Group (GITSG) initially reported that the median survival of patients undergoing pancreateoduodenectomy could be prolonged almost 2-fold by postoperative chemoradiation. In this study, patients were randomly assigned to either observation or RT combined with an intermittent bolus of 5-FU after resection. A standard split course of 4,000 cGy was used. 5-FU, 500 mg/m² daily for 3 days, was given concurrently with each 2,000-cGy segment of RT. The 5-FU regimen was then continued weekly for a full 2 years. In addition to a prolonged median survival, chemoradiation also resulted in a 2-year actuarial survival of 42%, compared with 15% in the control group.330

Other studies have also shown an advantage to adjuvant chemoradiation over observation after resection. EORTC conducted a phase III trial (40891) in patients with both ampullary and pancreatic adenocarcinoma assessing adjuvant radiotherapy and 5-FU versus observation alone after surgery. They found that the benefit of therapy was small in a subset of patients with pancreatic adenocarcinoma and...
was not statistically significant. At a median follow-up of 11.7 years, no statistically significant differences were observed in the different study arms with respect to PFS or OS for the subset of patients with pancreatic cancer.

More contemporary studies have compared different regimens incorporating chemoradiation. The Radiation Therapy Oncology Group study RTOG 9704 was a phase III study that evaluated postoperative adjuvant treatment of resected pancreatic adenocarcinoma using either gemcitabine or fluorouracil for 3 weeks before and 12 weeks after 5-FU–based chemoradiation for both groups. This trial, which utilized daily fractionated radiotherapy, included prospective quality assurance of all patients, including central review of preoperative CT imaging and radiation fields. Results of this study showed that, for patients with tumors of the pancreas head (representing 388 of the 451 patients enrolled in the trial), there was a non-statistically significant increase in OS in the gemcitabine arm compared with the 5-FU arm (median and 3-year survival of 20.5 months and 31% vs. 16.9 months and 22%; \( P = .09 \)); this benefit became more pronounced on multivariate analysis (HR, 0.80; 95% CI, 0.63–1.00; \( P = .05 \)). The 5-year analysis of RTOG 9704 showed that there was in fact no difference in OS between the two groups, although patients with tumors in the head of the pancreas showed a trend toward improved OS with gemcitabine (\( P = .08 \)) upon multivariate analysis.

The Role of Radiation in Adjuvant Regimens

The majority of the data comparing chemotherapy to chemoradiation in the adjuvant setting do not generally show an advantage to the addition of radiation. Results of ESPAC-1 suggested that the addition of radiation to adjuvant 5-FU chemotherapy may be unnecessary and perhaps even harmful (OS, 13.9, 21.6, and 19.9 months for chemoradiation, chemotherapy, and chemotherapy plus chemoradiation, respectively), although the ESPAC-1 trial has been criticized for lack of attention to quality control for RT. A phase II study by GERCOR randomized patients to adjuvant gemcitabine or adjuvant gemcitabine-based chemoradiation. No differences were seen in OS (24.4 months vs. 24.3 months) or DFS (10.9 months vs. 11.8 months) between the groups, but with only 45 patients in each arm no \( P \) values were reported. In addition, the multicenter, open-label, randomized phase III CapRI trial found that adjuvant chemoradiation with 5-FU, cisplatin, and interferon alpha-2b (IFN \( \alpha \)-2b) followed by 5-FU chemotherapy gave outcomes no better than adjuvant treatment with 5-FU alone.

A 2012 meta-analysis of 15 prospective, randomized trials found that adjuvant chemoradiation did not improve DFS, 2-year survival, or OS (odds ratio [OR], 0.99; \( P = .93 \)) compared to surgery alone, while adjuvant chemotherapy improved all 3 outcomes (OR for OS, 1.98; \( P < .001 \)). A 2013 meta-analysis of 9 trials found similar results, with HRs for death compared to no adjuvant treatment of 0.62 for 5-FU (95% CI, 0.42–0.88), 0.68 for gemcitabine (95% CI, 0.44–1.07), 0.91 for chemoradiation (95% CI, 0.55–1.46), 0.54 for chemoradiation plus 5-FU (95% CI, 0.15–1.80), and 0.44 for chemoradiation plus gemcitabine (95% CI, 0.10–1.81).

However, a population-based assessment of outcomes of patients in the NCDB with pancreatic cancer resected from 1998 to 2002 found the opposite result: chemoradiation gave better OS than chemotherapy in a performance-status–matched comparison to no adjuvant treatment (HR, 0.70; 95% CI, 0.61–0.80 vs. HR, 1.04; 95% CI, 0.93–1.18). A multi-institutional pooled analysis of 955 consecutive patients who had R0-1 resections for pancreatic cancer also supports the supposition that adjuvant chemoradiation improved survival compared to chemotherapy alone (OS, 39.9 months vs. 27.8 months; \( P < .001 \)).
To definitively clarify the role of chemoradiation following gemcitabine monotherapy in the adjuvant setting, RTOG is conducting trial 0848 (ClinicalTrials.gov NCT01013649). Patients without evidence of progressive disease after 5 cycles of gemcitabine-based chemotherapy are being randomized to 1 additional round of chemoradiation with capecitabine or 5-FU. The primary endpoint is OS, and the trial is estimated to be completed in 2020. Studies are presently investigating the potential role of SBRT in the adjuvant setting (eg, NCT02461836).

**Benefit of Adjuvant Chemoradiation in Patient Subsets**

It has been suggested that subsets of patients (eg, patients with R1 resections or positive lymph nodes) may be more likely to benefit from adjuvant chemoradiation.

Studies that have looked at R0 or R1 subsets of patients have found mixed results. For instance, patients treated in the ESPAC-1 trial did not derive a benefit from the addition of radiation to adjuvant chemotherapy, irrespective of margin status. In contrast, results from a prospectively collected database of 616 patients with resected pancreatic cancer at the Johns Hopkins Hospital found that adjuvant chemoradiation benefited both the R0 and R1 subsets compared to observation alone. The Mayo Clinic performed a retrospective review of 466 patients who had R0 resections for pancreatic adenocarcinoma, and found an OS benefit of adjuvant chemoradiation over observation. In addition, a retrospective review of greater than 1200 resected patients from the Johns Hopkins Hospital and the Mayo Clinic who received adjuvant 5-FU–based chemoradiation or were observed following resection found that chemoradiation improved outcomes regardless of margin status (R0: relative risk [RR], 0.61; 95% CI, 0.47–0.77; P < .001; R1: RR, 0.52; 95% CI, 0.36–0.74; P < .001). A meta-analysis of 4 RCTs found evidence for an increased survival benefit of adjuvant chemoradiation in the R1 subset (HR for death, 0.72; 95% CI, 0.47–1.10) over the R0 subset (HR for death, 1.19; 95% CI, 0.95–1.49).

Fewer analyses have looked at the role of chemoradiation in resected patients with positive lymph nodes. One retrospective review compared outcomes of 94 patients who underwent distal pancreatectomy at the Johns Hopkins Hospital and either received adjuvant chemoradiation or were just observed following resection. An exploratory subset analysis suggested that patients with positive lymph nodes derived greater benefit from adjuvant chemoradiation than those with negative nodes. In addition, a meta-analysis of 4 randomized controlled adjuvant trials found that chemoradiation had a similar lack of benefit in patients with positive and negative lymph nodes.

**Chemoradiation and SBRT for Locally Advanced Disease**

Chemoradiation is a conventional option for the management of unresectable locoregional pancreatic cancer, although the utility of chemoradiation in this population of patients is controversial. It is mainly used in selected patients who do not develop metastatic disease during initial chemotherapy.

A meta-analysis identified 15 RCTs (1128 patients) that compared chemoradiation to either chemotherapy or radiation in the locally advanced setting. Whereas combined modality therapy significantly improved survival compared to radiation alone, survival was the same when compared to those receiving chemotherapy alone. Increased toxicity was observed in the chemoradiation group.

The role of chemoradiation in locoregional pancreatic cancer was initially defined in a trial conducted in locally advanced disease by GITSG. In this study, the combination of bolus 5-FU and split-course radiation (total dose, 4000 cGy) was compared with radiation alone or...
with 6000 cGy combined with 5-FU. A nearly 2-fold increase in median survival (42.2 vs. 22.9 weeks) was observed with the regimen of bolus 5-FU and 4000 cGy compared with radiation alone. Subsequent generations of studies have sought to optimize the use of 5-FU, and most contemporary studies no longer use split-course radiation.\textsuperscript{355} Gemcitabine has also been used as a radiation sensitizer in the locally advanced setting.\textsuperscript{356-360} Some evidence suggests that concurrent gemcitabine and radiation can yield similar or better outcomes when compared with 5-FU–based chemoradiation in the setting of locally advanced disease.\textsuperscript{355,358,361,362} The use of capecitabine as a radiosensitizer has also been assessed in this setting and appears to be effective.\textsuperscript{363} Recently reported results of the phase II SCALOP trial showed that health-related quality-of-life scores (ie, cognitive functioning, fatigue, bloating, dry mouth, body image, future health concerns) tended to favor capecitabine-based chemoradiation, compared to gemcitabine-based chemoradiation.\textsuperscript{364} Therefore, when chemoradiation is recommended by the panel, fluoropyrimidine-based chemoradiation is generally preferred, compared to gemcitabine-based chemoradiation.

**Upfront Chemoradiation or SBRT in Locally Advanced Disease**

Results of 2 early randomized trials comparing upfront chemoradiation to chemotherapy in locally advanced disease were contradictory.\textsuperscript{365,366} Three phase II trials also assessed the upfront chemoradiation approach in locally advanced pancreatic adenocarcinoma, with median survival rates ranging from 8.2 to 9 months.\textsuperscript{356,367-369} Results from small, single-arm trials of upfront chemotherapy followed by chemoradiation in locally advanced disease have been discussed.\textsuperscript{370}

The phase III randomized ECOG-4201 trial, which assessed gemcitabine compared with gemcitabine plus RT followed by gemcitabine alone in patients with locally advanced, unresectable pancreatic cancer, was closed early due to poor accrual. However, an ITT analysis of data for the 74 patients enrolled in this study showed that median OS was significantly longer in the chemoradiation therapy arm of the study (11.1 months vs. 9.2 months; \( P = .017 \)).\textsuperscript{360} However, the poor accrual rate decreased its statistical power, there was no difference in PFS, and the confidence intervals for OS overlapped between the two groups of patients, leading some to state that the results do not rise to the level of evidence required to determine standard of care.\textsuperscript{371}

The benefit of chemotherapy versus chemoradiation was also addressed in the phase III FFCD-SFRO study from France, in which patients with locally advanced pancreatic cancer were randomly assigned to receive either gemcitabine alone or an intensive induction regimen of chemoradiation with 5-FU plus cisplatin followed by gemcitabine maintenance treatment.\textsuperscript{372} In this study, gemcitabine alone was associated with a significantly increased OS rate at 1 year compared with chemoradiation (53% vs. 32%; HR, 0.54; 95% CI, 0.31–0.96; \( P = .006 \)). This study was stopped before the planned accrual, because an interim analysis revealed that patients in the chemoradiation arm had a lower survival rate. Also, patients in the chemoradiation arm experienced severe toxicity and were more likely to receive a shorter course of maintenance therapy with gemcitabine, suggesting that the observed differences in survival were most likely attributable to the extreme toxicity of this particular chemoradiation regimen.

Upfront SBRT may be used in patients with locally advanced unresectable disease who are not candidates for combination systemic treatment. A retrospective analysis of 77 patients with unresectable disease demonstrated that while SBRT gave effective local control, it gave no improvement to OS and was associated with significant...
Toxicities. However, another retrospective review of 71 patients reported a median OS of 10.3 months with only 3 patients (4%) experiencing grade 3 toxicity. Hypofractionated dosing may also be used in these patients, with acceptable toxicity. The incorporation of simultaneous integrated boost is being investigated to improve the potential of SBRT for downstaging.

Thus, the role of upfront chemoradiation in the setting of locally advanced pancreatic cancer is still undefined. If patients present with poorly controlled pain or local invasion with bleeding, then starting with upfront chemoradiation therapy or SBRT is an option.

Chemoradiation or SBRT Following Chemotherapy in Locally Advanced Disease

Starting with 2 to 6 cycles of systemic chemotherapy followed by chemoradiation or SBRT is an option for selected patients with unresectable disease and good performance status who have not developed metastatic disease. This sequence is especially recommended in cases where: 1) it is highly unlikely that the patient will become resectable (ie, complete encasement of superior mesenteric/ceeliac arteries); 2) there are suspicious metastases; or 3) the patient may not be able to tolerate chemoradiation. Employing an initial course of chemotherapy may improve systemic disease control in these cases. In addition, the natural history of the disease can become apparent during the initial chemotherapy, thus allowing the selection of patients most likely to benefit from subsequent chemoradiation. For example, a retrospective analysis of outcomes from the GERCOR studies indicated that first-line treatment with chemotherapy may be a useful strategy for selecting patients with locally advanced disease who are more likely to benefit from subsequent chemoradiation therapy.

In the international phase III LAP07 RCT, patients with locally advanced pancreatic cancer (n = 269) received chemoradiation with capecitabine following four months of induction chemotherapy with either gemcitabine monotherapy or gemcitabine and erlotinib. Chemoradiation in this setting provided no survival benefit, compared to chemotherapy only (HR, 1.03; 95% CI, 0.79–1.34; P = .83). Differences were noted in other potentially meaningful outcomes such as time to reinitiation of therapy (159 days in the chemoradiation arm vs. 96 days in the control arm; P = .05) and local tumor progression (34% in the chemoradiation arm vs. 65% in the chemotherapy only arm; P < .0001).

SBRT following gemcitabine monotherapy in patients with locally advanced pancreatic cancer have been examined in phase II trials. This regimen was associated with low toxicity and favorable freedom from local disease progression. Because there are now more active chemotherapy regimens than gemcitabine monotherapy, additional studies are planned to assess the role of radiation after more active chemotherapy.

Advanced Radiation Techniques

Intensity-modulated radiation therapy (IMRT) is increasingly being applied for therapy of locally advanced pancreatic adenocarcinoma and in the adjuvant setting with the aim of increasing radiation dose to the gross tumor while minimizing toxicity to surrounding tissues. A retrospective treatment planning study evaluated the dose escalation that might have been possible in 15 patients with locally advanced, unresectable pancreatic adenocarcinoma if IMRT had been used instead of 3-D conformal planning. While the authors concluded that the IMRT plans would allow for significant increase in target volume dose with substantial dose reductions to local organs at risk, there is no
clear consensus on the appropriate maximum dose of radiation when IMRT is used. A recent systematic review including 13 IMRT studies showed that IMRT does not improve survival outcomes, compared to 3D-CRT. However, toxicities grade 3 or greater were more numerous in 3D-CRT, relative to IMRT (P = .017). These toxicities were mainly gastrointestinal, specifically nausea/vomiting and diarrhea. IMRT resulted in reduced grade 3/4 toxicities when the authors made a cross-study comparison of toxicities in patients who received a similar 5-FU–based regimen with 3-D conformal radiation in the RTOG 9704 trial. Comparing the 2 trials, rates of grade 3/4 nausea and vomiting were 0% vs. 11% (P = .024), and rates of grade 3/4 diarrhea were 3% vs. 18% (P = .017), suggesting that IMRT may be well tolerated and allow for higher radiation doses to the tumor. There is no clear consensus on the appropriate maximum dose of radiation when IMRT technique is used.

Intraoperative radiation therapy (IORT) can allow for higher doses of radiation because sensitive structures can be excluded from the radiation fields. IORT is sometimes administered to patients with borderline resectable disease who have received maximal neoadjuvant therapy to sterilize close or involved margins at the time of surgery, although data in this setting are lacking. It is also sometimes used when a patient is found to be unresectable at the time of surgery and in cases of locally recurrent disease. Most studies of IORT in patients with locally advanced pancreatic cancer found that while local control may be improved, no change in survival is evident with use of IORT because of the high frequency at which metastatic disease develops. Some groups, however, believe that IORT can offer benefits in very carefully selected patients with non-metastatic disease. Overall, there is no clear established role for IORT in patients with pancreatic cancer, and the panel believes it should only be performed at specialized centers.

Management of Metastatic Disease

The primary goals of treatment for metastatic pancreatic cancer are palliation and lengthened survival. Survival benefits are usually limited to patients with adequate performance status (ECOG 0-1, with patent biliary stent, and adequate nutritional intake). Systemic therapy is therefore recommended for patients with metastatic disease and good performance status, as described in Systemic Therapy Approaches, above, and in the guidelines.

Patients who present with poor performance status may benefit from single-agent chemotherapy (gemcitabine is a category 1 recommendation), but comfort-directed measures are always paramount (see Palliative and Supportive Care, below, and the NCCN Guidelines for Supportive Care, available at www.NCCN.org). An alternative option for these patients is palliative and best supportive care.

Patients with metastatic disease are generally not candidates for RT. However, palliative RT may be administered to patients who present with poor performance status (ie, patients who are elderly and/or not candidates for definitive treatment) with or without single-agent chemotherapy. A short course of RT may be administered to metastatic sites that cause pain (eg, osseous pain).

Before initiating cytotoxic therapy, an open dialogue regarding the goals and side effects of treatment should take place and, if needed, adjunctive strategies can be used (see Palliative and Supportive Care, below). Of note, patients with advanced disease may have abrupt changes in clinical status. Therefore, if treatment is begun, it should proceed with close follow-up. Patients may experience sudden onset of bleeding or thromboembolism, rapidly escalating pain, biliary stent occlusion, cholangitis, or other infections. Moreover, clinically...
meaningful tumor progression may develop quickly, and tumor-related symptoms may be inappropriately attributed to chemotherapy or other causes. For instance, patients who complain of intractable nausea and vomiting may have gastric outlet obstruction rather than chemotherapy-induced emesis. Peritoneal carcinomatosis may manifest as ascites or in its more subtle form, as abdominal bloating, as decreased oral intake, and as constipation.

For patients who do well on initial therapy, a chemotherapy holiday is appropriate, or maintenance therapy can be considered (see Possible Role of Maintenance Therapy in Advanced Disease, above). After progression, second-line therapy is possible, especially in patients who maintain a good performance status (see Second-Line Systemic Therapy in the Advanced Setting, above). Prior to commencing second-line therapy, serial 3D CT or MRI imaging of known sites of disease to determine therapeutic benefit is recommended by the panel. However, patients may demonstrate progressive disease clinically without objective evidence of progression (also for Management of Locally Advanced Disease; see below).

Management of Locally Advanced Disease

As in the metastatic setting, the primary goals of treatment of patients with unresectable, locoregional pancreatic cancer are palliation and lengthened survival. Also, as in metastatic disease, patients with locally advanced disease are treated with systemic therapy based on their performance status. Single-agent chemotherapy and palliative and best supportive care (including palliative RT) are options for patients with poor performance status, whereas patients with good performance status can be treated with more intensive therapy, as described in Systemic Therapy Approaches, above, and in the guidelines.

Historically, most studies in the locally advanced setting used gemcitabine monotherapy. However, there is an increasing emphasis on understanding the role of modern, more active regimens in locoregional unresectable disease. The experience with FOLFIRINOX in 22 patients with locally advanced pancreatic cancer at the Massachusetts General Hospital Cancer Center through February 2012 was reported. An overall response rate of 27% was observed, and the median PFS was 11.7 months. Five patients (23%) were able to undergo R0 resections, although 3 of these patients experienced distant recurrence by 5 months. It was also reported that 32% of patients receiving FOLFIRINOX required greater than or equal to 1 hospitalization or visit to the emergency department during treatment.

Other studies and case reports addressing the use of chemotherapy with or without chemoradiation in patients with locally unresectable disease have noted that the opportunity for curative intent resection occasionally arises. The panel believes that patients with a significant response to chemotherapy and/or chemoradiation may be considered for surgical resection, but acknowledges that such conversions are rare in patients with true locally advanced disease. Following resection, these patients have similar survival rates as those initially determined to be resectable.

Upfront chemoradiation or SBRT may be used in select patients (See Chemoradiation and SBRT for Locally Advanced Disease). The use of chemoradiation or SBRT following chemotherapy in locally advanced disease is also discussed above. If disease progression occurs in patients with locally advanced disease, chemoradiation is a treatment option if all of the following are true: good performance status is maintained, chemoradiation was not previously given, and the primary site is the sole site of progression.
Irreversible electroporation (IRE) is an ablative technique in which electric pulses are used to create nanopores that induce cell death similar to apoptosis. This technique has been used in patients with locally advanced pancreatic cancer.\(^{408,409}\) IRE may be safe and feasible\(^ {410}\) and may improve survival outcomes.\(^ {409}\) However, due to concerns about complications and technical expertise,\(^ {411}\) the panel does not currently recommend IRE for treatment of locally advanced pancreatic cancer.

### Management of Resectable and Borderline Resectable Disease

#### Surgical Management

Surgical resection is the only potentially curative technique for managing pancreatic cancer. However, more than 80% of patients present with disease that cannot be cured with surgical resection.\(^ {412}\) Early concerns about high mortality associated with various pancreatic resection procedures\(^ {413}\) have now been lessened by studies demonstrating an acceptably low (<5%) mortality in experienced centers (see Effect of Clinical Volume, below).\(^ {414}\) Even under the most optimal clinical trial conditions, however, the median survival of resected patients following adjuvant therapy ranges from 20.1 to 23.6 months.\(^ {218,290,291,334}\) Negative margin status (ie, R0 resection), tumor DNA content, tumor size, and absence of lymph node metastases are the strongest prognostic indicators for long-term patient survival.\(^ {415-417}\) With respect to margin status, there is evidence for the converse statement—the survival benefits of an R1 resection may be comparable to definitive chemoradiation without surgery.\(^ {418-420}\)

#### Criteria for Resection

The NCCN Panel recommends that decisions about diagnostic management and resectability always involve multidisciplinary consultation at high-volume centers with use of appropriate high-quality imaging studies to evaluate the extent of disease. Although it is clear that patients with visceral, peritoneal, or pleural metastases or with metastases to nodes beyond the field of resection derive no benefit from resection, institutions differ in their approaches to patients with locoregional disease involvement (pancreas and peripancreatic lymph nodes).

Based on their clinical experience with the primary management of pancreatic tumors, an expert consensus group developed criteria to define tumor resectability so as to improve patient selection for surgery and increase the likelihood of an R0 resection.\(^ {130,421}\) Other groups have also put forth definitions of resectability of pancreatic cancer.\(^ {422-424}\) A more restrictive definition of borderline resectable pancreatic tumors has also been described.\(^ {425}\) This definition uses degrees of contact (eg, interface between tumor and SMA measuring <180° of vessel wall circumference) rather than subjective terms such as abutment and impingement. The panel endorses this definition for use in clinical trials. Using any of these sets of criteria, tumors are classified as resectable; borderline resectable; or unresectable (ie, locally advanced or metastatic disease).

The panel has adapted the criteria put forth by other groups and lists its recommended criteria for defining resectability status in the guidelines. The consensus of the panel is that patients should be selected for surgery on the basis of curative intent as determined by the probability of obtaining negative (R0) resection margins. Overall, the likelihood of obtaining negative margins is the key criterion for consideration when determining whether a patient is a potential candidate for resection.\(^ {424,426}\) In this context, a borderline resectable lesion can be defined as one in which there is a higher likelihood of an incomplete resection. Patients at high risk for positive surgical margins are not considered to be good
candidates for an upfront resection. Furthermore, the panel recommends that patient factors be considered when deciding whether a patient is a surgical candidate. Age of the patient, comorbidities, performance status, and frailty are all things to be discussed during the multidisciplinary review. Please refer to the NCCN Guidelines for Older Adult Oncology (available at www.NCCN.org) for further discussion of the treatment of older patients.

**Primary Surgery for Pancreatic Cancer**

The nature and extent of the surgery for resectable tumors depend on the location and size of the tumor. Because tumors of the pancreatic body and tail cause symptoms late in their development, they are usually advanced at diagnosis and are rarely resectable. When tumors in the pancreatic tail are resectable, distal pancreatectomy, in which the surgeon removes the tail and body of the pancreas, as well as the spleen, is commonly performed. If the cancer diffusely involves the pancreas or is present at multiple sites within the pancreas, a total pancreatectomy may be required, where the surgeon removes the entire pancreas, part of the small intestine, a portion of the stomach, the common bile duct, the gallbladder, the spleen, and nearby lymph nodes. Patients with tumors in the head of the pancreas, who usually present because of jaundice, are treated with open or laparoscopic pancreatectoduodenectomy (ie, the Whipple procedure).

If the tumor is found to be unresectable during surgery, the panel recommends biopsy confirmation of adenocarcinoma at this time, if a biopsy was not performed previously. If a patient with jaundice is found to be unresectable at surgery, then the panel recommends surgical biliary bypass at that time. If a stent has been previously placed, then surgical biliary bypass could be considered. In addition, gastrojejunostomy can be considered if appropriate regardless of jaundice (category 2B for prophylactic gastrojejunostomy). Celiac plexus neurolysis can also be performed, especially when indicated by pain in a patient with jaundice (category 2B if no pain). See **Severe Tumor-Associated Abdominal Pain**, below, for more details about these procedures.

In patients with suspected borderline resectable disease for whom cancer is not confirmed following repeated biopsy with EUS-FNA (preferred), intraoperative biopsy is recommended. If resectable disease is found in these patients, then surgical resection followed by adjuvant therapy is recommended. If unresectable disease is found, then recommendations for management of locally advanced or metastatic disease should be followed (see above). If these patients present with jaundice, surgical biliary bypass and gastrojejunostomy (category 2B for prophylactic gastrojejunostomy) should be considered, as well as celiac plexus neurolysis for pain (category 2B if no pain).

**Pancreatoduodenectomy (Whipple Procedure)**

Achievement of a margin-negative dissection must focus on meticulous perivascular dissection of the lesion in resectional procedures, recognition of the need for vascular resection and/or reconstruction, and the potential need for extra-pancreatic organ resection. Of course, the biology of the cancer might not allow for an R0 resection even with the most meticulous surgery.

Medial dissection of pancreatic head lesions is best achieved by complete mobilization of the PV and SMV from the uncinate process (assuming no evidence of tumor infiltration). Further, skeletonization of the lateral, posterior, and anterior borders of the SMA down to the level of the adventitia will maximize uncinate yield and radial margin (see Figure 1). Optimal dissection and skeletonization of the SMA can be achieved using ultrasonic or thermal dissectors (Harmonic scalpel or LigaSure). Division of the retroperitoneal tissues between the uncinate...
process and the SMA with a stapler or a clamp and cut technique may leave up to 43% of the soft tissue between the uncinate process and the SMA in situ and result in suboptimal clearance and increase the risk of an R1 resection.\textsuperscript{431,432}

Analysis of the pancreatic neck and bile duct at time of surgery by frozen section may be considered. A retrospective analysis of 1,399 patients who underwent pancreaticoduodenectomy showed that additional resection to achieve a negative surgical margin following analysis of a positive frozen section of the pancreatic neck is not associated with improved survival.\textsuperscript{433} Frozen sections should be taken approximately 5 mm from the transection margin, with the clean-cut side facing up, to avoid cautery artifact that may confound analysis and result in false negatives. If tumor is located within 5 mm of margins, further excision of the pancreas should be considered to ensure at least 5 mm of clearance.

In the absence of frank venous occlusion noted on preoperative imaging, the need for lateral venorrhaphy or complete PV or SMV resection and reconstruction to achieve an R0 resection may be suggested, but it is often not known until division of the pancreatic neck has occurred. Tethering of the carcinoma to the lateral wall of the PV is not uncommon and requires careful dissection to free the vein from the pancreatic head if it is possible to do so. Differentiation of tumor infiltration into the vein wall from tumor-related desmoplasia is frequently impossible to ascertain. The liberal use of partial or complete vein resection when vein infiltration is suspected during Whipple procedures has been studied.\textsuperscript{434-436} On evaluation of excised vein specimens, only 60% to 70% had histologic evidence of frank tumor involvement, and R0 resections were still not obtainable in 10% to 30% of patients despite increasing the magnitude of the operative procedure. However, if an R0 resection is obtained with vein excision, longevity appears similar to those with R0 resections without venous involvement, with no significant increase in morbidity and mortality. These data support an aggressive approach to partial or complete vein excision if tumor infiltration is suspected, although acceptance of this concept (particularly with respect to vein resection) is not universal.

Although numbers are more limited, similar findings have been noted with respect to hepatic arterial resection and reconstruction.\textsuperscript{436,437} Others, however, have noted poor short- and long-term outcomes with arterial resection.\textsuperscript{438,439} While further data with respect to arterial resection are clearly needed, judicious utilization of this technique would appear to be reasonable in very select populations.

A population-based study of 10,206 patients from the Nationwide Inpatient Sample from years 2000 through 2009 found that vascular reconstruction (about 90% venous and 10% arterial) is associated with a higher risk of intraoperative and postoperative complications.\textsuperscript{439} No difference in mortality was seen.

**Distal Pancreatectomy**

The goals of left-sided resection are similar to those of pancreaticoduodenectomy, although they are often more difficult to achieve because of the advanced stage at which most of these cancers are discovered. Spleen preservation is not indicated in distal pancreatectomy for adenocarcinoma, and an R0 distal pancreatectomy for adenocarcinoma mandates en bloc organ removal beyond that of the spleen alone in up to 40% of patients.\textsuperscript{440,441} In addition, similar to the Whipple procedure, lateral venorrhaphy, vein excision and reconstruction, and dissection to the level of the celiac axis and SMA adventitia should be performed if complete tumor clearance can be achieved.\textsuperscript{441,442} Utilization of these radical resections is associated with an increase in blood loss, transfusion requirements, operating time,
length of stay, and morbidity, but mortality remains rare.\textsuperscript{440-442} Encouragingly, tumor clearance (R0 resection) has been reported in up to 72% to 91% of patients, with long-term survival equivalent to those having standard resection for more localized disease.\textsuperscript{441,442} Local recurrence, however, remains problematic even with pathologically negative margins.\textsuperscript{442}

There is an increasing role for laparoscopic distal pancreatectomy. A meta-analysis including 29 observational studies with 3,701 patients showed that laparoscopic distal pancreatectomy may decrease intraoperative blood loss ($P < .01$), time to first oral intake ($P < .01$), and length of hospital stay ($P < .01$), as compared to open distal pancreatectomy.\textsuperscript{443} Results from 172 patients treated at the Mayo Clinic found significant benefits in the patients who had laparoscopic versus open resections in blood loss, the need for blood transfusions, and the length of hospital and intensive care unit stays without any difference in oncologic outcomes.\textsuperscript{444} In addition, results from a meta-analysis of 4 studies of 665 total patients suggest that the laparoscopic method is safe and results in shorter hospital stays.\textsuperscript{445} Furthermore, results from a population-based, retrospective cohort study that included 8957 patients showed similarly that the laparoscopic approach can decrease complication rates and shorten hospital stays.\textsuperscript{446}

**Portal Vein Resection**

Vascular invasion has been a conventional contraindication to pancreatic resection. Early attempts at resection and reconstruction of the SMA and SMV in the 1970s were associated with poor results in a few patients who underwent “regional” pancreatectomy.\textsuperscript{447} Both autologous and synthetic grafts were used for arterial and venous reconstructions. As morbidity from pancreatoduodenectomy decreased, a subset was identified of patients who were in need of resection of the SMV wall to achieve negative margins during removal of their tumors. Thus, in the 1990s, there was renewed interest in vein resection for complete resections. The group from the University of Texas MD Anderson Cancer Center has championed this approach, demonstrating that vein resection and reconstruction can allow for complete resection and is not associated with increased morbidity or mortality when compared with patients who did not require vein resection.\textsuperscript{448} Furthermore, long-term outcome is not significantly worse for patients undergoing venous resection during pancreatoduodenectomy compared to patients who receive standard pancreatoduodenectomy.\textsuperscript{449}

Although compelling, this approach has not been universally accepted. During the 1990s, several studies reported operative mortality of 0% to 16.5%, 3-year Kaplan-Meier survival of 12% to 23%, and median survival of 5 to 14 months in patients receiving vein resection.\textsuperscript{450-453} One study found that properly selected patients with adenocarcinoma of the pancreatic head who required vein resection ($n = 141$) had a median survival of approximately 2 years that did not differ from those having standard pancreatoduodenectomy and was superior to historical patients believed to have locally advanced disease who did not receive surgical treatment.\textsuperscript{436} A meta-analysis of 22 retrospective studies (2890 patients) found that vein resection resulted in perioperative morbidity and mortality equal to that of standard resection, but R0 resection rates were lower in that group.\textsuperscript{454} In a multi-institutional database analysis of 492 patients undergoing pancreaticoduodenectomy, R0 resection rates were no different between the 14% who had vein resection compared to those without venous involvement (66% vs. 75%; $P = \text{NS}$).\textsuperscript{455} Nevertheless, a few groups have recommended caution and only use vein resection for selected patients.

**Pylorus Preservation**

Reconstruction options for the stomach after pancreatoduodenectomy center on preservation of the pylorus. Traverso and Longmire\textsuperscript{456}
reported the modern use of pylorus preservation in 1978. The hypothesis was that preservation would improve emptying and provide nutritional benefit, but the benefits have been inconsistent to date. A systematic review comparing a classic Whipple operation to pylorus-preserving pancreaticoduodenectomy (including eight RCTs with 512 patients) showed no significant differences for mortality, morbidity, and survival, but some perioperative measures (ie, operating time, intraoperative blood loss, red blood cell transfusion) were better in patients who received pylorus-preserving pancreaticoduodenectomy, relative to those who received a classic Whipple. Therefore, though more data from high-quality RCTs are needed, pylorus-preserving pancreaticoduodenectomy is an acceptable alternative to classic pancreatoduodenectomy performed with antrectomy.

Pancreatic Anastomosis

Efforts have focused on preventing pancreatic leaks and fistulas, which are morbid and potentially lethal complications of pancreatoduodenectomy. Pancreaticojejunostomy has traditionally been the standard reconstruction and is the major focus of morbidity and mortality after pancreatoduodenectomy because of leaks, abscess formation, and fistulas from this anastomosis. A randomized study at Johns Hopkins Hospital found no difference in fistula rates after pancreaticojejunostomy and pancreaticogastrostomy. However, a more recent multicenter, randomized, superiority trial compared the outcomes of 329 patients undergoing pancreatoduodenectomy with either pancreaticojejunostomy or pancreaticogastrostomy. A significant difference was seen in the primary outcome measure of postoperative fistulas, which occurred in 19.8% of patients in the pancreaticojejunostomy group and 8.0% of patients in the pancreaticogastrostomy group (OR, 2.86; 95% CI, 1.38–6.17; P = .002). An increase in grade ≥3a postoperative complications was seen, however, in the pancreaticogastrostomy group (24% vs. 21%). Criticisms of this trial have been published. Although a meta-analysis of 4 RCTs (676 patients) concluded that pancreaticogastrostomy is associated with a lower risk of fistula formation than pancreaticojejunostomy (RR, 0.41; 95% CI, 0.21–0.62), the optimal approach to anastomosis remains undefined.

Surgeons have also examined various other options for the pancreaticojejunal anastomosis; end-to-end, end-to-side, duct-to-mucosa, and invaginating techniques have all proven to be safe and effective. Results of a prospective trial show that pancreatic fistula can be almost entirely avoided by a technique that combines placement/tying of sutures under magnification with meticulous attention to blood supply. Stents used in the 1930s and 1940s continue to be used today, but data suggest that they do not decrease leak rates.

In addition to technical modifications, octreotide has been examined for its ability to decrease postoperative pancreaticojejunal leaks in patients undergoing pancreatic resections. However, octreotide did not decrease fistula rates when assessed in 2 prospective, randomized, double-blind, placebo-controlled studies (at the University of Texas MD Anderson Cancer Center and Johns Hopkins Hospital). Pasireotide, in contrast, significantly decreased the rate of grade ≥3 fistula, leak, or abscess in a single-center, double-blind RCT of 300 patients (9% in pasireotide group vs. 21% in placebo group; RR, 0.44; 95% CI, 0.24–0.78; P = .006). Finally, the use of fibrin glue sealant does not appear to decrease the rate of pancreatic fistulas.

Extended Lymphadenectomy

The role of lymph node dissection as a component of pancreatoduodenectomy has been explored. In the 1970s and 1980s, pathology and autopsy studies demonstrated a high incidence of nodal
metastasis (sometimes as high as 80%), leading some groups to propose a more aggressive lymphadenectomy in an attempt to regionally control disease. A standard lymphadenectomy in patients undergoing pancreatoduodenectomy entails removal of nodes at the duodenum and pancreas and on the right side of the hepatoduodenal ligament, the right side of the SMA, and the anterior and posterior pancreaticoduodenal lymph nodes. An extended lymphadenectomy is most commonly performed in the United States by removing not only the nodes removed in the standard procedure, but also the soft tissue in the retroperitoneum from the hilum of the right kidney to the left lateral border of the aorta on the right side, and from the PV to the origin of the inferior mesenteric artery on the left.

Several prospective, randomized trials have addressed the role of lymphadenectomy in patients undergoing pancreatoduodenectomy. The Italian Multicenter Lymphadenectomy Group reported on a series of 81 patients randomly assigned to pancreatoduodenectomy with or without extended lymph node resection. Although the statistical power was low, this study did not support the concept that an extended lymphadenectomy was a good prognostic factor. A larger randomized prospective trial was performed at Johns Hopkins Hospital from 1996 through 2001 to evaluate the role of extended lymph node dissections. The group of patients who received the regional lymphadenectomy in addition to pancreatoduodenectomy had longer operation times, but overall median survival did not differ between the 2 groups at 1, 3, and 5 years. A randomized multicenter trial in Japan came to similar conclusions. Furthermore, multiple systematic literature reviews and meta-analyses of RCTs comparing pancreatoduodenectomy with standard versus extended lymphadenectomy support the conclusion that the extended procedure does not have any impact on survival. In addition, patients undergoing extended lymphadenectomy have increased rates of postoperative diarrhea compared to patients undergoing the standard resection.

The information to date thus does not show any survival advantage to performing a regional lymphadenectomy in addition to the standard pancreatoduodenectomy. At this point in time, data suggest that nodal metastases are a marker of systemic disease and that their removal is unlikely to alter OS. One exception might be in the situation of an otherwise R0 resection with clinically positive adenopathy outside the standard field of dissection. Overall, outside of a clinical trial, a regional lymphadenectomy should not be considered as a routine part of the Whipple procedure, although consideration can be given to sampling of the aortocaval and common hepatic artery nodes, as those with positive nodes in these positions have inferior prognoses.

**Preoperative Biliary Drainage**

The main goals of preoperative biliary drainage are to alleviate the symptoms of pruritus and cholangitis and to potentially make surgery less morbid by improving liver function preoperatively. Although controversial, several studies have suggested that pancreatoduodenectomy is associated with higher perioperative mortality when done in the setting of hyperbilirubinemia. Stenting of the biliary system can improve symptoms and liver function, but it is not clear whether these changes can decrease the mortality rate of the Whipple procedure. Several prospective and retrospective studies have failed to show decreased mortality in patients with preoperative biliary drainage. A retrospective analysis from a prospective database of 593 patients treated with pancreatoduodenectomy at MD Anderson Cancer Center found that self-expandable metal stents did not affect postoperative complications, 30-day mortality, length of stay, anastomotic leak, margin status, or determination of unresectability.
during resection, although more wound infections and longer operative times were observed in this group.\textsuperscript{497} In contrast, a multicenter, randomized trial comparing preoperative biliary drainage with surgery alone for 202 patients with cancer of the pancreatic head characterized by obstructive jaundice showed a nearly 2-fold increase in the rate of serious complications in the stented group (74\% vs. 39\%; RR in the surgery alone group, 0.54; 95\% CI, 0.41–0.71; \(P<.001\)). However, no significant differences in surgery-related complications, length of hospital stay, or mortality were observed.\textsuperscript{498}

Based on these reports, most groups who perform resection without neoadjuvant treatment advocate selective use of decompression only in patients who are symptomatic, septic, coagulopathic, have renal insufficiency, or in whom surgical resection is significantly delayed. The panel includes in this group patients who present with jaundice and potentially resectable disease if symptoms of cholangitis or fever are present or if they have significant pruritus and an expected delay to surgery of longer than 1 week.

For patients with jaundice undergoing neoadjuvant induction therapy before pancreatic resection, biliary decompression is necessary before initiation of therapy and appears to be well tolerated with minimal increase in perioperative morbidity. The University of Texas MD Anderson Cancer Center reported on its experience with more than 300 patients, 57\% of whom had preoperative biliary drainage as part of a neoadjuvant chemoradiation program.\textsuperscript{499} It was found that wound complications were significantly increased in the drainage group; however, no other association was found for sepsis, fistulæ, or death. Placement of a stent is thus required prior to administration of neoadjuvant therapy for patients with jaundice.\textsuperscript{500-503}

The panel notes that stents are an evolving technology. The choice of stents includes plastic and metal; fully covered, partially covered, or uncovered; rigid; or self-expanding (also see the discussion on stents in \textit{Palliative and Supportive Care}, below). While any stent can become occluded, several groups have reported better patency with metal stents.\textsuperscript{501-503} Metal stents are generally viewed as more permanent than plastic stents. Covered metal stents may give more durable patency, since the cover prevents tumor ingrowth,\textsuperscript{504} but the reported differences between covered and uncovered stents are not dramatic.\textsuperscript{504,505} Furthermore, migration is more of an issue with covered stents.\textsuperscript{505} This issue has led to the introduction of partially covered stents,\textsuperscript{506} though these stents may still migrate in a substantial number of patients.\textsuperscript{507,508} Most metal stents used today are self-expanding. Their small initial diameters make them easy to place, and their placement rarely requires dilation.\textsuperscript{506} Several panel members reported that their institutions use plastic stents in patients with short life expectancies (<3 months).\textsuperscript{506} A clinical trial is currently recruiting patients to compare metal and plastic stents for preoperative biliary decompression in patients with pancreatic cancer (ClinicalTrials.gov NCT01191814). In the absence of level-1 data, the panel consensus is that short, self-expanding metal stents (SEMS) are preferred because they are easy to place without dilation, are unlikely to interfere with the subsequent resection, and have a longer patency time than plastic stents. The panel cautions against placement of a metal stent prior to tissue proof of malignancy; a plastic stent should be placed if tissue diagnosis has not been confirmed.

**Effect of Clinical Volume**

Several studies have examined the effect of institutional volume on patient outcomes. The fundamental premise was that the decreasing morbidity and mortality seen in the 1980s and 1990s were the direct result of large, single-institution experiences. Moreover, the concern
was that if surgeons performed pancreatoduodenectomy less frequently, patients might have increased morbidity and mortality. A group from Memorial Sloan Kettering Cancer Center examined the issue in 1995 and found that in a cohort of almost 2000 patients, high-volume centers in New York State had significantly less mortality than low-volume centers (4% vs. 12.3%). High volume was defined as more than 50 cases per year, and this relationship correlated in a regression analysis. Of note, 75% of the cases in New York State were performed in low-volume centers. Several other studies have assessed regional outcomes with pancreatoduodenectomy from U.S. hospitals. These studies have reported decreased mortality, hospital length of stay, and overall cost at higher-volume centers (or with surgeons who perform the resections frequently) when compared with low-volume centers. Interestingly, this effect was also seen in reports from Canada and the Netherlands.

The definitions of high and low volume varied among all these studies. However, a striking difference was seen when the mortality rates from pancreatoduodenectomy in very-low-volume (0–1 procedure/year) and low-volume (1–2 procedures/year) hospitals were compared with rates in higher-volume hospitals (>5 procedures/year). In-hospital mortality rates at these very-low-volume and low-volume hospitals were significantly higher than at high-volume hospitals (16% and 12%, respectively, vs. 4%; \( P < .001 \)). The importance of hospital volume in improving survival after pancreatic cancer surgery is even more marked when pancreatoduodenectomy is compared to other major surgeries. In a retrospective analysis of data from the national Medicare claims database and the Nationwide Inpatient Sample, hospitals performing 6 to 16 and greater than 16 procedures per year were classified as “high” and “very-high” volume centers. In this study, 6 or more pancreatic resections were performed at only 6.3% of hospitals. The largest difference in operative mortality between very-low-volume (16.3%) and high-volume (3.8%) centers was seen for pancreatoduodenectomy, as compared to major surgery at any other site, further reinforcing the magnitude of the effect that high-volume centers can have specifically on pancreatic cancer outcomes.

Furthermore, a study involving 301,033 patients with pancreatic adenocarcinoma included in the NCDB that evaluated the treatment patterns of 1667 hospitals over a 19-year period showed that patients were more likely to receive multimodality therapy at academic institutions considered to be high-volume hospitals. In addition, a systematic review showed that margin status correlates with hospital volume, with negative margin rates ranging from 55% in low-volume centers to 76% for very-high-volume centers (\( P = .008 \)). This review also found that 5-year survival rates were higher in high-volume centers. In contrast, hospital readmission after pancreatoduodenectomy appears to be more of a function of patient characteristics than hospital or surgeon volume.

The NCCN Panel recommendation is that pancreatic resections should be done at institutions that perform a large number (at least 15–20) of pancreatic resections annually.

Pathology

Progress in treating pancreatic adenocarcinoma is encumbered by a lack of uniformity among treating physicians in defined areas that include pathologic analysis and reporting. A more standardized approach in this area could maximize the chances of a more complete and consistent pathology report that is similar among pathologists in the same institution and among institutions around the world. Ultimately, a more consistent approach to patient assessment, surgical technique, and pathologic evaluation of the resected pancreatic specimen from
Specimen Orientation, Sectioning, Pathologic Analysis, and Reporting

The primary purpose of pathologic analysis of the pancreatic specimen is to determine the pathologic stage of the tumor by evaluating the type, grade, size, and extent of the cancer. Pathology synoptic reports (protocols) are useful for reporting results from examinations of surgical specimens; these reports assist pathologists in providing clinically useful and relevant information. In 2004, the Commission on Cancer (CoC) of the American College of Surgeons mandated the use of specific checklist elements of the protocols as part of its Cancer Program Standards for Approved Cancer Programs. The pathology synoptic reports from the College of American Pathologists (CAP) comply with the CoC requirements, and the latest revisions to the CAP Pancreatic (Exocrine) protocol were issued in August 2016. The NCCN Pancreatic Adenocarcinoma Panel currently supports the CAP pathology synoptic reports. The proposal included in the guidelines (see Pathologic Analysis: Specimen Orientation, Histologic Sections, and Reporting in the algorithm) is an abbreviated minimum analysis of pancreatic cancer specimens from the CAP recommendations. In addition to the standard TNM staging, other variables are included, all of which have prognostic implications in the evolution of this disease.

Lymph Node Counts and Lymph Node Ratio

The CAP recommendations include a count of the number of lymph nodes recovered and the number of involved nodes. Retrospective database analyses have found that patients with N0 disease have a better prognosis with an increasing number of examined lymph nodes. These results suggest that a significant portion of patients with N0 disease might be understaged. Based on these data, groups have recommended the minimum number of lymph nodes examined to be from 11 to 17 to provide optimal staging and to serve as a quality indicator. The panel believes that every effort should be made to identify all regional lymph nodes within the pancreatic specimen. For patients with N1 disease, lymph node ratio (positive node/nodes examined) appears to be related to prognosis. For instance, in one analysis, patients with greater than 15% of examined positive nodes had a 5-year survival rate of 21.7%, while those with greater than 15% positive nodes had a 5.2% 5-year survival rate ($P = .0017$).

Whipple Specimen

Specimen orientation and inking involves both a pathologist and surgeon, as this will help to ensure accurate assessment of the size and extent of the tumor. There should be either direct communication between the surgeon and pathologist for proper orientation and margin identification, or the surgeon should identify the important margins with a clearly understood and documented method (ie, written on the pathology requisition). For example, the distal and proximal margins of the SMV and SMA, as well as the bile duct margin, should be marked.

One of the impediments to comparison of data across institutions is the variability in the names given to various margins. Definitions of the margins and uniformity of nomenclature are critical to accurate reporting. The panel’s recommended definitions are included in the Pathologic Analysis: Specimen Orientation, Histologic Sections, and Reporting section in algorithm. Margins defined include the SMA (retroperitoneal/uncinate) margin, the posterior margin, the PV groove margin, the proximal and distal PV margins, the pancreatic neck...
(transection) margin, and the bile duct margin (see Figure 2). Other margins analyzed in Whipple specimens include the proximal and distal enteric margins (en face sections) and the anterior surface (closest representative). The anterior surface is not a true margin, but identification and reporting of this surface when positive may portend a risk of local recurrence, and so should be reported in all cases. Collectively, these pancreatic tissue surfaces constitute the circumferential transection margin. Designating the various specific margins with different colored inks will allow recognition on microscopy.

The approach to histologic sectioning of a Whipple specimen is determined by the unique characteristics of the tumor, but is also influenced by institutional preferences, expertise, and experience. There is no one correct way to dissect a Whipple specimen. Options include axial, bi- or multi-valve slicing, and perpendicular slicing (see Figure 3). Some experts in the field bisect the pancreas along probes placed in the bile and pancreatic ducts and then serially section along each half of the pancreas. Axial slicing provides an overall assessment of the epicenter of the tumor relative to the ampulla, bile duct, duodenum and pancreas, and all of the pancreatic circumferential tissue margins (see Figure 4).

The most important aspects of dissection are clear and accurate assessment of the margins. It is currently unknown what constitutes an adequate margin in pancreatic carcinoma resection specimens. A standardized definition of this would allow better stratification of patients into adjuvant regimens following surgical extirpation. For instance, if less than 1-mm clearance is associated with an unacceptably high incidence of local recurrence, then strong consideration for postoperative RT might be indicated if not received preoperatively. The panel strongly recommends reporting tumor clearance in millimeters for all margins (as noted in the Pathologic Analysis: Specimen Orientation, Histologic Sections, and Reporting section of the algorithm) to allow prospective accumulation of these important data for future analysis.

A retrospective review compared the outcomes of 169 patients with R0 resections of close margins (within 1 mm) to 170 patients with wider margins (>1 mm) and found an improvement in OS with wider margins (35 months vs. 16 months; \( P < .001 \)). In fact, patients with close-margin R0 resections had a median survival time similar to that of the R1 population (16 months vs. 14 months; \( P = .6 \)). Consistent with these results, another retrospective review of 285 patients found that those with R1 resections, defined as tumor ≤1 mm from the margin, had a significantly worse local recurrence-free survival than those with R0 resections (HR, 4.27; 95% CI, 2.07–8.81). Finally, a recent study, which used a standardized pathologic protocol that involved multicolor inking and careful evaluation of multiple margins distances, found that patients with R1 resections (tumor at 0 mm) had a median survival of 17.7 months, while those with R0 resections had a median survival of 32.9 months (\( P = .10 \)). Together, these results suggest that an appropriate definition of a negative margin may be greater than 1 mm.

Attached organs resected with the specimen en bloc require serial sectioning to assess not only direct extension, but metastatic deposits as well.

**Distal Pancreatectomy Specimen**

In left-sided resections, the peripancreatic soft tissue margins and the pancreatic neck are assessed (see Figure 5). Additionally, involvement of the splenic vessels should be documented, and invasion of the spleen is important to determine, because direct tumor invasion constitutes a pT3 pathologic stage. Frozen section analysis of the pancreatic neck is recommended. Definitions of the proximal pancreatic (transection) margin, the anterior (cephalad) peripancreatic (peripheral)
surface, and the posterior (caudad) peripancreatic (peripheral) margin are included in the guidelines (see Pathologic Analysis: Specimen Orientation, Histologic Sections, and Reporting in the algorithm).

**Perioperative Therapy**

Even with R0 resections, recurrence rates are very high in this disease. Therefore, additional therapy is required for all patients with resected pancreatic adenocarcinoma.

**Postoperative (Adjuvant) Therapy**

Results of many trials have shown that adjuvant therapy improves outcomes over observation following resection (see sections on Systemic Therapy Approaches and on Radiation and Chemoradiation Approaches, above). While results of RTOG 9704 cannot be directly compared with the results of CONKO-001, ESPAC-1, or ESPAC-3 trials because of differences in treatment design, timing of imaging, and patient characteristics (eg, patients enrolled in CONKO-001 were more likely to be lymph node-negative and to have positive resection margins than those in RTOG 9704; and CONKO-001 excluded patients with high postoperative CA 19-9 or CEA levels), it is interesting to note that median OS for patients in the gemcitabine arm of CONKO-001 (22.8 months), the gemcitabine-containing arm of RTOG 9704 (20.5 months), the bolus 5-FU/leucovorin arm of ESPAC-1 (20.1 months), and the gemcitabine and 5-FU/leucovorin arms of the ESPAC-3 study (23.6 and 23.0 months) are remarkably similar. Results of the ESPAC-4 phase III randomized trial (N = 730), in which gemcitabine combined with capecitabine was compared to gemcitabine monotherapy for the adjuvant setting, showed that median survival was greater for participants randomized to receive the combination regimen (28.0 months), relative to patients randomized to receive gemcitabine monotherapy (25.5 months) (HR, 0.82; 95% CI, 0.68–0.98; P = .032).

In the CONKO-005 phase III randomized trial, gemcitabine administered with erlotinib was compared to gemcitabine administered alone in the adjuvant setting. This combination regimen did not significantly improve OS or DFS, compared to gemcitabine monotherapy.

Based on the data discussed above, no definite standard has been established in the adjuvant treatment of pancreatic cancer at this time. Chemotherapy alone with gemcitabine (category 1), 5-FU/leucovorin (category 1), gemcitabine/capecitabine (category 1), or continuous infusion 5-FU are listed in the guidelines as options for adjuvant treatment. Capecitabine monotherapy is also a treatment option for the adjuvant setting (category 2B). The panel considers capecitabine to be a reasonable alternative to 5-FU/leucovorin only in this setting as a last choice in patients for whom other options are inappropriate or unacceptable. Gemcitabine, 5-FU/leucovorin, or continuous infusion 5-FU before gemcitabine- or fluoropyrimidine-based chemoradiation is also recommended as an adjuvant treatment, with subsequent chemoradiation being an option. To date, no studies have demonstrated superiority of giving chemoradiation before versus after chemotherapy in the adjuvant setting.

Regardless of the therapy being considered it is important to evaluate the patient for extent of disease prior to therapy, because some patients have early recurrence within the first few weeks following surgery. In addition, the panel recommends restaging a patient with imaging following systemic chemotherapy if chemoradiation is planned.

A recent retrospective analysis of data from patients in the ESPAC-3 trial found that completion of the full course of chemotherapy was an independent prognostic factor for survival, but that time to treatment initiation after surgery was not. These results suggest that delaying chemotherapy until patients adequately recover could possibly improve
outcomes. The panel therefore recommends that adjuvant treatment be initiated within 12 weeks, after adequate recovery from surgery.

S-1 is an oral chemotherapy drug that is being used in Asia. Results of the phase III RCT JASPAC-01 trial (N = 385), in which S-1 was compared to gemcitabine in the adjuvant setting, showed that median OS was greater for S-1 (46.5 months; 95% CI, 37.8–63.7), compared to gemcitabine (25.5 months; 95% CI, 22.5–29.6). Three- and 5-year survival rates were 59.7% and 44.1%, respectively, for S-1, and 38.8% and 24.4%, respectively, for gemcitabine. S-1 was generally well-tolerated, and the treatment of patients randomized to receive gemcitabine was more likely to be discontinued, relative to the treatment of patients randomized to receive S-1 (P = .005). Grade 3 of 4 adverse events that were more likely to be reported in patients receiving gemcitabine include leucopenia, neutropenia, aspartate aminotransferase, and alanine aminotransferase, while stomatitis and diarrhea were more common in patients receiving S-1.

Ongoing clinical trials in the adjuvant setting include ESPAC-4 (www.controlled-trials.com/ISRCTN96397434), which is comparing gemcitabine with capecitabine to gemcitabine alone; RTOG 0848 (ClinicalTrials.gov NCT01013649), which is assessing gemcitabine with or without subsequent chemoradiation; and a phase II study comparing FOLFIRINOX with albumin-bound paclitaxel (ClinicalTrials.gov NCT02243007).

**Preoperative (Neoadjuvant) Therapy**

The standard approach to therapy in patients with resectable disease has been postoperative treatment, with median survivals in the range of 20.1 to 23.6 months under the most optimal clinical trial conditions. However, it is becoming increasingly apparent that patients with borderline resectable disease, who are at higher risk for R1 resections, are potentially in need of a different management approach. Contemporary approaches to perioperative treatment have focused on neoadjuvant therapy for patients with borderline resectable disease with the goal of improving OS. Neoadjuvant therapy is also sometimes used in patients with resectable disease, especially in those with high-risk features. The putative benefits of neoadjuvant therapy include increasing the likelihood that a higher proportion of patients with resectable disease will receive chemotherapy and/or radiation; the potential to downsize tumors so as to increase the likelihood of a margin-free resection (ie, conversion to resectable status); the potential to select for surgery those patients with more stable disease or disease that is more responsive to therapy; and the treatment of micrometastases at an earlier stage. Moreover, surgery following neoadjuvant treatment appears to be safe.

EUS-FNA is the preferred method of obtaining histologic confirmation of disease, and such confirmation is necessary before administering neoadjuvant therapy. A repeat biopsy should be performed in cases where the initial biopsy results do not confirm cancer. In addition, staging laparoscopy, performed to evaluate for the possible presence of metastatic disease, can be considered before neoadjuvant therapy. Furthermore, patients for whom neoadjuvant therapy is planned should be assessed for jaundice, and placement of a stent (preferably a short, SEMS, as discussed in Preoperative Biliary Drainage, above) is recommended prior to initiation of neoadjuvant therapy in patients with jaundice.

Retrospective analyses from patients at one NCCN Member Institution showed that neoadjuvant chemoradiation is associated with better local control, relative to neoadjuvant chemotherapy, though significant differences in survival were not found. Practices vary with regard to chemotherapy and chemoradiation. Acceptable regimens include
FOLFIRINOX, gemcitabine/albumin-bound paclitaxel, and gemcitabine/cisplatin (for patients with BRCA1/2 or other DNA repair mutations).

Chemoradiation following chemotherapy is sometimes included in the neoadjuvant setting. Doses for neoadjuvant chemoradiation that have been reported include 36 Gy in 2.4 Gy/fraction, or 45 to 54 Gy in 1.8 to 2.0 Gy/fraction.\(^{406,551}\) The role of chemoradiation with more active chemotherapy regimens needs to be tested.

Pancreatic protocol CT or MRI of the abdomen and pelvis, and chest imaging (CT preferred) should be repeated following neoadjuvant therapy, and staging laparoscopy can be considered at this time if not previously performed. Surgical resection should only be attempted if there is a high likelihood of achieving an R0 resection. Surgery is ideally performed 4 to 8 weeks after therapy. Surgery can be performed more than 8 weeks following therapy, but radiation-induced fibrosis may potentially make surgery more difficult. Importantly, results from retrospective studies suggest that radiographic response does not correlate with pathologic response.\(^{552,553}\) Therefore, if no apparent tumor shrinkage is observed after neoadjuvant treatment and no extrapancreatic progressive disease is evident, surgery should still be attempted.

Neoadjuvant Therapy in Borderline Resectable Disease

Patients with borderline resectable disease should be considered for neoadjuvant therapy, followed by restaging and resection in patients without disease progression precluding surgery. The use of neoadjuvant therapy in the setting of borderline resectable disease has been a highly debated topic. However, although there is no high-level evidence supporting its use, most NCCN Member Institutions now prefer an initial approach involving neoadjuvant therapy, as opposed to immediate surgery, for patients with borderline resectable disease. Neoadjuvant therapy should preferably be administered at or coordinated through a high-volume center. Upfront resection in patients with borderline resectable disease is no longer recommended, as of the 2016 version of these guidelines.

Several trials have shown that preoperative treatment of borderline resectable pancreatic adenocarcinoma can be effective and well-tolerated.\(^{554-561}\) A phase I/II trial of neoadjuvant therapy in borderline resectable disease allowed 4 of 26 patients (15%) to be resected.\(^{558}\) A randomized phase II trial comparing 2 different neoadjuvant regimens in borderline resectable disease was terminated early due to poor accrual, but 5 of 21 patients (24%) were resected.\(^{557}\) A multi-institutional phase II trial found that full-dose gemcitabine, oxaliplatin, and radiation given preoperatively to patients with resectable (n = 23), borderline resectable (n = 39), or unresectable disease (n = 6) found the approach to be feasible with an overall R0 resection rate of 53%.\(^{556}\) In this study, 63% of all evaluable patients underwent resection, with 84% of those patients achieving an R0 resection.

In 2 retrospective reviews, 31% to 35% of patients with borderline resectable disease who completed neoadjuvant therapy had R0 resections.\(^{562,563}\) A systematic review and meta-analysis of 19 cohort studies found that patients with unresectable disease (including both borderline resectable and unresectable) undergoing neoadjuvant chemoradiation therapy had similar 1-year survival outcomes as patients who were initially deemed resectable.\(^{564}\) In this study, 40% of treated patients were ultimately resected.

It is important to note that no randomized phase III trials have compared the approach of neoadjuvant therapy in borderline resectable disease compared to the approach of taking these patients to surgery without...
initial therapy, and the best regimens to use in the borderline neoadjuvant setting are unknown. Several phase II clinical trials are currently underway to determine the R0 resection rate following neoadjuvant chemotherapy in patients with borderline resectable or unresectable locally advanced disease (eg, ClinicalTrials.gov NCT00557492). In addition, the Alliance A021101 trial (NCT01821612) is a single-arm pilot study evaluating the safety and efficacy of FOLFIRINOX before capecitabine-based chemoradiation and surgery in this population. Preliminary results including 22 patients from multiple centers showed that median OS was 21.7 months, and 68% of patients underwent resection. Out of the 15 patients who underwent resection, all but one had negative margins, and 2 had a complete response. However, the number of grade 3 or higher adverse events was considerable, with 64% of patients experiencing one of these events. Other initial results in patient series suggest that neoadjuvant regimens including FOLFIRINOX are a promising approach in patients with borderline resectable disease.

Chemotherapy followed by SBRT may also be safe and feasible in the neoadjuvant setting, and may improve the potential for resection in patients with borderline resectable or locally advanced disease. However, further studies are needed before SBRT is recommended as a treatment option for patients with borderline resectable disease.

**Neoadjuvant Therapy in Resectable Disease**

An observational retrospective propensity score that matched analyses of 15,237 patients with resected pancreatic cancer showed that those who received neoadjuvant therapy had better OS than those who received upfront resection (median survival 26 months vs. 21 months, respectively; HR, 0.72; 95% CI, 0.68–0.78; P < .01). A number of studies have evaluated the use of neoadjuvant chemoradiation in patients with resectable disease. A retrospective review of the collective experience at the University of Texas MD Anderson Cancer Center suggested that the use of preoperative chemoradiation therapy in patients with resectable disease is advantageous. The authors suggest that preoperative therapy gives a selection advantage because approximately 25% of patients who are restaged after therapy are found to have progressive disease and are therefore spared the morbidity of a surgical procedure that would not benefit them. In this analysis of 132 consecutive patients, the authors reported that combined preoperative chemoradiation and pancreatoduodenectomy yielded a median survival of 21 months, and 32% of patients were alive without evidence of disease at a median follow-up of 14 months. The MD Anderson group has continued to champion this approach both for its ability to select patients for resection and for cost-effectiveness.

Other potential advantages of the neoadjuvant approach in patients with resectable disease have also been described, including sterilization of the field before resection potentially reducing spread during surgery; increased rates of R0 resections; decreased incidence of pancreatic fistulas; prevention of delays or reductions of adjuvant therapy after surgery; and improved delivery of chemotherapy and radiosensitizing oxygenation.

Although most studies investigating the neoadjuvant experience in patients with resectable pancreatic cancer are retrospective, several small phase II studies have been published. In a randomized phase II trial evaluating the safety and efficacy of gemcitabine-based chemotherapy regimens as neoadjuvant therapy for patients with resectable pancreatic cancer, more patients receiving gemcitabine with cisplatin were able to undergo resection compared with those in the gemcitabine-only arm.
In a prospective trial, preoperative radiation with concurrent gemcitabine was administered to 86 patients with resectable disease, and patients were restaged 4 to 6 weeks following completion of neoadjuvant treatment. Although all patients were able to complete neoadjuvant therapy, at the time of restaging, only 73 (85%) patients were able to undergo surgery; the majority of the remaining patients were precluded from undergoing a pancreatoduodenectomy due to the presence of more advanced disease. Similar results were observed in another phase II trial involving preoperative gemcitabine/cisplatin followed by gemcitabine-based chemoradiation. In this study, which enrolled 90 patients, 79 patients were able to complete neoadjuvant therapy, and 52 patients underwent surgery. Again, the main reason patients were precluded from surgery was the finding of more advanced disease at restaging following completion of neoadjuvant therapy. A cross-study comparison of these results suggests that inclusion of preoperative chemotherapy prior to initiation of gemcitabine-based chemoradiation did not improve survival. These results provide support for restaging patients with abdominal (pancreas protocol), pelvic, and chest imaging and diagnostic laparoscopy before committing them to laparotomy after neoadjuvant therapy.

Although evidence suggests that there may be a better chance of margin-negative resection with preoperative therapy, results of randomized trials addressing this issue are needed. A recent randomized phase II trial, which was terminated early because of slow accrual, compared gemcitabine/cisplatin neoadjuvant chemoradiation with upfront surgery; both arms received adjuvant chemotherapy. With only 66 patients eligible for analysis, no significant differences were seen in R0 resection rate (52% vs. 48%), (y)pN0 rate (39% vs. 30%), or OS (25.0 months vs. 18.9 months), although all results favored the neoadjuvant arm and no safety issues were noted. The phase III NEOPA trial, with OS as the primary endpoint, is currently recruiting patients with resectable pancreatic cancer to compare neoadjuvant gemcitabine chemoradiation therapy to upfront surgery in this population (ClinicalTrials.gov NCT01900327). A phase II trial with R0 resection as the primary endpoint is also ongoing (ClinicalTrials.gov NCT01389440).

At this time, the panel does not recommend neoadjuvant therapy for clearly resectable patients without high-risk features, except in a clinical trial. For selected patients who appear technically resectable but have poor prognostic features (ie, markedly elevated CA 19-9; large primary tumors; large regional lymph nodes; excessive weight loss; extreme pain) consideration can be given to neoadjuvant therapy after biopsy confirmation, and therapy should be administered preferably at or coordinated through a high-volume center.

**Adjuvant Treatment After Neoadjuvant Therapy**

For patients who received neoadjuvant treatment, data supporting additional therapy after surgery are lacking. The consensus of the panel is that patients who have received neoadjuvant chemoradiation or chemotherapy may be candidates for additional chemotherapy following surgery and multidisciplinary review. When chemotherapy is given, the choice of regimen may be based on response seen to neoadjuvant therapy and other clinical considerations, such as performance status and patient tolerability.

Adjuvant chemotherapy or adjuvant chemoradiation should only be considered for pre-treated patients who have adequately recovered from surgery and have no evidence of recurrence or metastatic disease; treatment should ideally be initiated within 4 to 8 weeks. It is recommended that the patient undergo a pretreatment baseline assessment following surgery, including CT scan and CA 19-9 level, to
evaluate for the presence of metastatic disease before adjuvant chemoradiation is initiated. Further, the panel recommends restaging a patient with imaging following systemic chemotherapy, if it will precede chemoradiation.

**Surveillance of Patients with Resected Disease**

Although data on the role of surveillance in patients with resected pancreatic adenocarcinoma are very limited, recommendations are based on the consensus that earlier identification of disease may facilitate patient eligibility for investigational studies or other forms of treatment. The panel recommends history and physical examination for symptom assessment every 3 to 6 months for 2 years, then every 6 to 12 months. CA 19-9 determinations and follow-up CT scans every 3 to 6 months for 2 years after surgical resection are category 2B recommendations, because data are not available to show that earlier treatment of recurrences, following detection by increased tumor marker levels or CT scan, leads to better patient outcomes. In fact, an analysis of the SEER-Medicare database showed no significant survival benefit for patients who received regular surveillance CT scans.

**Management of Recurrent Disease After Resection**

As cross-sectional body imaging has improved, small-volume metastatic disease or local recurrence is being detected in patients with resected pancreatic cancer who are otherwise maintaining good functional status. As many as 50% of them will continue to maintain a sufficiently good performance status to consider second-line therapy. These patients will, however, ultimately progress.

For patients experiencing a recurrence of disease following resection, the panel recommends consideration of confirmatory biopsy (category 2B). In all cases of recurrent disease, a clinical trial is the preferred option; palliative and best supportive care without additional therapy should also be an option, especially for patients with poor performance status. For patients with local disease recurrence, surgical resection may be considered in select cases (ie, good performance status, location of recurrence is in the pancreas only), though there is currently no evidence to support this recommendation. Chemoradiation or induction chemotherapy followed by SBRT can be considered in patients with local disease recurrence in the pancreatic bed, if radiation has not been previously administered, or an alternative chemotherapy regimen can be given. However, there are limited data to support specific RT recommendations for recurrent disease. For patients for whom there is evidence of metastatic disease (with or without a local recurrence), treatment decisions are influenced by the length of time from completion of adjuvant therapy to the detection of metastases. If adjuvant therapy was completed less than 6 months prior to development of metastatic disease, the panel recommends that an alternative chemotherapy option be administered. When this period is greater than 6 months, systemic therapy as previously administered or an alternative systemic regimen is recommended. Recommended regimens for patients with previous adjuvant treatment and good performance status are gemcitabine/albumin-bound paclitaxel and FOLFIRINOX.

**Management of Isolated Pulmonary Metastases**

Some patients have isolated lung metastases after resection of localized pancreatic adenocarcinoma. A growing body of evidence in this population suggests that these patients have a prolonged survival compared to patients with metastases in other locations. Preliminary data also suggest that pulmonary metastasectomy may be advantageous in this population. More data are needed before
recommendations can be made regarding the management of pulmonary metastases of pancreatic cancers.

**Palliative and Supportive Care**

A significant subset of patients with pancreatic cancer will require substantial palliative interventions that are, in many respects, unique to the disease. The multidisciplinary management of symptoms due to biliary obstruction, gastric outlet obstruction, and cancer-related pain is of primary importance. The main objective of palliative care is to prevent and ameliorate suffering while ensuring optimal quality of life. Palliative surgical procedures are best reserved for patients with longer life expectancies.

**Biliary Obstruction**

Approximately 65% to 75% of patients with pancreatic cancer develop symptomatic biliary obstruction. For patients diagnosed with unresectable disease and biliary obstruction upon initial evaluation, the best palliation is provided by an endoscopic biliary stent, especially when anticipated survival is limited. In most cases, a permanent SEMS is recommended unless biliary bypass is performed (also see the discussion on stents in *Preoperative Biliary Drainage*, above). Stent occlusion that causes recurrent cholangitis is a well-known complication of plastic (temporary) biliary stents and typically occurs within 3 months of insertion. Metal stents are wider in diameter than plastic stents (i.e., less likelihood of blockage) and become embedded in the bile duct, whereas plastic stents are more likely to become occluded but can be replaced. Results of an RCT of 100 patients at a single center randomly assigned to receive either a plastic stent or a covered SEMS inserted endoscopically indicated that median patency times were 1.8 and 3.6 months ($P = .002$), respectively. A meta-analysis comparing metal and plastic biliary stents placed endoscopically in patients with pancreatic adenocarcinoma characterized by biliary obstruction showed similar results. This study suggested that the risk of recurrent biliary obstruction was lower for the metal stents (RR, 0.52; 95% CI, 0.39–0.69), although no significant differences in technical/therapeutic success, complications, or 30-day mortality were found. Another randomized trial showed that covered SEMS had longer patency than uncovered SEMS in the setting of biliary obstruction due to pancreatic cancer, because covered stents prevented the ingrowth of tumor.

When a biliary stent cannot be placed (often because the endoscope cannot be advanced past the neoplasm that is obstructing the gastric outlet), percutaneous biliary drainage with subsequent internalization may be necessary. An alternative is to sequentially dilate the duodenum endoscopically, place a metallic biliary stent, and then place an enteral stent. Durable palliation of biliary obstruction can often be achieved with an expandable metallic biliary endoprosthesis (e.g., Wallstent, Boston Scientific) in this situation.

For patients with jaundice and potentially resectable disease who are found to have unresectable tumors following laparotomy, an open biliary-enteric bypass provides durable palliation of biliary obstruction and can be combined with procedures that palliate symptoms resulting from gastric outlet obstruction and cancer-related pain. The panel recommends stenting or an open biliary-enteric bypass with or without gastrojejunostomy (category 2B for prophylactic gastrojejunostomy and covered SEMS inserted endoscopically) and with or without celiac plexus neurolysis (category 2B in patients without pain). See *Gastric Outlet Obstruction* and *Severe Tumor-Associated Abdominal Pain* below for more detailed information on these procedures. Bypass of the common bile duct (choledochojejunostomy) or common hepatic duct (hepaticojejunostomy) to the jejunum is preferred to bypass of the gallbladder (cholecystojejunostomy) since
choledochojejunostomy/hepaticojejunostomy provide more durable and reliable palliation of biliary obstruction.  

Biliary decompression is also required for jaundiced patients with disease progression precluding surgery with or without neoadjuvant therapy. Here, stenting or biliary bypass is recommended, with or without gastrojejunostomy (category 2B for prophylactic gastrojejunostomy\(^{599,600}\)) and with or without celiac plexus neurolysis (category 2B in patients without pain). One final circumstance requiring biliary drainage is in jaundiced patients with locally advanced or metastatic disease (those for whom surgical resection will not be attempted). In this situation, a SEMS is preferred unless biliary bypass was performed at the time of laparoscopy or laparotomy. If cancer has not been biopsy-confirmed in the setting of locally advanced disease in a patient with jaundice, brushings can be obtained at the time of stent placement.

### Gastric Outlet Obstruction

Symptomatic gastric outlet obstruction occurs in 10% to 25% of patients with pancreatic cancer.  

Patients with locally advanced or metastatic disease and a short life expectancy or poor performance status who develop gastric outlet obstruction may be palliated with an endoscopically placed enteral stent after biliary drainage is assured.  

An alternative for these patients with poor performance status is percutaneous endoscopic gastrostomy (PEG) tube placement. For a fit patient with a life expectancy greater than 3 to 6 months (ie, locally advanced disease) who develops gastric outlet obstruction, an open or laparoscopic gastrojejunostomy (duodenal bypass) with or without a jejunostomy (J) tube should be considered since it may provide more durable and effective palliation of gastric outlet obstruction than an enteral stent.  

Nevertheless, placement of an enteral stent is also an option for these patients.

For patients with potentially resectable disease who undergo a laparotomy and are found to have unresectable disease, a prophylactic gastrojejunostomy should be performed for those deemed to be at risk of developing symptomatic gastric outlet obstruction (category 2B). The role of prophylactic gastrojejunostomy in otherwise asymptomatic patients who are found to have unresectable cancers at the time of laparotomy has been evaluated. Two RCTs have investigated the role of prophylactic gastrojejunostomy for unresectable periampullary cancer, the majority arising from the head of the pancreas.  

In both studies, approximately 20% of patients who did not undergo a prophylactic gastrojejunostomy developed late gastric outlet obstruction that required therapy. A meta-analysis found similar results, with development of gastric outlet obstruction in 2.5% of patients in the prophylactic gastrojejunostomy group and 27.8% of those not receiving gastrojejunostomy.  

In both studies, prophylactic retrocolic gastrojejunostomy significantly decreased the incidence of late gastric outlet obstruction but did not extend the length of stay or increase complication rates, such as delayed gastric emptying.

### Severe Tumor-Associated Abdominal Pain

Most patients with locally advanced or metastatic pancreatic cancer experience cancer-related pain. General principles for cancer-related pain management can be found in the NCCN Guidelines for Adult Cancer Pain (available at www.NCCN.org). Patients with severe tumor-associated abdominal pain should be treated with around-the-clock narcotics. However, some patients will be unresponsive to narcotics or will experience undesirable side effects. Because advanced pancreatic cancer often infiltrates the retroperitoneal nerves of the upper abdomen,
celiac plexus neurolysis should be considered (category 2B, except when indicated by pain in a patient with jaundice who is found unresectable at surgery, for which the recommendation is a category 2A). In several RCTs, celiac plexus neurolysis significantly improved pain relief in patients with advanced pancreatic cancer.\(^\text{601,603,608}\) In a study of 96 patients with pain related to suspected pancreatic cancer, half were randomized to EUS-guided celiac plexus neurolysis at the time of EUS if unresectable adenocarcinoma was confirmed.\(^\text{602}\) These patients reported better pain relief at 3 months \((P = .01)\), suggesting that early EUS-guided celiac plexus neurolysis may be beneficial. A recent meta-analysis of 7 RCTs concluded that celiac plexus neurolysis improved pain scores at 4 weeks but not at 8 weeks in patients with pancreatic cancer.\(^\text{609}\) The effectiveness of ethanol celiac plexus neurolysis for pain in resectable pancreatic and periampullary adenocarcinoma was examined in a recent RCT \((N = 467)\).\(^\text{610}\) The use of this technique was not found to significantly impact postoperative pain. Minimally invasive techniques including EUS-guided (preferred if available) and percutaneous fluoroscopic- or CT-guided celiac plexus neurolysis are recommended, but laparoscopic, thoracoscopic, and open approaches can also be used.

In selected patients with severe local back pain refractory to narcotic therapy, palliative RT may be considered to ameliorate pain, bleeding, and/or local obstructive symptoms, in the settings of both metastatic and non-metastatic disease, if not already given as part of primary therapy. In such cases, radiation is given with or without concurrent chemotherapy to the primary tumor plus a margin (typically 25–36 Gy in 2.4–5 Gy fractions), or radiation alone is given to the metastatic site. The dose used should take into account the burden of disease, normal tissue tolerance, and expected survival.

**Pancreatic Exocrine Insufficiency**

Exocrine enzyme insufficiency in pancreatic cancer is caused by tumor-induced damage to the pancreatic parenchyma and/or blockage of the pancreatic duct, or by surgical removal of pancreatic tissue, and results in an inadequate production of digestive enzymes.\(^\text{611,612}\) This deficiency in pancreatic enzymes results in inadequate absorption of fat, carbohydrates, and proteins, leading to steatorrhea, abdominal cramps, weight loss, and malnutrition.\(^\text{613}\) Oral pancreatic exocrine enzyme replacement therapy is recommended for patients with pancreatic cancer who have symptoms of exocrine enzyme deficiency. Because pancreatic exocrine insufficiency occurs in up to 94% of patients undergoing pancreatic surgery,\(^\text{614,615}\) therapy may be initiated without diagnostic tests. Enteric-coated mini-microspheres containing preparations of pancreatic enzymes are taken orally (25,000–75,000 units of lipase for a main meal and 10,000–25,000 units of lipase for a snack, depending on fat content), with half of the dose taken at the start of the meal and half taken in the middle of the meal.\(^\text{613}\) For patients with disease that does not respond to this therapy, doses of the enzyme preparation can be increased, and inhibition of gastric secretion with a proton pump inhibitor can also be considered.\(^\text{613,614}\) Patients with a clinical suspicion of pancreatic exocrine insufficiency despite appropriate replacement may need a more thorough nutritional evaluation.

**Thromboembolic Disease**

The risk of developing venous thromboembolic disease is substantially increased in patients with pancreatic cancer.\(^\text{616,617}\) The panel recommends low-molecular-weight heparin (LMWH) as preferred therapy over warfarin for patients with pancreatic cancer who develop a venous thromboembolism (VTE). Support for this recommendation comes from results of 2 large, prospective, randomized clinical trials:
CLOT and CONKO 004. In the CLOT study, an approximately 2-fold decrease in the incidence of recurrent VTE at 6 months was observed in patients with advanced or metastatic cancer diagnosed with a VTE who were treated with the LMWH, dalteparin, compared with those treated with an oral anticoagulant.\(^6\)

Results from the CONKO 004 trial showed that patients randomized to receive enoxaparin \((n = 160)\) experienced fewer symptomatic VTEs, relative to patients receiving chemotherapy only \((n = 152)\) (HR, 0.40; 95% CI, 0.19–0.83; \(P = .01\)).\(^6\) PFS and OS did not significantly differ between the two groups, however. In a pilot trial conducted in preparation for the CONKO 004 trial, the risk of developing symptomatic VTE was significantly lower for patients in the LMWH arm of the study with no significant increase in bleeding observed in this group compared to those not receiving enoxaparin.\(^6\)

The panel does not recommend prophylactic LMWH at this time, due to the lack of evidence regarding impact on survival. Please see the NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease for more information (available at [www.NCCN.org](http://www.NCCN.org)).

**Future Clinical Trials: Recommendations for Design**

In 2007, a meeting was convened by the National Cancer Institute's Gastrointestinal Cancer Steering Committee in recognition of the failure of a number of phase III trials to show clinically significant benefit for patients with pancreatic cancer and to address the importance of integrating basic and clinical knowledge in the design of clinical trials in pancreatic cancer. Meeting participants included representatives from industry, government, and the community, as well as academic researchers and patient advocates. Several important themes emerging from this meeting are summarized below, and the recommendations put forward by the committee are endorsed by the NCCN Pancreatic Adenocarcinoma Panel.\(^6\)

- With the emergence of new agents to treat pancreatic cancer, particularly biologics, clinical trial strategies incorporating principles of molecular biology and new imaging methods as well as results from preclinical studies are important.
- For patients enrolled in clinical trials, banking of tumor tissue samples should be required along with paired blood and serum samples.

**Depression, Pain, and Malnutrition**

For many patients, a diagnosis of pancreatic cancer may result in significant psychosocial distress, including anxiety, depression, and sleep disturbances.\(^6\) In fact, the suicide rate in male patients with pancreatic cancer is reportedly 11 times that of the general population.\(^6\) Empathetic discussion about the natural history of this disease and its prognosis and the provision of support and counseling both by the primary oncology team and specialized services may help to alleviate this distress. The panel recommends that patients be screened and evaluated for depression and other psychosocial problems following the NCCN Guidelines for Distress Management (available at [www.NCCN.org](http://www.NCCN.org)).

Because pain and malnutrition are also prevalent in patients with pancreatic cancer, the panel recommends that patients with locally advanced or metastatic pancreatic cancer receive a nutritional evaluation with a registered dietitian and a formal evaluation by a Palliative Medicine Service, when appropriate. Additional resources are detailed in the NCCN Guidelines for Palliative Care and the NCCN Guidelines for Adult Cancer Pain (available at [www.NCCN.org](http://www.NCCN.org)).
Biomarkers that serve as surrogate markers of the anticancer effects of investigational agents should be sought, and assays to measure such biomarkers should be well validated.

Clinical trials should enroll homogeneous patient populations with respect to disease stage (ie, separate trials for patients with locally advanced disease and metastatic disease) and patient performance status. Criteria for selecting study populations should take into account the putative differential efficacy of the agent (ie, vaccines in patients with early-stage disease).

Phase III trials should not be initiated in the absence of clinically meaningful efficacy and safety signals in the phase II setting.

Phase II and III clinical trials should have a primary endpoint of OS.

Quality control standards for preoperative imaging interpretation, pathologic assessment of tumor specimens, and surgical selection criteria are critical when evaluating adjuvant therapies.

A 2011 consensus report from a group of European experts came to many of the same conclusions. Additionally, the group states that FOLFIRINOX can be considered as a new standard treatment option in selected patients in future clinical trials, but that gemcitabine should remain the standard for most patients. An international expert panel also met to discuss current and future pancreatic cancer research and came to similar conclusions. In addition, the Intergroup Pancreatic Cancer Task Force’s Tissue Acquisition Working Group has made recommendations regarding the prospective collection and sharing of tissue to accelerate the discovery of predictive and prognostic biomarkers. These recommendations include centralization of biorepositories and mandatory collection of tissue (when there is sufficient material), blood, serum, and plasma in all phase III trials.

ASCO also recently convened a working group to discuss designs for pancreatic cancer clinical trials that would accomplish meaningful clinical improvements. This group concluded OS should be the primary endpoint of first-line, metastatic pancreatic cancer trials. They also concluded that trials should aspire to a 3- to 4-month improvement in OS in gemcitabine-eligible and gemcitabine/albumin-bound paclitaxel-eligible patients and a 4- to 5-month improvement in OS for FOLFIRINOX-eligible patients to give results with true clinical impact.

To determine appropriate historic controls for single-arm phase II trials based on gemcitabine, an algorithm has been developed, based on an analysis of a database of cooperative group trials that can be used to calculate historic benchmarks for OS and PFS.

**Neoadjuvant Clinical Trials**

For neoadjuvant trials, study populations should be well defined and standardized. The panel endorses use of a restrictive definition of borderline resectable disease in clinical trials, such as that defined in an Intergroup trial. Endpoints should also be standardized and could include resection rates, R0 resection rates, local recurrence rates, pathologic response rates, DFS, and OS.

**Targeted Therapies**

Poly (ADP-ribose) polymerase (PARP) inhibitors provide a promising avenue of treatment for cancers associated with BRCA1/2 mutations. In a phase II trial assessing the efficacy and safety of olaparib, an oral PARP, the tumor response rate for patients with metastatic pancreatic cancer and a germline BRCA1/2 mutation (n = 23) was 21.7% (95% CI,
Data from the phase II RUCAPANC trial including 19 patients with a BRCA1/2 mutation and relapsed disease showed an objective response rate of 11% in patients who were administered the PARP inhibitor rucaparib. The phase III randomized POLO trial (NCT02184195), in which the effectiveness of maintenance olaparib monotherapy following cisplatin, carboplatin, or oxaliplatin is being assessed, is currently in process.

Summary

Resection remains the only chance for a cure for pancreatic adenocarcinoma, and most resectable patients should undergo surgery without delay, followed by adjuvant therapy. Patients with borderline resectable disease and select patients with resectable disease can undergo neoadjuvant therapy in the hopes of improving the chances for an R0 resection or can immediately undergo surgery. Additional therapy is an option for those patients whose disease recurs following surgery. Patients with locally advanced unresectable disease and good performance status can undergo chemotherapy and chemoradiation with second-line therapy if performance status is maintained after progression. Patients with good performance status presenting with metastatic disease can undergo chemotherapy and can undergo second-line therapy if performance status is maintained after progression. Specific palliative measures are recommended for patients with advanced pancreatic adenocarcinoma characterized by biliary or gastric obstruction, severe abdominal pain, or other tumor-associated manifestations of the disease.

Overall, in view of the relatively high likelihood of poor outcomes for patients with all stages of pancreatic cancer, the NCCN Panel recommends that investigational options be considered in all phases of disease management.
Table 1: Selected Genetic Syndromes with Associated Pancreatic Cancer Risk

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Gene</th>
<th>Estimated Cumulative Risk of Pancreatic Cancer</th>
<th>Estimated Increased Risk Compared to General Population</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peutz-Jeghers syndrome</td>
<td>STK11</td>
<td>11%–36% by age 65–70 years^74</td>
<td>132-fold^73</td>
</tr>
<tr>
<td>Familial pancreatitis</td>
<td>PRSS1,</td>
<td>40%–53% by age 70–75 years^78–80</td>
<td>26-fold to 87-fold^36,78–80</td>
</tr>
<tr>
<td></td>
<td>SPINK1, CFTR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Melanoma-pancreatic cancer syndrome</td>
<td>CDKN2A</td>
<td>14% by age 70^86</td>
<td>20-fold to 47-fold^82,83</td>
</tr>
<tr>
<td></td>
<td></td>
<td>17% by age 75 years^83</td>
<td></td>
</tr>
<tr>
<td>Lynch syndrome</td>
<td>MLH1, MSH2 (MSH6)</td>
<td>4% by age 70 years^94</td>
<td>9-fold to 11-fold^94,95</td>
</tr>
<tr>
<td>Hereditary breast-ovarian cancer syndrome</td>
<td>BRCA1, BRCA2</td>
<td>1.4%–1.5% (women) and 2.1%–4.1% (men) by age 70^97,102</td>
<td>2.4-fold to 6-fold^97,101,102</td>
</tr>
<tr>
<td>Familial pancreatic cancer</td>
<td>Unknown in most families (family X is an exception)*</td>
<td>≥3 first-degree relatives with pancreatic cancer: 7%–16% by age 70^63</td>
<td>≥3 first-degree relatives with pancreatic cancer: 32-fold^68</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2 first-degree relatives with pancreatic cancer: 3% by age 70^63</td>
<td>2 first-degree relatives with pancreatic cancer: 6.4-fold^68</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1 first-degree relative with pancreatic cancer: 4.6-fold^68</td>
</tr>
</tbody>
</table>

*One family (family X) with a mutation in the *palladin* (*PALLD*) gene has been identified.^^532

---

[^74]: Reference or data source.
[^73]: Reference or data source.
[^78–80]: Reference or data source.
[^82]: Reference or data source.
[^83]: Reference or data source.
[^84]: Reference or data source.
[^85]: Reference or data source.
[^94]: Reference or data source.
[^97]: Reference or data source.
[^101]: Reference or data source.
[^102]: Reference or data source.
[^63]: Reference or data source.
### Table 2: Potential Indications for Various Therapies in the Treatment of Pancreatic Adenocarcinoma

<table>
<thead>
<tr>
<th>Regimen</th>
<th>Resectable (adjuvant)</th>
<th>Borderline Resectable/Resectable (neoadjuvant)</th>
<th>Locally Advanced (category recommendations for good performance status only unless otherwise noted)</th>
<th>Metastatic (category recommendations for good performance status only unless otherwise noted)</th>
<th>Second-Line Therapy (good performance status only)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gemcitabine</td>
<td>√ (category 1)</td>
<td></td>
<td>√ (category 1 for poor performance status)</td>
<td>√ (category 1 for good and poor performance status)</td>
<td>√ (if previously treated with fluoropyrimidine-based therapy)</td>
</tr>
<tr>
<td>Gemcitabine/albumin-bound paclitaxel</td>
<td></td>
<td></td>
<td>√</td>
<td>√ (category 1; preferred)</td>
<td>√ (if previously treated with fluoropyrimidine-based therapy)</td>
</tr>
<tr>
<td>Gemcitabine/erlotinib</td>
<td></td>
<td></td>
<td>√</td>
<td>√ (category 1)</td>
<td>√ (if previously treated with fluoropyrimidine-based therapy)</td>
</tr>
<tr>
<td>Gemcitabine/cisplatin</td>
<td></td>
<td></td>
<td>√ (especially for patients with BRCA1/2 or other DNA repair mutations)</td>
<td>√ (especially for patients with BRCA1/2 or other DNA repair mutations)</td>
<td>√ (if previously treated with fluoropyrimidine-based therapy)</td>
</tr>
<tr>
<td>Gemcitabine/capecitabine</td>
<td>√ (category 1)</td>
<td></td>
<td>√</td>
<td>√</td>
<td>√ (if previously treated with fluoropyrimidine-based therapy)</td>
</tr>
<tr>
<td>Fixed-dose-rate gemcitabine</td>
<td></td>
<td></td>
<td>√ (poor performance status only; category 2B)</td>
<td>√ (poor performance status only; category 2B)</td>
<td>√ (if previously treated with fluoropyrimidine-based therapy)</td>
</tr>
<tr>
<td>GTX [fixed-dose-rate gemcitabine/docetaxel/capecitabine]</td>
<td></td>
<td></td>
<td>√ (category 2B)</td>
<td>√ (category 2B)</td>
<td>√ (if previously treated with fluoropyrimidine-based therapy)</td>
</tr>
<tr>
<td>Treatment</td>
<td>Category</td>
<td>Comment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------------------------------------</td>
<td>-------------------</td>
<td>-------------------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5-FU/leucovorin</td>
<td>√ (category 1)</td>
<td>√ (if previously treated with gemcitabine-based therapy)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5-FU/leucovorin/liposomal irinotecan</td>
<td></td>
<td>√ (category 1 if previously treated with gemcitabine-based therapy and metastatic disease)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FOLFIRINOX</td>
<td>√</td>
<td>√ (category 1; preferred)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Capecitabine</td>
<td>√ (category 2B)</td>
<td>√ (poor performance status only; category 2B)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Continuous infusion 5-FU</td>
<td>√</td>
<td>√ (poor performance status only; category 2B)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluoropyrimidine/oxaliplatin (eg, FOLFOX, CapeOx)</td>
<td>√ (category 2B)</td>
<td>√ (category 2B)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chemoradiation</td>
<td>√ (following induction chemotherapy, with or without subsequent chemotherapy)</td>
<td>√ (in select patients who are not candidates for combination therapy, and following induction chemotherapy in select patients without systemic metastases)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


Figure 1. Complete mobilization of the superior mesenteric (SMV) and portal veins, and separation of the specimen from the right lateral border of the superior mesenteric artery (SMA)."
Figure 2. Whipple specimen with labeled margins.
Figure 3. Slicing of pancreatoduodenectomy specimens.\textsuperscript{523}

Courtesy of Mr. Paul Brown, Specialist Medical Illustrator, St James's University Hospital Leeds
Figure 4. Slicing of the pancreatoduodenectomy specimen in the axial plane to allow circumferential assessment of tumor.
Figure 16-4, from Hruban, Ralph et al. Tumors of the Pancreas: Afip Atlas of Tumor Pathology, American Registry of Pathology, Washington DC 2007

Figure 5. Slicing of the distal pancreatectomy specimen. 538
References


16. Vrieling A, Bueno-de-Mesquita HB, Boshuizen HC, et al. Cigarette smoking, environmental tobacco smoke exposure and pancreatic cancer...


139. McNulty NJ, Francis IR, Platt JF, et al. Multi--detector row helical CT of the pancreas: effect of contrast-enhanced multiphasic imaging on enhancement of the pancreas, peripancreatic vasculature, and...


428. Venkat R, Edil BH, Schulick RD, et al. Laparoscopic distal pancreatectomy is associated with significantly less overall morbidity compared to the open technique: a systematic review and meta-


457. Huttnar FJ, Fitzmaurice C, Schwarzer G, et al. Pylorus-preserving pancreaticoduodenectomy (pp Whipple) versus pancreaticoduodenectomy (classic Whipple) for surgical treatment of...


513. Rosemurgy AS, Bloomston M, Serafini FM, et al. Frequency with which surgeons undertake pancreaticoduodenectomy determines length...


569. Artinyan A, Anaya DA, McKenzie S, et al. Neoadjuvant therapy is associated with improved survival in resectable pancreatic...


631. Domchek SM, Hendifar AE, McWilliams RR, et al. RUCAPANC: An open-label, phase 2 trial of the PARP inhibitor rucaparib in patients (pts) with pancreatic cancer (PC) and a known deleterious germline or somatic BRCA mutation. ASCO Meeting Abstracts 2016;34:4110. Available at: http://meeting.ascopubs.org/cgi/content/abstract/34/15_suppl/4110.
